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Marfan syndrome (MFS) is one of several related disorders that is driven by 
increased TGFβ signaling. While TGFβ can stimulate both canonical (Smad2/3) and 
noncanonical (MAPK; ERK, JNK, p38) cascades, this work has identified a novel and 
critical role for ERK1/2 activation in aortic aneurysm pathogenesis in Marfan mice, while 
inhibition of ERK1/2 activation represents a novel therapeutic strategy for the disorder.   
Angiotensin II influences aortic growth in Marfan mice, but the contribution of its 
type 1 receptor (AT1R) and type 2 receptor (AT2R) was unknown. This has direct 
clinical relevance, as the relative therapeutic merits of selective AT1R blockade using 
losartan versus inhibition of signaling through both receptors using the ACE inhibitor 
enalapril remained unknown. We find that losartan shows superior efficacy to enalapril in 
Marfan mice, this is mediated by their differential effects on ERK1/2 activation, and 
losartan’s full protective effect requires intact AT2R signaling.  
Calcium channel blockers (CCBs) are used in Marfan patients, although evidence 
for their efficacy is limited. Surprisingly, we find that CCBs accelerate aortic growth, 
dissection and premature lethality in Marfan mice, while Marfan patients taking CCBs 
show increased odds for aortic dissection and need for aortic surgery. CCBs enhance 
ERK1/2 activation via PKCβ, while PKCβ inhibition using enzastaurin or the clinically 
available agent hydralazine rescues aortic growth and ERK1/2 activation in Marfan mice, 
and hence represents a novel therapeutic strategy for the disorder.  
Finally, we have identified mutations in the proto-oncogene SKI, a repressor of 
TGFβ, as the cause of Shprintzen Goldberg syndrome, and mutations in TGFB2 ligand as 
the cause of a Loeys-Dietz like syndrome. We have also found strain-specific differences 
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in aortic aneurysm severity between Marfan mice on C57BL/6J and 129S6 backgrounds, 
and have identified likely causal genes in QTLs on chromosomes 5 and 11 that link with 
severe disease, reach genome wide significance, and show additive epistasis.  
In summary, this work has sought to enhance our understanding of disease 
pathogenesis in MFS and related conditions, to elucidate a series of novel genetic and 
pharmacological modifiers of disease progression, and to identify a number of novel 
therapeutic strategies as a result. 
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Diagnosis of Marfan Syndrome 
 
Marfan syndrome (MFS) is an autosomal dominant systemic connective tissue 
disorder with an estimated frequency of 2 to 3 per 10,000 individuals. About one-quarter 
to one-third of new cases occur as a result of a de novo germinal mutation. As with many 
dominant traits, sporadic cases of MFS are associated with advanced paternal age, 
presumably because age predisposes to de novo mutations in spermatocytes.1 Most 
infants with severe MFS are isolated cases, which is unsurprising since the more severe 
the phenotype the less the likelihood of survival to reproductive age.  
Inheritance of mutations in FBN1 from both parents has been suggested in a few 
severely affected children,2,3 and proven by molecular analysis.4 The penetrance of MFS 
is high, although sensitive tests such as echocardiography and ocular slit-lamp 
examination may be required to detect subtle features at an early age. Intrafamilial 
variability is often impressive, even though affected family members possess the same 
FBN1 mutation.  
Diagnosis is based on clinical criteria (Table 1-1).5 In the absence of a conclusive 
family history of MFS, the diagnosis can be established in four ways (as defined by the 
revised Ghent nosology (Revised Ghent Nosology, 2010):5 
1. The presence of aortic root dilatation (Z-score ≥2 when standardized to age and 
body size) or dissection, and ectopia lentis allows the unequivocal diagnosis of MFS, 
irrespective of the presence or absence of systemic features, except when there are signs 
indicative of the overlap conditions Shprintzen-Goldberg syndrome (SGS), Loeys-Dietz 
syndrome (LDS) or vascular Ehlers-Danlos syndrome (vEDS).  
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In the absence of a family history, a diagnosis can be reached in one of four scenarios: 
 (1) Aortic diameter at Sinuses of Valsalva Z-score ≥2 AND Ectopia Lentis = MFS* 
 (2) Aortic diameter at Sinuses of Valsalva Z-score ≥2 AND FBN1 mutation = MFS 
 (3) Aortic diameter at Sinuses of Valsalva Z-score ≥2 AND Systemic Score ≥7 = MFS* 
 (4) Ectopia Lentis AND FBN1 mutation known to associate with aortic aneurysm = MFS 
In the presence of a family history, a diagnosis can be reached in one of three scenarios: 
 (5) Ectopia Lentis AND Family History of MFS = MFS 
 (6) Systemic Score ≥7 AND Family History of MFS = MFS* 
 (7) Aortic diameter at Sinuses of Valsalva Z-score ≥2 if older than 20 years or ≥3 if 
younger than 20 years AND Family History of MFS = MFS* 
* Caveat: without discriminating features of SGS, LDS or vEDS AND after TGFBR1/2 
and COL3A1 testing, and collagen biochemistry, if indicated. 
 
Table 1-1: Current diagnostic criteria for MFS (Revised Ghent Nosology, 2010).5 
 
2. The presence of aortic root dilatation (Z-score ≥2) or dissection, and the 
identification of a bona fide FBN1 mutation, is sufficient to establish the diagnosis, even 
when ectopia lentis is absent. Criteria that enhance confidence in the pathogenetic 
potential of FBN1 mutations include: missense mutations that substitute or create 
cysteine residues, alter one of the conserved residues important for calcium binding in 
epidermal growth factor (EGF)-like domains, create a premature termination codon 
(nonsense mutations), delete or insert coding sequence, or disrupt the consensus sequence 
for pre-mRNA splicing. Evidence for pathogenicity of other types of missense mutations 
includes: absence in at least 400 ethnically-matched control chromosomes and co-
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segregation with disease in the family, or de-novo occurrence in a sporadic case (with 
confirmation of paternity). Definitive evidence of linkage to a predisposing FBN1 
haplotype can substitute for an FBN1 mutation for diagnostic purposes, but this linkage 
analysis requires at least six informative meioses in the patient’s family to confirm the 
MFS-associated FBN1 allele. 
 
 
 Wrist AND thumb sign = 3 (wrist OR thumb sign = 1) 
 Pectus carinatum deformity = 2 (pectus excavatum or chest asymmetry = 1) 
 Hindfoot deformity = 2 (pes planus = 1) 
 Pneumothorax = 2 
 Dural ectasia = 2 
 Protrusio acetabuli = 2 
 Reduced US/LS AND increased arm/height AND no severe scoliosis = 1 
 Scoliosis or thoracolumbar kyphosis = 1 
 Reduced elbow extension = 1 
 Skin striae = 1 
 Myopia >3 diopters = 1 
 Mitral valve prolapse (all types) = 1 
 Facial features (3/5) = 1 (dolichocephaly, enophthalmos, downslanting palpebral 
fissures, malar hypoplasia, retrognathia) 
 Maximum: 20; ≥7 indicates systemic disease. US/LS = upper segment/ lower segment. 
 
Table 1-2: Systemic feature scoring in MFS (Revised Ghent Nosology, 2010).5 
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3. Where aortic root dilatation (Z-score ≥2) or dissection is present but ectopia 
lentis is absent and the FBN1 status is either unknown or negative, a diagnosis of MFS is 
confirmed by the presence of sufficient systemic findings (≥7 points; see Table 1-2). 
However, features suggestive of SGS, LDS or vEDS must be excluded and appropriate 
alternative genetic testing (for mutations in TGFBR1/2, COL3A1 and other newly-
discovered genes, as well as collagen biochemistry) should be performed. 
4. In the presence of ectopia lentis but the absence of aortic root 
dilatation/dissection, the identification of an FBN1 mutation previously associated with 
aortic disease is sufficient to make the diagnosis of MFS. If the FBN1 mutation is not 
unequivocally associated with cardiovascular disease in either a related or unrelated 
proband, the patient should be classified as ‘ectopia lentis syndrome.’   
In a patient with a positive family history of MFS (where a family member has 
been independently diagnosed using the above criteria), the diagnosis can be established: 
1. In the presence of ectopia lentis. 
2. With a systemic score ≥7 points (as per Table 1-2). 
3. In the presence of aortic root dilatation (Z-score ≥2 in individuals ≥20 years 
old, or Z-score ≥3 in individuals <20 years old).  
In the case of scenarios 2 and 3 (i.e. a systemic score ≥7 or aortic root dilatation), features 
suggestive of SGS, LDS or vEDS must again be excluded and appropriate alternative 
genetic testing should be performed (as mentioned previously). 
Special consideration should be given to young individuals (<20 years old) 
without a positive family history, who may not fit into one of these four scenarios. In the 
absence of an FBN1 mutation, if they have insufficient systemic features (<7) and/or 
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borderline aortic root measurements (Z-score <3), the term ‘non-specific connective 
tissue disorder’ should be used until later echocardiographic evaluation shows aortic root 
dilation (Z-score ≥3). If an FBN1 mutation is identified in a sporadic or familial case, but 
aortic root measurements are still below a Z-score of 3, the term ‘potential MFS’ should 
be used until the aorta reaches threshold. Neonatal MFS is not considered as a separate 
category, but rather represents the severe end of the disease spectrum.  
In adults, there are 3 main alternative diagnoses (Table 1-3): ectopia lentis 
syndrome (ELS), MASS phenotype (myopia, mitral valve prolapse (MVP), borderline 
(Z<2) aortic root enlargement, skin and skeletal findings), and MVP syndrome. Finally, 
some patients remain difficult to classify due to phenotypic overlap with other 
syndromes, the evolving nature of our understanding of connective tissue diseases, the 
absence of a mutation after screening of appropriate genes, and/or divergence between 
phenotype and genotype. However, these patients should be uncommon and will 
hopefully benefit from better definition of still unrecognized phenotypes in the future. 
 
In the absence of a family history of MFS, alternative diagnoses to MFS include: 
 (1) Ectopia Lentis +/- Systemic Score AND FBN1 mutation not known to associate with 
aortic aneurysm or no FBN1 mutation = Ectopia Lentis syndrome 
 (2) Aortic diameter at Sinuses of Valsalva Z-score <2 AND Systemic Score ≥5 (with at 
least one skeletal feature) without Ectopia Lentis = MASS phenotype 
 (3) Mitral Valve Prolapse AND Aortic diameter at Sinuses of Valsalva Z-score <2 AND 
Systemic Score <5 without Ectopia Lentis = Mitral Valve Prolapse syndrome 
 
Table 1-3: Current criteria for alternative diagnoses to MFS (Revised Ghent Nosology, 2010).5 
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Clinical Features of Marfan Syndrome 
Cardiovascular Manifestations 
Mitral valve prolapse (MVP), due to redundancy of the valve tissue, enlargement 
of the valve annulus, and elongation of the chordae tendineae, is the most common 
manifestation of MFS in childhood, and its progression to severe mitral regurgitation is 
the most frequent indication for cardiovascular surgery before age 10 years.6,7,8 While 
MVP is common in the general population (2 to 3 percent of young adults) and in other 
connective tissue disorders; up to two-thirds of people with MFS eventually develop it.9 
Left ventricular enlargement secondary to aortic regurgitation or intrinsic cardiac failure 
can increase the tension on the chordae and mitigate MVP.10 Tricuspid valve prolapse is 
also common, but is of far less clinical importance. Histopathology of the atrioventricular 
valves shows myxomatous degeneration, with thickening, lengthening and excessive 
accumulation of proteoglycan in the valves.11 
Many MFS patients incur progressive dilatation of the proximal aorta, as well as 
the main pulmonary artery, with onset frequently in utero.12,13 These manifestations are 
very important for both the diagnosis and prognosis of the disorder. Transthoracic 
echocardiography is the method of choice for both identification and monitoring of aortic 
root dilatation. Since aortic dilatation is gradual, and vessel caliber naturally increases as 
a result of physiological growth during childhood and adolescence, use of growth curves 
that normalize aortic diameter to body surface area is essential.14,15,16 Proximal aortic 
dilatation occurs in association with elastic fiber degeneration in the aortic media.85,17 
Aortic dissection is currently the leading cause of death in MFS. About 90 percent 
of dissections begin with a tear in the intima just above the sinotubular junction (type A 
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dissection) and then progress distally to involve the entire aorta. Retrograde dissection 
with bleeding into the pericardial sac accounts for most acute mortality. About 10 percent 
of dissections begin in the distal aorta (type B dissection), usually in the proximal 
descending thoracic aorta. Predisposition to dissection appears to track in families, 
suggesting that different mutations in FBN1 might predispose to dissection.18,19,20 
Dilatation of the proximal aorta also leads to stretching of the aortic valve commissures, 
with resultant aortic regurgitation (AR) during diastole. This can be detected by Doppler 
echocardiography prior to the onset of an audible murmur. Early detection is critical, as 
AR can cause left-ventricular enlargement and failure. In fact, before the era of effective 
cardiovascular surgery, AR was a common cause of death in MFS.21 The larger the aortic 
root diameter, the greater the likelihood of both AR and aortic dissection.22,23,24,25 While 
mild pulmonary valve regurgitation is common, serious complications resulting from 
pulmonary dilatation are rare.26 
In terms of other components of the cardiovascular system, predisposition to 
abdominal aortic aneurysm is present but does not appear to be strong; this needs to be 
re-evaluated as MFS patients are only now beginning to live to an age at which such 
aneurysms typically occur in the general population.27,28 Dilatation and dissection of 
other elastic arteries has been reported in MFS, but the risk of occurrence is low in any 
individual patient.29,30,31,32,33,34 Some people with MFS are prone to dysrhythmia, often in 
association with MVP.35 Primary myocardial dysfunction, with a course similar to 




Lens dislocation from the center of the pupil (ectopia lentis) in the absence of 
trauma, is the ocular hallmark of MFS, and is present in approximately 50 to 60 percent 
of patients.37,38 In MFS, the microfibril-containing zonules, which extend from the limbus 
of the lens to the ciliary body, become elongated and can eventually break. Lens 
displacement in MFS is often upward, may be congenital, and can progress during 
periods of somatic growth. Iridodonesis (fluttering of the iris) when the eye 
accommodates is a useful bedside indicator of lens dislocation, but may not be present in 
subtle ectopia lentis. A slit-lamp examination after maximal pupillary dilatation is an 
essential part of the diagnostic examination. However, due to hypoplasia of the ciliary 
muscle, pupillary dilatation with the usual mydriatic agents is often suboptimal. 
The cornea is often flatter than normal in MFS, as measured by keratometry,39 
although laser correction of the cornea (e.g. PRK or LASIK) should be avoided due to the 
other ocular issues. Despite the flattening of the cornea, myopia (near-sightedness) due to 
axial elongation of the globe occurs, and is the most common ocular feature (70-80% of 
patients). This increased axial length increases the risk of spontaneous retinal detachment 
in MFS patients.40 Extirpation of the lens also increases the risk of retinal detachment, but 
newer surgical techniques (including artificial lenses) have mitigated this issue. An 
increased incidence of strabismus,41 along with early-onset glaucoma and cataract 
formation,42 are becoming more apparent as patients live longer. Failure to detect and 
correct abnormal visual acuity (from any cause) in young children with MFS can result in 
persistent amblyopia (irreversible loss of normal vision), and therefore early diagnosis 




At any age, people with MFS are generally taller than age- and gender-matched 
unaffected family members; while this often translates to being tall for the general 
population, this is not always the case. Their tall stature is due to overgrowth of the long 
bones, resulting in disproportionately long legs, arms and digits, termed 
dolichostenomelia. This results in a decreased upper-to-lower segment ratio (US/LS),43 
and an increased arm-span to height ratio.44,45  Tubular bone overgrowth can lead to 
deformity of the anterior chest,46,47 due to the ribs either pushing the sternum inwards 
(pectus excavatum), outwards (pectus carinatum) or inwards on one side and outwards on 
the other side (asymmetric pectus deformity). While pectus excavatum is common in 
MFS, some component of pectus carinatum has higher specificity for this diagnosis. The 
pathogenesis of bone overgrowth in MFS is unclear, although fibrillin-1 is present in both 
the perichondrium and periosteum. 
The skull is often elongated (dolichocephaly), the face long and narrow, the palate 
narrow and highly arched, the mandible underdeveloped (retrognathism), and the teeth 
crowded.48 Lateral curvature of the spine (scoliosis) occurs in more than half of people 
with MFS, tends to worsen during periods of rapid growth,49,50,51,52,53 and often develops 
in young patients.54 The spine normally consists of a cervical lordosis, an upper thoracic 
kyphosis, and a lumbar lordosis; any of these can be reversed, reduced, or accentuated in 
MFS. Ligamentous laxity, generalized joint hypermobility and joint pain are common in 
MFS,55,56 especially of the digits, elbows, knees (genu recurvatum) and feet (pes planus). 
Joint dislocations are uncommon, although the incidence of spondylolisthesis and 
congenital hip dislocation are increased in MFS. 56,57,58,59,60 Paradoxically, congenital 
11 
 
joint contractures are also common in MFS (especially of the elbows and fingers), and 
hammer-toe deformities can develop. Another skeletal problem that develops with age is 
erosion of one or both acetabulae (protrusio acetabuli).61,62,63,64,65 In part, this tendency 
may reflect an underlying predisposition to osteoporosis.66,67,68,69 With improved survival 
from cardiovascular complications, degenerative skeletal problems, such as osteoarthritis, 
osteoporosis, protrusio acetabula, and joint laxity are becoming more apparent in patients. 
Pulmonary Manifestations 
Spontaneous pneumothorax, due to rupture of an apical bleb in the lung, occurs in 
approximately 5-10 percent of MFS patients, most commonly in adolescence.70,71,72, 73 
Some children with severe MFS have cystic lung disease,74 and adult patients appear to 
be more prone to emphysematous changes,75,76,77 particularly if they smoke. While the 
high proportion of elastic tissue in the lung would suggest prominent pulmonary 
involvement in MFS,115, 116 dynamic lung function seems surprisingly well preserved. By 
contrast, the combination of pectus excavatum and thoracic vertebral deformity can 
produce severe restrictive deficits. 117, 78 Obstructive sleep apnea (OSA) may be more 
common in MFS due to laxity of the hypopharyngeal tissue, retrognathia or both.79,80,81 
Integument Manifestations 
The dura consists primarily of connective tissue (and contains fibrillin-1). It 
stretches in response to normal cerebrospinal fluid (CSF) pressure, with upright posture 
exerting maximal force in the lumbosacral region. In MFS, the apparently weakened dura 
fails to prevent this pressure from eroding the adjacent bone of the vertebral bodies. This 
not only increases the size of the neural canal (dural ectasia),82,83,84 but dura containing 
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CSF also erodes the neural foramina and may protrude into the pelvis, in the form of 
arachnoid cysts or anterior meningoceles.85,86,87,88,89 Since spinal nerve roots usually 
course over these cysts, pain and neurological abnormalities in the distribution of the 
lower lumbar and sacral nerve roots can occur in MFS.90 Furthermore, in women with 
MFS, care should be taken to avoid misinterpreting these cysts as ovarian in origin.  
Hernias of various types are more common in MFS. Inguinal hernias can occur in 
infancy or at any other time, and tend to reoccur after standard surgical repair, suggesting 
a potential benefit for the use of a reinforcing mesh at the time of initial operation. 
Surgical incisional hernias frequently occur, as do congenital diaphragmatic hernias.91,92 
The most characteristic skin manifestation of MFS is stretch marks (striae 
atrophicae), which occur in areas of the body that do not usually possess them.93,94 They 
tend to begin in early adolescence over the thighs, shoulders, lumbar area, back and 
breasts. Rather than fading as adolescent stretch marks often do, in MFS they change 
from being violaceous to depigmented and more extensive. Abdominal stretch marks in 
pregnancy (striae gravidarum) can be very apparent. For the most part, MFS patients’ 
skin is not unusually fragile, so skin wounds do not typically require greater attention. 
Unusually thin or translucent skin, or a strong predisposition for dystrophic scars or easy 
bruising should prompt consideration of alternative diagnoses (e.g. LDS or vEDS).  
Other Manifestations 
Skeletal muscle is underdeveloped in some people with MFS, and can leave 
patients with a somewhat ‘myotonic’ facial appearance and downward sloping shoulders. 
MFS tends to be associated with an impaired ability to initiate and sustain muscle 
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hypertrophy, despite adequate nutrition and exercise. Subcutaneous adipose tissue is also 
underdeveloped in MFS. This feature, especially when coupled with muscular 
hypoplasia, accounts for the asthenic appearance of some patients, especially children 
with severe disease. As people with MFS age, adiposity does increase, particularly in the 
truncal region. Occasionally, people with MFS have cystic areas in the liver, kidneys, or 
both; whether these are pleiotropic manifestations of the disease remains unclear. 
Learning difficulties have been described in MFS, although this appears to associate with 
attention deficit hyperactivity and verbal-performance discrepancies,95,96 rather than 
issues with native intelligence.135  As can be expected with any young person that has an 
unusual appearance, chronic health problems or limitations on activity, difficulties with 
psychosocial coping can arise,97 but are certainly not unique to MFS. 
Prognosis and Life Expectancy 
A retrospective review of causes of death in MFS, performed before medical and 
surgical therapy had any effect, showed an average age of death in the fourth or fifth 
decade of life, with some severely affected children dying much younger.44 Most patients 
died from complications of aortic regurgitation or aortic dissection. Following the 
introduction of sensitive screening methods (i.e. echocardiography) and effective aortic 
replacement surgery, people with MFS can now have near-normal life expectancy, 
particularly those who underwent aortic root surgery after 1980. However, there is still 
much associated morbidity, placing both physical and mental stresses on patients and 
their families, particularly during adolescence. Awareness of these issues and referral for 
support services may facilitate a more positive perspective toward the condition.  
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Management of Marfan Syndrome 
 
The diagnosis of Marfan syndrome requires a multidisciplinary assessment that 
generally includes a geneticist for general assessment and anthropomorphic 
measurements, an ophthalmologist for slit-lamp examination, and a cardiologist for 
cardiovascular imaging. After establishing the clinical diagnosis, management focuses on 
the prevention of complications and genetic counseling. In view of the potential 
complexity of management required by some individuals, referral to a multidisciplinary 
center with experience in MFS is advisable. The primary care physician should work in 
concert with the patient’s personal medical team (subspecialists) to coordinate a rational 
approach to the monitoring and treatment of potential problems. Management falls into 
several categories: lifestyle modifications; management of the cardiovascular, ocular, and 
skeletal systems; endocarditis prophylaxis; and genetic counseling. 
Lifestyle modifications 
Exercise: Due primarily to the risk of acute aortic dissection, patients should be 
counselled not to engage in contact sports, competitive athletics, or isometric exercise. 
However, most patients should be encouraged to remain active with aerobic activities 
performed in moderation. This may improve neuromuscular tone in infancy, and promote 
skeletal, cardiovascular, and psychosocial health in the long term.  
Pregnancy: For MFS patients who become pregnant, genetic counseling should be 
undertaken. Prospective parents should be informed of the 50% risk that offspring will 
inherit a genetic predisposition to the disorder. Before current standards for surgical 
repair of the aortic root, early experience indicated a high risk of aortic dissection during 
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pregnancy.98 More recent analyses have indicated that the risk of aortic enlargement is 
related to the size of the aortic root before pregnancy, and in the setting of an aortic root 
size less than 4cm, the risk of pregnancy is low.99,100 Importantly, the risk of pregnancy-
associated aortic dissection and death extends into the first few weeks post-partum. If 
systemic anticoagulation with warfarin during pregnancy in the setting of a mechanical 
prosthetic valve is required, it is associated with an increased risk of fetal demise and 
warfarin embryopathy.101 Low molecular weight heparin, given subcutaneously during 
pregnancy, seems safer than warfarin, as it does not cross the placenta, although it is 
expensive, can result in heparin-induced thrombocytopenia, and might not prevent 
prosthetic valve thrombosis.102,103,104 Close monitoring by an obstetrician and a 
cardiologist is mandatory.  
Monitoring of the cardiovascular system 
Routine monitoring of aortic growth is essential to decrease the risk of aortic 
dissection. Patients should have annual assessment by transthoracic echocardiography of 
the aortic root, sinotubular junction, and ascending aorta. Both the absolute size of the 
aorta in its greatest diameter and its rate of growth should be monitored to allow surgical 
intervention to be planned, if necessary. At times, technical difficulties limit views of the 
proximal aorta, especially in patients with significant pectus deformity of the sternum. In 
such cases, CT or MR angiography are suitable alternatives. More frequent imaging is 
indicated if the aortic size is approaching a threshold for surgery or if rapid growth is 
observed. Routine imaging of the entire aorta should also be performed in all patients 
after aortic root surgery or in patients who are known to have enlargement or dissection 
of the transverse or descending aorta. 
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Medical management of the cardiovascular system 
β-adrenergic receptor blockade to delay or prevent aortic aneurysm progression 
and/or dissection has been the standard of care in MFS for nearly 40 years, based on the 
theory that these agents decrease proximal aortic shear stress by lowering blood pressure. 
β-blockers are probably beneficial due to both their negative inotropic and negative 
chronotropic effects. Although small, most published studies have shown benefit with β-
blocker therapy in MFS, including in children.105,106 The only randomised trial assessing 
the effect of β-blockers in MFS found the normalized rate of aortic dilatation to be lower 
in propranolol-treated patients than in controls. Furthermore, fewer patients treated with 
propranolol reached a primary clinical endpoint of aortic regurgitation, aortic dissection, 
cardiovascular surgery, congestive heart failure, or death.107  
A more recent trial compared treatment with a β-blocker (propranolol or atenolol) 
to treatment with the angiotensin converting enzyme (ACE) inhibitor enalapril. Patients 
were not randomized, the β-blocker dose was not titrated to physiological response, and 
aortic change did not seem to be normalized to body size. Although benefit was shown to 
be greater in those patients treated with enalapril, most enalapril-treated patients were 
either newly-enrolled or had discontinued β-blockers owing to intolerance.108 Whether 
this presented a bias, either due to low motivation to continue therapy, or due to the 
inclusion of individuals in the ACE inhibitor arm who were never destined to develop 
aortic enlargement, remains unknown. In practice, the dose of β-blocker needed to 
achieve a therapeutic response is highly variable and is not predicted by body weight or 
age; hence failure to titrate the β-blocker dose represents a major limitation of the study.  
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Around 10–20% of patients with MFS are intolerant of β-blockers. Reasons 
include asthma, depression, and fatigue. Among such individuals, use of calcium channel 
blockers (CCBs) has been considered on the basis of a report showing that such treatment 
can slow the rate of aortic growth in MFS, although the trial was non-randomised and 
uncontrolled. At this time there is insufficient evidence for either the efficacy or safety of 
CCBs in MFS to support their routine use. There is also more recent evidence to suggest 
that angiotensin receptor blockers (ARBs) may have significant therapeutic efficacy in 
both mice and humans with MFS, which will be discussed in more detail in later 
chapters. Among the trials that have assessed the use of drug therapy for aortic aneurysm 
in MFS, it is important to note that aortic growth is not stopped or reversed, but is simply 
slowed by treatment. Thus, in the setting of aortic enlargement, despite treatment with 
pharmacological agents to slow the rate of aortic growth, one should remain vigilant for 
further aortic enlargement with at least yearly measures of aortic dimensions.  
Surgical intervention of the cardiovascular system 
The rate of acute aortic dissection is directly proportional to the maximum 
diameter of the aorta. Elective surgery to repair the aortic root is typically recommended 
in adults when the maximum aortic diameter exceeds 5cm,109,110 although earlier surgical 
intervention is recommended for individuals with an increase in aortic diameter 
exceeding 1cm/year or with a family history of aortic dissection at a size less than 5cm. 
Composite surgical replacement of the aortic root and valve was pioneered in the late 
1960s,111 with various coronary vessel reimplantation modifications suggested over the 
years.112 Due to the risks of thromboembolism and the lifetime requirement of warfarin 
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anticoagulation in patients who have a mechanical prosthetic aortic valve, recent efforts 
have focused on maintaining a native aortic valve (a so-called ‘valve-sparing’ procedure) 
where possible.113,114 To date, no randomised trials of valve replacement versus valve-
sparing surgery have been undertaken, but intermediate-term data appear promising.115 
The approach is particularly attractive for young children or young women who 
anticipate pregnancy. It should be noted that with the advent of valve-sparing procedures, 
the emergence of significant aortic regurgitation represents an additional independent 
threshold for consideration of prophylactic aortic root replacement.  
The mitral valve may also require surgical correction if mitral regurgitation 
becomes severe.116 Valve repair is preferable to replacement because it avoids the need 
for anticoagulation. Interestingly, despite the connective tissue defect in the mitral 
apparatus, valve repairs hold up well in the majority of patients (including children).117 
Life expectancy has improved dramatically following introduction of surgical 
repair of the aorta, with people now living on average into their seventh decade.151, 118 
However, planned surgical intervention is preferable to urgent or emergent care. In 675 
MFS patients who underwent aortic root replacement surgery at ten experienced surgical 
centers across North America and Europe, mortality was 1.5% for elective surgery, 2.6% 
for urgent surgery (within 7 days of surgical consultation), and 11.7% for emergency 
surgery (within 24 hours of surgical consultation).160 People having surgery after a 
dissection do less well, mainly because complications from chronic dissection accrue and 
additional aortic surgery is usually necessary.151, 119 Sometimes the entire aorta may even 




Management of the ocular system 
While ectopia lentis can play a major role in establishing a clinical diagnosis of 
MFS, patients are also at increased risk of retinal detachment, glaucoma, and cataract. 
Myopia (short-sightedness caused by excess elongation of the eyeball) is reported in most 
patients, and may predispose to amblyopia in early childhood. Thus, patients should 
undergo comprehensive yearly assessments by an ophthalmologist, ideally one who has 
expertise in the disorder. Lens dislocation can generally be managed with eyeglasses or 
contact lenses; occasionally, surgical removal of the lens is needed to achieve adequate 
vision. This can be followed by artificial lens implantation (pseudophakia) once growth is 
complete. People with MFS should avoid surgical correction of myopia such as radial 
keratometry due to the high risk of subsequent complications (e.g. globe rupture). 
Management of the skeletal system  
The skeletal manifestations of MFS often require no specific intervention, 
although severe orthopedic issues do require input from a skilled orthopedist. The spine 
should be evaluated at least annually in children and adolescents until growth is complete 
in order to detect scoliosis.121,122,123,124 Bracing should be considered for progressive 
curvature, although it is generally inadequate to manage severe and progressive scoliosis, 
which often requires surgical stabilization once curvature exceeds 40°. Pectus deformity 
is largely a cosmetic issue, although often significant enough to warrant surgery. Good 
cosmetic results for pectus excavatum can generally be achieved with the minimally-
invasive Nuss procedure,125 although continued rib growth will lead to recurrent 
deformity if the procedure is performed too early.126 Many patients with pectus deformity 
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have restrictive lung disease, while surgical intervention can lead to a significant 
improvement in forced vital capacity (FVC), especially in patients older than 11 years of 
age.127 For patients with severe pectus excavatum who also require cardiac surgery, a 
staged process is preferable to a combined approach.128,129,130 Adult height can be reduced 
if hormonal treatment is begun before puberty,131 although no controlled trials of 
hormonal modulation have been reported, and girls tend to be treated much more 
frequently than boys.132,133 
Genetic Counseling  
The heritable nature of MFS makes recurrence risk (genetic) counseling 
mandatory. Approximately 30% of cases are the first affected individuals in their 
families. On average, fathers of these spontaneous cases are 7 to 10 years older than 
fathers in the general population. This paternal age difference suggests that these cases 
represent new mutations, with minimal chance of their other children getting the disease. 
However, due to rare reports of gonadal mosaicism (i.e. a parent having sperm or eggs 
with varying genetic content) in an unaffected parent, the recurrence risk for parents of a 
spontaneous case can be reported as low, but not zero. Recurrence risk counseling is best 




Etiology and Pathogenesis of Marfan Syndrome 
Historical Perspective 
In 1955, McKusick suggested that MFS was likely to be due to defective elastic 
fibers.11 Histopathologic studies demonstrated elastic fiber fragmentation and decreased 
elastin content in both the skin and media of the aorta. 134,192, 134,135,136, 137 Subsequent 
work also documented apparent abnormalities of elastin metabolism in MFS patients, 
including decreased urinary excretion of desmosines, increased elastin solubility, 
decreased desmosine and isodesmosine content of extracted protein, and increased elastin 
susceptibility to digestion by pancreatic elastase.210,138,139,140,141 These results pointed 
towards a decrease in the density and/or quality of elastin crosslinking in MFS. 
Despite early speculation,142 the elastin gene was a poor candidate gene for MFS. 
Most significantly, MFS involves tissues that are devoid of elastin, including the ciliary 
zonules and the skeleton.143 Furthermore, ultrastructural, biochemical and immunological 
analyses identified a component of the elastic fiber that surrounded the amorphous core, 
and had a distinct staining pattern and susceptibility to enzymatic digestion.24,144,145,146 
These so-called microfibrils were 8 to 14nM in diameter and were present in all elastic 
tissues. They were also found in tissues that lacked elastin, including the dermal-
epidermal junction in the skin, tendons, fascia, periosteum, corneal stroma, and blood 
vessel adventitia, in various basement membranes, and in renal glomerular mesangium. 
Of particular note was that the ciliary zonules that hold the lens in place in the eye were 
composed of fibrillar aggregates that showed remarkable ultrastructural and biochemical 
resemblance to elastin-associated microfibrils.147,148  
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Streeten et al. first proposed an etiologic link between microfibrils and MFS, after 
observing that an antibody prepared against sonicated bovine zonules immunolabeled 
both zonular and elastin-associated microfibrils with an identical periodicity.149 
Locus and Gene Identification 
In 1986, Sakai and colleagues first identified fibrillin-1, a 350-kDa glycoprotein 
component of extracellular microfibrils.26 They demonstrated that fibrillin-1 is present in 
microfibrillar aggregates of all tissues affected by MFS, including the vascular wall, 
ciliary zonules, skin, hyaline cartilage, perichondrium, and alveolar wall.150 Subsequent 
immunohistochemical analysis showed that in the vast majority of MFS patient tissues, 
there were diminished amounts of microfibrils in the skin, fibroblast culture or both.27,28 
Examination of fibrillin-1 metabolism in skin fibroblasts cultured from MFS patients 
demonstrated diminished ECM incorporation of fibrillin-1 in about 85 percent of cases,30 
with some showing defects in fibrillin-1 synthesis or secretion.  
In 1991, linkage analysis using anonymous markers mapped the MFS locus to the 
long arm of chromosome 15, allowing a tentative assignment to 15q15-q21.1.32,33 By this 
time, a portion of the cDNA encoding fibrillin-1 had been isolated,36,37 allowing the gene 
to be mapped to a position coincident with the MFS locus at 15q21.1.37–39 Finally, 
mutational analysis of fibrillin-1 cDNA from MFS patients revealed a recurrent de novo 
missense mutation in FBN1 in two unrelated patients.39 With a cumulative lod score in 
excess of 100, linkage demonstrated an absence of locus heterogeneity for the classic 
MFS phenotype.32–35,37,39, 151,152,153 Although subsequent publications reported a second 
locus for MFS on chromosome 3p,154 these analyzed a single kindred in which the 
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segregating phenotype only showed partial overlap with MFS.155 Thus, FBN1 mutations 
appear to be the predominant, if not sole, cause of the classic MFS phenotype. 
Fibrillin-1 Gene and Protein 
The 8616-bp coding sequence of the FBN1 gene is comprised of 65 exons that 
span approximately 200kb of genomic DNA.156,157,158 The presence of three alternatively 
utilized, in-frame exons upstream of the exon containing the putative initiating 
methionine in both human and murine genes generated some ambiguity regarding the site 
of fibrillin-1 translation initiation.231,159 However, the first coding exon of the porcine 
gene was shown to contain an in-frame termination codon upstream of the putative 
initiating methionine.233 In view of the extreme amino acid conservation of fibrillin-1 in 
mammals, these data strongly suggested that the putative initiating methionine was 
indeed the only translation start site of fibrillin-1. 
Fibrillin-1 is a cysteine-rich 350-kDa glycoprotein with a complex modular 
organization that is shared by the fibrillin family of proteins.26,231,232,160 It consists of five 
distinct regions (A to E; Fig.1-1).231,232 Exon 1 encodes a signal peptide, followed by a 
unique, short, basic N-terminal sequence that does not show homology with any other 
identified proteins (region A). The C-terminal sequence encoded by exons 64 and 65 
(region E) is also unique, although a high concentration of basic residues and a sub-
sequence surrounding two cysteines are conserved between fibrillin-1 and fibrillin-
2.231,232,235 Both the N- and C-termini possess propeptide cleavage sites containing the 







Figure 1-1. Domain organization of fibrillin-1, fibrillin-2 and LTBP-1. The character of each domain type 
is shown at the bottom. Fibrillin-1 is divided into 5 regions (A-E). F, furin-like propeptide cleavage sites; 
Neo, regions associated with neonatal presentation of severe disease. The position of an RGD sequence in 
fibrillin-1 is indicated.  
 
Exon 10 encodes region C, which in the case of fibrillin-1 has a high 
concentration of proline residues (38 percent), whilst in fibrillin-2 it is glycine-
rich.231,232,235  The region possesses 10 perfect tandem repeats of PXXP where P is proline 
and X is any residue (commonly also a proline). This structure is common in Src 
homology 3 (SH3) domain ligands, but fibrillin-1 lacks the characteristic positions for 
interspersed and critical R (argine) and L (leucine) residues.166 Rather, this sequence in 
fibrillin-1 appears to form a polyproline II (PPII)-helix, which tend to be found 
connecting major structural parts of a molecule, since their high conformational mobility 
confers flexibility.167 They are frequently located on the surface of proteins where they 
can serve as sites of intermolecular interactions, often linking with other PPII-helices. 
PPII-helices are conserved in protein families and are found in all serine proteinases, 
including neutrophil elastase, an enzyme known to cleave fibrillin-1.242,168 Rotary shadow 
analysis of fibrillin monomers reveals a characteristic bend in this region,224 suggesting 
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that region C contributes to the inherent distensibility of microfibrils.231,232 The region is 
also able and sufficient to induce dimerization of recombinant peptides, suggesting that it 
may have a role in nucleation during microfibrillar assembly.169,170 Finally, the region 
contains sites susceptible to cleavage by matrix metalloproteinases (MMPs), which have 
been implicated in the pathogenesis of MFS.171,172 
Regions B and D comprise the bulk of the protein and are encoded largely by 
exons 2 to 9 and 11 to 63, respectively.232 Both regions possess repeated cysteine-rich 
domains, like those of epidermal growth factor precursor (EGF-like) and latency-
inducing transforming growth factor β-binding proteins (LTBP-like). EGF-like motifs are 
found in many types of proteins, including vitamin K-dependent clotting factors and 
components of the ECM. One consistent feature is the presence of six predictably spaced 
cysteine residues that interact via disulfide linkage (1–3, 2–4, 5–6) to form an antiparallel 
β-pleated sheet.173  
A subset of EGF-like domains, including 43 of the 47 found in fibrillin-1, satisfy 
the consensus for calcium binding (Fig.1-2), and are hence classed as calcium binding 
epidermal growth factor (cbEGF)-like domains. Calcium binding is required to maintain 
the rigid, rod-like structure of tandemly-repeated motifs and to promote protein-protein 
interactions.231,174,175,176,177,178,179,180 However, binding is only possible in the presence of 
a correct domain structure, as dictated by the three intradomain disulfide bonds and a 
number of highly conserved residues that define the consensus sequence (D/N)X(D/N) 
(E/Q)Xn(D*/N*)Xm(Y/F) where n and m are variable and the asterisk indicates potential 
β-hydroxylation (Fig.1-2).181,182 Conserved residues stabilize the calcium binding pocket 
at the N-terminus of an adjacent cbEGF-like domain, by mediating interdomain 
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hydrophobic packing interactions.183,184 Disruption of either domain folding or calcium 
binding has been shown to result in conformational changes and enhanced proteolytic 
degradation of single domains, recombinant peptides or intact monomers, as well as 





Figure 1-2. A representative cbEGF-like domain from fibrillin-1. Residues conserved in this domain type 
are indicated using the single letter amino acid code. Lines indicate disulfide bonds between cysteine 
residues. Shading indicates the residues that comprise the calcium-binding consensus. Residues shown in 
italics (positions 13 and 21) are critical for interdomain hydrophobic packing. Representative mutations in 
FBN1 are shown. Asterisks indicate mutations associated with mild phenotypes. 
 
LTBP-like domains contain eight conserved cysteine residues that pair via 
intramolecular disulfide linkage (1–3, 2–6, 4–7, 5–8).246 While this domain contributes to 
the covalent association between LTBP-1 and the latency-associated propeptide (LAP) of 
TGF-β1 through disulfide bond exchange,247, 248 the ability of the seven homologous 
domains in fibrillin-1 to participate in intermolecular interactions has not yet been shown. 
However, the RGD sequence within the fourth LTBP-like domain of fibrillin-1 has been 
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shown to support cell adhesion through interaction with integrins αvβ3, αvβ6 and 
α5β1.189,190,191  By contrast, little is known about the function of the other conserved 
residues in the LTBP-like domains of fibrillin-1. A third cysteine-rich domain, termed the 
hybrid motif, occurs once in region B and once in region D, and likely manifests fusion 
between LTBP-like and EGF-like motifs during evolution.232 The functional 
characteristics of this domain are yet to be unexplored. 
Microfibril Assembly 
Fibrillin-1 is synthesized in a precursor form which undergoes proteolytic 
cleavage at both the N- and C-termini.236–240 Both processing events occur at multibasic 
sites that resemble the consensus sequence for PACE/furin-like proteases. Current 
evidence suggests that C-terminal cleavage is calcium-dependent and occurs 
intracellularly in a secretory pathway compartment.239 The N-terminal sequence, 
including the proline-rich region of fibrillin-1 and flanking cysteine-rich domains, is 
sufficient to induce dimer formation.244,245 Dimers apparently form intracellularly and are 
stabilized by disulfide linkage.244 Further polymerization occurs in the extracellular 
space, but may be dependent on the formation of intracellular intermediate structures. 
The C-terminal sequence beyond the propeptide cleavage site negatively regulates early 
steps in homopolymerization,236,240 perhaps through direct intramolecular interactions 
with critical N-terminal domains. 
Other posttranslational modifications include extensive glycosylation, beta 
hydroxylation of specific Asn residues within cbEGF-like domains, and calcium 
binding.26,231,192 About one-third of cysteines are in their free sulfhydryl form, and may 
participate in intermolecular interactions. Epitope mapping studies suggest that fibrillin-1 
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monomers self-assemble into macroaggregates, characterized by parallel arrays of 
linearly-extended structures in a head-to-tail orientation.193 Adjacent monomers or 
microfibrillar bundles appear to connect predominantly via disulfide linkage, although 
transglutaminase cross-links have also been observed in tissue extracts.194 
FBN1 Mutations in Marfan Syndrome 
To date, over 1000 different FBN1 mutations have been identified in patients with 
MFS or related phenotypes.40,195,196,197,198 Approximately one quarter are do-novo 
mutations, and there is a paternal age effect in sporadic cases. More than 90 percent of 
mutations are unique to single individuals or families, and the remainder is present in 
only a handful of apparently unrelated probands. The vast majority of patients possess 
heterozygous mutations. Compound heterozygote and homozygote cases have been 
documented and are associated with prenatal of early postnatal lethality.199,200 Virtually 
all pedigrees are autosomal dominant, although rare cases of autosomal recessive 
inheritance have been described. Fried et al. identified 2 girls with MFS, who had non-
consanguineous and unaffected parents that possessed FBN1 mutations.201 The first 
autosomal recessive pedigree to be confirmed molecularly involved 2 affected cousins 
from a consanguineous Turkish family who were homozygous for a R485C mutation. All 
4 healthy parents were heterozygous.202 
All types of FBN1 mutations have been identified in MFS. About 20 percent 
create premature termination codons (PTCs), 10 percent perturb splicing, a small number 
cause small in-frame deletions or insertions, and the remainder (about 70 percent) causes 
missense substitutions. The majority of missense mutations (about 80 percent) occur 
within the 47 tandemly repeated EGF-like domains of fibrillin-1.256,257 Beyond the few 
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residues in each EGF-like domain that are known to have functional significance, nearly 
all of the intervening residues in human fibrillin-1 are identical in mouse, pig, and 
cow.233,234,203 Many mutations substitute one of the highly conserved cysteine residues or 
create cysteine residues within the calcium-binding consensus sequence, or residues 
important for interdomain hydrophobic packing interactions.40,252,270–273 If not a cysteine, 
mutations in EGF-like domains typically involve proline or glycine residues, changes to 
which have either been predicted or shown to alter protein folding and stability.252,262,204 
With few exceptions, missense mutations that cause MFS, but occur outside cbEGF-like 
domains, also tend to involve cysteine, proline, or glycine residues.  
FBN1 mutation detection in MFS is an extremely inefficient process, leading 
some to infer locus heterogeneity. However, it is difficult to reconcile this hypothesis 
with extensive linkage evidence for a single predominant locus at a map position 
coincident with FBN1.32–35,37,39,225,226–228 Due to the varying clinical presentations and 
screening techniques, it is difficult to arrive at a meaningful estimate of mutation 
detection sensitivity, which has been documented anywhere between 10 and 95 
percent.272,205,206,207,208 It may be that MFS was overly diagnosed prior to the 
establishment of stringent criteria, hence lowering screening sensitivity.209 In one 
particularly revealing study, the efficiency of screening was directly proportional to the 
size and degree of clinical characterization of the family,282 ranging from 78 percent in 
families with four or more affected members, to 17 percent if only one affected member 
was analyzed. Thus studies that rely on historic and/or incomplete clinical data may 
include phenotypes other than MFS, and hence artificially underestimate the sensitivity of 
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mutation identification. Mutations or rearrangements in non-coding sequence may also 
contribute, although locus heterogeneity still cannot be definitively excluded. 
There is conflicting evidence as to whether the FBN1 mutations in MFS operate 
via a dominant negative or haploinsufficient mechanism of action. On the one hand, a 
dominant negative mechanism is inferred by an autosomal dominant mode of inheritance, 
and the pre-requisite multimerization of fibrillin-1 monomers to form microfibrils. This is 
supported by immunohistochemical analysis and biochemical characterization of cultured 
patient dermal fibroblasts, which in most cases display a dramatic reduction of 
extracellular fibrillin-1, far below the 50 percent level that would be expected in a 
haploinsufficiency model.28,30,210,211,212 Similarly, individuals harboring a mutation 
(R2726W) that prevents C-terminal propeptide processing of fibrillin-1, where the mutant 
gene product is synthesized and secreted but lacks the ability to interact with wild-type 
protein derived from the normal allele, have been reported to have isolated skeletal 
manifestations.236 However, the skeletal findings were subtle and/or inconsistent among 
mutation carriers in this family, and subsequent reports have documented normal 
phenotypes in unrelated carriers of the same mutation, leaving in question the pathogenic 
potential of this allele in isolation. 
There is evidence that reduced expression of fibrillin-1 (resulting from 
haploinsufficiency for FBN1) may also result in clinically-apparent MFS. First, 
transgenic overexpression of mutant fibrillin-1, in the context of two normal Fbn1 alleles, 
was shown to be insufficient to cause the vascular changes of MFS seen in mice 
heterozygous for a comparable missense mutation (C1039G; of note, mice possess 2 
additional amino acids in exon 10 of the Fbn1 gene compared to humans; hence the 
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‘C1039G’ mouse model actually has a mutation in codon 1041, but is termed C1039G to 
reflect the equivalent human codon).213 Second, mice heterozygous for a null Fbn1 allele 
showed similar alterations in aortic wall architecture as C1039G/+ mice. In addition, the 
transgenic addition of a wild-type allele to C1039G homozygous mice prolonged survival 
in these animals.213 Most informatively there are rare reports of typical MFS (with the 
possible exception of ectopia lentis) in association with deletion of an entire FBN1 
allele.214 Thus a normal complement of fibrillin-1 might be needed to initiate productive 
microfibrillar assembly. Although the haploinsufficiency-imposed reduction in 
microfibrillar abundance may or may not be sufficient in isolation to lead to classic MFS, 
it seems critical to the context within which a dominant negative effect can achieve 
clinical significance. These data suggest that boosting fibrillin-1 expression could be a 
productive therapeutic strategy for the disease, and implicate genetic modifiers in the 
modulation of disease severity.  
In reality, either a dominant negative or a haploinsuffient mechanism of action, or 
both, may be operating in any given scenario. The analysis of mice harboring targeted 
Fbn1 alleles has provided further insight. Homozygosity for a wild-type allele (+/+) is 
associated with a normal microfibrillar matrix and phenotype. Functional 
haploinsufficiency can result from mutant allele-derived protein being unable to interact 
with WT allele-derived fibrillin-1, or following efficient degradation of mutant mRNA 
derived from heterozygous nonsense alleles. Both situations appear to lead to relatively 
mild phenotypes that can include aortic enlargement but typically exclude ectopia 
lentis.236,280,281,215,216 Near-haploinsufficiency, as occurs in mgR/+ or mgΔ/+ mice, is 
associated with either an absent or particularly mild disease phenotype, respectively.217,218  
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The functional loss in patients with missense mutations and classic MFS, resulting 
from a dominant negative interaction, appears to be recapitulated in homozygous mgR 
mice.293 The severe and rapidly progressive phenotype that manifests in neonatal MFS 
patients is presumably caused by alleles with extreme dominant-negative 
activity.280,219,220 This phenotype appears to be recapitulated in mice that are homozygous 
for the mgΔ allele.292 Additional loss of function in humans is seen with the inheritance of 
two mutant FBN1 alleles, leading to either prenatal fetal loss or perinatal lethality.44 An 
equally severe phenotype is seen when mgR and mgΔ alleles occur in compound 
heterozygosity, suggesting that homopolymers of mutant monomers retain more function 
than heteropolymers, and that proper alignment of specific domains in adjacent 
monomers is critical for the assembly or integrity of microfibrils. 
Higher Order Pathogenesis of MFS 
There are several factors that have been proposed to modulate the clinical 
heterogeneity in MFS. At the genetic level, they include: the mutation location; the type 
of mutation; transcriptional efficiency of the mutant and/or normal FBN1 alleles; and the 
possible influence of modifier genes. At the protein level, they include: translational 
efficiency; post-translational modification(s); intracellular degradation, abnormal 
trafficking and/or extracellular degradation of mutant protein. Finally it may be a 





Mutation location: The low rate of recurrent mutations and the high degree of 
intrafamilial clinical variability have limited the identification of clear phenotype-
genotype correlations. One clear exception is the clustering of mutations in exons 24 to 
27 and 31 to 32 that are associated with a severe and rapidly-progressive form of MFS 
that is evident at birth.280,221,222,223 Characteristics of this severe form of MFS include 
cardiovascular complications requiring surgery during childhood, abnormal faces and 
ears, with or without the presence of congenital contractures.224 Interestingly, multiple 
types of mutation are represented in these patients, and many mutations within these 
exons can also cause classic or even mild forms of the disease.40,270,272, 280,225 There 
appears to be no way to predict whether a given mutation in these exons will be 
associated with mild, classic or atypically severe MFS.  
A few mutations that occur within variable loop regions of EGF-like domains are 
associated with very mild forms of disease. Notably, mutation R1170H was identified in 
two families with minor skeletal involvement, with or without mitral valve prolapse, but 
none of the major manifestations of MFS.226,227 Such mutations may allow for the 
deposition of stable microfibrils that have limited function, as there is data to suggest a 
correlation between the degree of reduction in fibrillin-1 deposition, and both disease 
severity and clinical outcome.285 
Mutation type: As a general rule, mutations in exons 24-27 and 31-32 causing the 
in-frame loss or gain of central coding sequence, either through genomic deletions, 
insertions or splicing errors, are associated with more severe disease.40,294 In contrast, 
many mutations that create a PTC, which results in rapid degradation of mutant 
34 
 
transcripts, cause a milder phenotype that may not even meet diagnostic criteria for 
MFS,280, 281, 290, 291  although there are clear exceptions.301,228 This is consistent with a 
dominant-negative contribution to disease severity. 
It also appears that the nature of the substitution in missense mutations is not the 
sole determinant of phenotypic expression. For example, substitution of the highly 
conserved asparagine (N) residue at consensus position 10 in Fig.1-2 can result in classic 
MFS (codons 548, 1893), MFS without eye involvement (codon 2144), or isolated 
ectopia lentis (codon 1173).40,270 Similarly, while substitution of one of the cysteine 
residues in cbEGF-like domains of fibrillin-1 is almost invariably associated with classic 
MFS,300 the severity of the phenotype can vary considerably. 
Interestingly, there is a reported case of unilateral MFS.229 The patient was found 
to possess striking differences in apparent content of microfibrillar fibers by indirect 
immunofluorescence of skin and fibroblast cultures, when multiple homologous samples 
derived from different sides of the patient's body were compared.230 In contrast, no 
differences in apparent content of type III collagen or in the biosynthesis and apparent 
structure of types I and III procollagens were found. HLA types and chromosome 
heteromorphisms were identical in fibroblasts from both sides of the body, eliminating 
the formal possibility of chimerism and suggesting that a postzygotic mutation accounted 
for the asymmetric manifestation of the disorder in this patient. 
Transcriptional efficiency of the mutant FBN1 allele: Singh et al. screened the 
three 5’ alternatively-spliced exons (C, B and A) of the FBN1 gene in 41 patients with 
MFS in which no mutations had been identified in the 65 exons.231 They identified 5’ 
sequence variants in 6 unrelated patients, which included a +1G4A variant at the exon A 
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donor splice site. This lead to a disruption of the donor splice site that is predicted to alter 
the reading frame. Evolutionary conservation and the absence of the variant in controls 
suggested a possible pathogenic role, although no functional studies were performed. 
Analysis of the FBN1 gene in 101 unrelated MFS patients who again had no mutations in 
exons 1 to 65 by standard genetic testing, led to the identification of large deletions in 2 
patients: 26.8 kb & 302.5 kb.232 A negative family history suggested that both arose de 
novo, and both involved putative FBN1 regulatory or promoter regions. A reduction in 
transcription was confirmed by transcript analysis.  
Transcriptional efficiency of the normal FBN1 allele: An FBN1 deletion patient 
(46,XXdel(15)(q15q22.1)) was found to possess fibrillin-1 mRNA and protein levels that 
were significantly higher than expected for a single FBN1 allele, suggesting upregulation 
of transcription of the remaining allele.233 Furthermore, RNA analyses identified a 
variable reduction in total FBN1 transcript (78 to 27%) in 3 related individuals carrying a 
PTC-causing mutation, compared with unaffected control individuals.233 Both pulse-
chase analysis of fibrillin-1 biosynthesis and RNase protection analyses demonstrated 
that these differences were due to variation in the expression of the normal FBN1 allele 
and not nonsense-mediated decay (NMD) of the mutant RNA. This suggests that 
differences in expression from the normal FBN1 allele may also contribute to the clinical 
variability that is seen in MFS. 
Modifier Genes: As previously noted, fibrillin-1 and fibrillin-2 show remarkable 
conservation of domain organization and sequence, and both are integral components of 
microfibrils. Variation in the temporal and spatial pattern of expression of the two 
proteins, suggests that they contribute to distinct microfibrillar beds.235,234 As a general 
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rule, fibrillin-2 expression occurs earlier in development and concentrates in elastic fiber-
rich tissues at the onset of elastogenesis, while fibrillin-1 expression is seen somewhat 
later in morphogenesis, and can be found in both elastic and non-elastic tissues. This is 
thought to explain why FBN2 mutations lead to a distinct clinical phenotype (CCA) and 
have never been found to cause or modify the MFS phenotype. 
 
Protein Influences 
Incorrect protein folding: Whiteman et al. studied 3 missense mutations in 
cbEGF13 and found differences between them.235 Both C1117Y and C1129Y mutants, 
expressed as recombinant fragments of fibrillin-1, were retained and accumulated within 
cells. While both underwent core glycosylation, they lacked the complex glycosylation 
observed in secreted fragments from the normal allele. Co-immunoprecipitation showed 
their association with the endoplasmic reticulum (ER) chaperone protein calreticulin. By 
contrast, the G1127S mutant (with its more modest change in EGF domain folding) 
showed the same glycosylation and trafficking profiles as the normal protein. This 
suggests that the G1127S mutation may cause disease through an extracellular dominant-
negative effect, while C1117Y and C1129Y may cause disease either by an intracellular 
dominant-negative effect or haploinsufficiency. It also highlights the heterogeneity that 
can occur even between mutations that are very similar in nature and location. 
Susceptibility to proteolytic degradation: Mutant fibrillin-1 appears to be more 
susceptible to proteolytic degradation than protein derived from a normal FBN1 allele. A 
study of 2 typical mutations in cbEGF modules of fibrillin-1 (N548I and E1073K), when 
expressed in mammalian cells as recombinant proteins, showed a much greater 
susceptibility of the fragments to proteolytic degradation by various proteases compared 
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to normal fibrillin-1.236 Most cleavage sites mapped close to the mutations, indicating 
local structural changes in the mutated cbEGF modules, while other cleavage sites were 
observed at distances beyond the domain containing the mutation, suggesting longer 
range structural effects within tandemly repeated cbEGF modules. In this context, 
plasmin was shown to be a fibrillin-1 degrading enzyme.  
Matrix metalloproteinases (MMPs) are another class of extracellular proteases 
which appear to play a role in MFS. Segura et al. first described an upregulation of both 
MMP2 and MMP9 in the ascending aortas and aortic valves of MFS patients.237 
Subsequent work in the MgR/MgR and C1039G/+ mouse models indicated that both 
mRNA and protein expression of MMP-2 and -9 were increased in the ascending aortas 
of these mice compared to WT littermates, and this was accompanied by severe elastic 
fiber fragmentation.238,239 Furthermore, specific inhibitors of MMP2 and MMP9, or the 
broad-spectrum MMP inhibitor doxycycline, improved elastic fiber integrity and 
prevented aneurysm formation in C1039G/+ mice.240 Finally, in the MgR/MgR mouse 
model, which typically dies by 6 months of age from aortic dissection, treatment with 
doxycycline prolonged survival by reducing the rate of aortic dissection.241 
Interaction with other proteins: A large number of other proteins have either been 
extracted from or immunolocalize to extracellular microfibrils. Collectively referred to as 
microfibril-associated glycoproteins (MAGPs), or later as microfibril-associated proteins 
(MFAPs), their contribution to the structure and function of microfibrils is largely 
unknown. Microfibril-associated protein 2 (MFAP-2), also known as microfibril-
associated glycoprotein 1 (MAGP-1), may mediate interactions between microfibrils and 
other proteins, including elastin and type VI collagen.242,243  Fibulin-2 was found to 
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directly interact with fibrillin-1, but its expression is far more limited than fibrillin-1, is 
dynamic in response to injury, and is often concentrated at the interface between 
microfibrils and the amorphous elastin core.244,245 Despite intensive investigation, no 
mutations in any of these proteins have been associated with MFS, suggesting that their 
contribution to microfibrillar structure and/or function may be minor or redundant. 
Latent transforming growth factor β-binding proteins (LTBPs), of which there 
have been 4 identified (LTBPs 1-4) also associate with and/or form part of microfibrils. 
Like the fibrillins, LTBPs contain a conserved pattern of eight cysteine (8Cys) domains, 
and long tandem arrays of EGF-like domains, some of which include a consensus 
sequence for calcium binding. Human LTBPs 1, 2 and 4 also contain an Arg-Gly-Asp 
(RGD) sequence that potentially promotes interaction with integrin(s). It has become 
evident in recent years that LTBPs are involved in the assembly, secretion and targeting 
of TGFβ to sites at which it is stored and/or activated. LTBPs also appear to exert effects 
independent of those associated with TGFβ, for example as structural matrix proteins.  
Alternative use of promoters produces two major isoforms of LTBP1, defined as 
LTBP1S and LTBP1L. LTBP1L has an N-terminal extension of 346 amino acids which 
LTBP1S does not. The third 8Cys domain of human LTBP1, which includes a putative 
N-glycosylation site, is necessary and sufficient for disulphide bonding to the TGFβ SLC. 
The solution structure of the 8Cys domain suggests that hydrophobic contacts may be 
important for recognition of LAP by LTBP1. To date no human diseases have been 
associated with mutations in LTBP1, although animal models have shed light onto the 
role of the protein. Todorovic et al. assessed the in vivo role of Ltbp1L.246 Ltbp1L-null 
animals die shortly after birth from persistent truncus arteriosus (PTA) and interrupted 
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aortic arch (IAA), due to aberrant cardiac neural crest (CNC) development and decreased 
TGFβ activity. Ltbp1L is also crucial for heart valve development and homeostasis,247 
since Ltbp1L-null mice show two different valve pathologies: hypoplastic endocardial 
cushions in early valvulogenesis, followed by hyperplastic valves in late valvulogenesis. 
This appears to be a result of altered epithelial-to-mesenchymal transition (EMT).321 
LTBP2 has approximately 45% amino acid identity to LTBP1 and 25% identity to 
fibrillin-1, but unlike other LTBP family members it does not bind to latent forms of 
TGFβ. The C-terminal region of LTBP2 competes with LTBP1 for specific binding to the 
N-terminal region of fibrillin-1, but not fibrillin-2, in microfibrils. Mutations in LTBP2 
have been shown to cause eye abnormalities. Ali et al. identified homozygous nonsense 
mutations in LTBP2 in 4 consanguineous Pakistani families and in 8 Gypsy individuals 
with primary congenital glaucoma (PCG).248 Homozygous 1-bp deletions in 2 
consanguineous Iranian families with PCG,249 and homozygosity for an R299X mutation 
in 12 Roma/Gypsy probands with PCG,250 have since been identified. Mutations in 
LTBP2 can also cause an abnormally small ocular lens (microsperophakia). Kumar and 
colleagues identified homozygosity for a frameshift mutation in LTBP2 in 3 affected 
brothers from a consanguineous Indian family, in which PCG was excluded and none had 
any systemic involvement.251 Consistent with these ocular manifestations, LTBP2 
expression has been shown to be high in human eyes, including in the trabecular 
meshwork and ciliary processes (structures thought to be involved in primary congenital 
glaucoma) and in the lens capsule.323 By contrast, mice with a targeted disruption of the 
Ltbp2 gene die between embryonic day 3.5 and 6.5.252 Consistent with this, widespread 
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expression of Ltbp2 has been observed in connective tissues in mice, including in the 
spinal cord, cardiac, skeletal muscle, and renal and seminiferous tubules.322 
Mutations in LTBP3 have been associated with abnormal tooth and skeletal 
development. Noor and colleagues identified a homozygous nonsense mutation in LTBP3 
in 2 affected members of a consanguineous Pakistani family who showed an absence of 
many of their permanent teeth, and an apparent increase in bone density in their spine and 
skull base.253 These findings indicated an important role for LTBP3 in axial skeleton 
development. Consistent with this, mice homozygous for an Ltbp3-null mutation develop 
craniofacial malformations by day 10.254 By 2 months, they have pronounced rounding of 
their cranial vault, extension of the mandible beyond the maxilla, and kyphosis. By 9 
months of age, they also develop osteosclerosis and osteoarthritis, all of which are 
consistent with perturbed TGFβ signaling in the skull and long bones. 
LTBP4 binds in a covalent complex with TGFβ-LAP and associates with the 
ECM. Mutations in LTBP4 have been associated with cutis laxa and severe pulmonary, 
gastrointestinal, and urinary abnormalities (Urban-Rifkin-Davis syndrome).255 All 
mutations identified to date have been located in hybrid or 8cys domains. Similarly, mice 
lacking Ltbp4 develop severe pulmonary emphysema, cardiomyopathy, and colorectal 
cancer.256 These highly tissue-specific abnormalities are associated with a lack of LTBP4 
deposition in the ECM, profound defects in elastic fiber structure, and increased TGFβ 
activity in cultured fibroblasts. This suggests that LTBP4 serves as both a structural 
component of the ECM and as a local regulator of TGFβ signaling. 
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Regulatory Role for Microfibrils 
The formation of microfibrillar aggregates and subsequent deposition of 
amorphous elastin are both temporally and spatially linked. This association led to the 
hypothesis that microfibrils represent an elastin precursor or regulate elastin deposition 
during embryonic development.219,220 The deficiency in elastic fiber number and 
architecture observed in mature vascular lesions in MFS was thought to represent a 
primary failure of elastogenesis. This was believed to result in a structural weakness of 
tissues and a diminished capacity to modulate stress (such as hemodynamic stress created 
by blood passing through the aorta), predisposing to secondary damage. Given that elastic 
fiber formation is virtually complete by early postnatal life, and that fibrillin-1 is not 
expressed after early childhood,219,220,257 there appeared to be very little opportunity to 
intervene in this pathogenic sequence. This boded poorly for the development of 
therapeutic strategies aimed at improving the integrity of tissues such as the aorta. 
However, it became evident that certain manifestations of MFS, such as bone 
overgrowth or skeletal muscle/fat hypoplasia, were difficult to reconcile with a 
pathogenetic model that significantly invoked a structural failure of tissues. Furthermore, 
mutations in FBN1 appeared to have effects independent of their role with elastic fibers. 
This was based on the observation that patients with supravalvar aortic stenosis (SVAS), 
who are hemizygous for the elastin gene, and elastin knockout mice, have a clinical 
phenotype that is quite distinct from MFS.258,259 In addition to the structural role of 
microfibrils, it was becoming increasingly clear that they also play a critical role in the 
regulation of certain cytokines. In doing so, microfibrils could therefore influence cellular 
performance, including proliferation, migration, synthetic repertoire and cell death.260   
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Fibrillin-1 shares a high degree of homology with the latent transforming growth 
factor beta (TGF) binding proteins.261 The TGF cytokines are secreted as large latent 
complexes (LLCs), consisting of TGF, latency-associated peptide (LAP) and one of 
three latent TGF-binding proteins (LTBPs 1, 3 or 4).262 Upon secretion, the LLC is 
sequestered in the ECM. TGF signaling requires release of the mature cytokine, 
interaction with cell-surface receptors, and initiation of downstream signaling 
cascades.263 The degree of homology between the fibrillins and the LTBPs prompted the 
hypothesis that extracellular microfibrils might participate in the regulation of TGF 
activation. It was subsequently shown that fibrillin-1 controls TGF activation,264 and 
that both humans with MFS and fibrillin-1 deficient mice show excess TGF signaling 
(nuclear accumulation of phosphorylated Smad 2 or 3 proteins; pSmad2/3) in the aortic 
root, lung, skeletal muscle and mitral valve.265,266,267 Furthermore, administration of 
TGF-neutralizing antibody (NAb) is able to rescue the phenotypes in all these tissues, in 
association with blunted Smad2/3 activation.  
It was then assessed whether this new regulatory role for microfibrils could lead 
to the identification of any novel therapeutic strategies for MFS. Losartan is an FDA-
approved and clinically-available angiotensin II type 1 receptor (AT1R) blocker (ARB) 
that lowers blood pressure, a desirable effect in individuals with aortic aneurysm. It had 
also been shown to attenuate TGF signaling in certain disease states, such as chronic 
renal failure, by reducing the expression of TGF ligands, receptors, and 
activators.268,269,270,271 C1039G/+ mice at 2 months of age were randomized to receive 
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placebo, propranolol (the current standard of care for MFS) or losartan. The doses of 
propranolol and losartan were titrated to achieve comparable hemodynamic effects.  
Propranolol treatment slowed the rate of aortic growth compared to placebo-
treated animals. However, losartan treatment resulted in a growth rate that was 
significantly less than the propranolol group and indistinguishable from WT mice. 
Furthermore, while propranolol did not achieve any significant reduction in aortic wall 
thickness or architectural change compared to placebo, losartan treatment fully 
normalized both of these parameters. Similar phenotypic rescue has also been observed in 
the lung, mitral valve (our unpublished data) and skeletal muscle.339,340,341 The 
phenotypic rescue achieved by losartan in each of these tissues correlated with a 
reduction in Smad2/3 activation, while there was no apparent difference in Smad2/3 
activation between placebo- and propranolol-treated animals. 
In support of the relevance of all this work to humans, a recent study assessing the 
effect of ARBs in a small cohort of pediatric patients with MFS who had severe aortic 
root enlargement despite previous alternate medical therapy, showed that ARBs 
significantly slowed the rate of aortic root and sinotubular junction dilatation (both of 
which occur in MFS), whereas the distal ascending aorta (which does not normally 
become dilated in MFS) remained unaffected.272 In light of this growing body of 
evidence, a multi-center prospective clinical trial to assess the potential therapeutic 
benefit of ARBs in patients with MFS is underway.273  
Circulating TGF concentrations may represent a novel biomarker for aneurysm 
progression and response to therapy in MFS.274 In C1039G/+ mice, circulating total 
TGF1 concentrations increased with age and were elevated in older untreated mice 
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compared with wild-type littermates. Losartan-treated C1039G/+ mice had lower total 
TGF1 concentrations compared with age-matched C1039G/+ mice treated with placebo, 
and circulating total TGF1 levels were indistinguishable from those of age-matched WT 
mice. A correlation was observed between circulating TGF1 levels and aortic root 
diameter in C1039G/+ and wild-type mice.357 In humans, circulating total TGF1 
concentration was elevated in patients with MFS compared to control individuals. 
Furthermore, MFS patients treated with losartan or β-blocker showed significantly lower 
total TGF1 concentration compared with untreated MFS patients.  
Further evidence for the broad relevance of dysregulated TGF signaling in 
inherited aortic aneurysm conditions came with the identification of the genetic defect in 
a subset of patients previously characterized as having classic MFS, and all individuals 
with Loeys-Dietz syndrome (LDS).275,276 First, Mizuguchi and colleagues described that 
mutations in the gene encoding the type II TGF receptor (TGFBR2) exactly recapitulate 
the classic MFS phenotype.359 While the presentation of these individuals is atypical for 
MFS (e.g., absence of lens dislocation, normal height, lack of dolichostenomelia, high 
rate of non-penetrance), the authors reported heterozygous loss-of-function mutations in 
patients with many features of the disorder.  
It was difficult, however, to reconcile the inferred mechanism of decreased TGF 
signaling with the increase seen in mouse models of MFS.341,277,278 Loeys and colleagues 
went on to show that all patients with LDS are heterozygous for loss-of-function 
mutations in either of the genes encoding the type I or type II TGF receptor (TGFBR1 or 
TGFBR2).358 Furthermore, heterozygosity for these mutations associated with 
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paradoxically enhanced TGF signaling in the aortic wall, as seen in both mice and 
people deficient for fibrillin-1. It remains to be determined whether enhanced TGF 
signaling relates to an intrinsic property of mutant receptor complexes or more indirect 
and nonproductive compensatory mechanisms. 
TGFβ is a multipotent cytokine that inhibits cell proliferation and migration, 
while promoting cellular differentiation and matrix deposition. However, its effects are 
pleiotropic and vary by tissue, and even cell-type. Interestingly, the embryologic origin of 
VSMCs appears to determine their response to TGFβ.279,280,281,282,283 VSMCs of 
mesodermal origin (such as those that populate the proximal aortic root and descending 
aorta) show reduced proliferation and migration in response to TGFβ, as well as a neutral 
response in collagen production. VSMCs derived from neural crest (such as those that 
populate the more distal ascending aorta and transverse arch) show the opposite response, 
with the induction of cellular proliferation, migration and collagen production in response 
to TGFβ. If aberrant activation of TGFβ is indeed involved in MFS, this differential 
response of VSMCs to TGFβ and/or the interface between cells of discordant origin and 
character may help to explain zones of predisposition for aneurysm.284 
Analysis of Stiff Skin Syndrome (SSS) and the tight skin (Tsk) mouse has 
provided further evidence for a role of fibrillin-1 in TGF signaling. SSS is characterized 
by hard, thick skin, usually over the entire body, which limits joint mobility and causes 
flexion contractures. About 40 cases have been reported. It was recently shown that all 
patients sequenced harbor a mutation in exon 37 of FBN1, which encodes the N-terminal 
portion of the fourth (of seven) TGF-binding protein-like domains (N-TB4).285 All of 
the mutations involved the creation or removal of a cysteine residue within a domain type 
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known to be highly dependent on a defined spacing of eight cysteines for proper folding 
via intradomain disulfide linkages.286,287,288 Exon 37 encodes the only RGD sequence in 
fibrillin-1 – a motif that mediates cell-matrix interactions via integrin-binding. This 
correlated with direct evidence for failure of integrin-mediated events when cells were 
plated on recombinant fibrillin-1 fragments harboring SSS mutations.368 
In SSS, there is haphazard labeling of giant and dense chords of stubby 
microfibrils that lack deep dermal projections or apparent basement membrane 
associations seen in normal skin. Furthermore, the dermis in SSS patients is packed 
tightly with abnormally dense collagen bundles. Whereas normal microfibrillar 
projections from the dermo-epidermal junction (DEJ) are devoid of elastin, elastin is 
present in microfibrillar aggregates near the DEJ in SSS, which colocalizes with fibrillin-
1. Since TGFβ is a critical profibrotic cytokine and the predominant influence of 
excessive microfibrillar deposition in SSS could involve excess concentration of TGFβ in 
focal areas of the skin, TGFβ activity was assessed.368 Increased nuclear accumulation of 
pSmad2 and expression of connective tissue growth factor (CTGF), a target of TGFβ 
signaling, were identified in the dermis of SSS patients relative to controls. Hence altered 
cell-matrix interactions in SSS appear to accompany excessive microfibrillar deposition, 
impaired elastogenesis, and increased TGFβ concentration and signaling in the dermis. 
In Tsk mice, homozygosity for this naturally-occurring mutation causes early 
embryonic death. Heterozygosity is associated with progressive tissue fibrosis, 
obstructive lung changes, and autoimmunity.289,290 Tsk mice harbor a large genomic 
duplication in the Fbn1 gene, resulting in the tandem repeat of exons 17 to 40 in the 
mRNA.291,292 The fate of the mutant protein is the subject of ongoing investigation.293,294 
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Early evidence suggested that mutant monomers interact with each other, but lack the 
ability to interact with normal fibrillin-1.376 It is difficult to reconcile the Tsk phenotype 
with the idea that microfibrils are simply structural elements. Interestingly, the 
duplication within the mutant protein spans the region of fibrillin-1 that shows greatest 
homology to the LTBPs.374 In an in-vitro binding assay, TGFβ shows increased affinity 
for the Tsk gene product.377 The internally-duplicated product may result in a gain-of- 
function, which leads to upregulated fibrosis, hence explaining the lack of phenotypic 
overlap between Tsk and MFS mice. In addition, autoantibodies to fibrillin-1 have been 
identified in Tsk mice and in patients with scleroderma and other related connective 
tissue disorders.295,296 The functional significance of this observation remains unknown. 
An enhanced understanding of multiple disease processes has resulted from the 
study of mice with genetic disruptions in the elastin-microfibrillar apparatus. While the 
precise sequence of events mediating the MFS phenotype have yet to be fully elucidated, 
it is important to note that certain VSMC and connective tissue abnormalities observed in 
MFS are also seen in more common disease processes, such as non-syndromic aortic 
aneurysm, hypertension, and atherosclerosis.297,298,299 Elastic fiber calcification and 
degradation, as well as intimal hyperplasia, are also present during the normal aging 
process. It is therefore possible that an acquired loss of elastic matrix-cell attachments, 
and consequent destructive changes, are integral to the pathogenesis of disorders resulting 
from a wide variety of genetic predispositions. 
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Differential Diagnosis of Marfan Syndrome 
 
The list of disorders sharing phenotypic overlap with MFS in one or more organ 
system is extensive.18,19 Establishment of an international nosology for heritable 
connective tissue disorders formalized the diagnostic criteria for discriminating them.284 
Diagnostic distinctions offer prognostic value and influence clinical management. The 
following discussion only describes conditions that show strong phenotypic overlap with 
MFS, or in which mutations in fibrillin-encoding genes have been documented. 
MASS Phenotype and Mitral Valve Prolapse Syndrome 
A common clinical conundrum is determining whether a tall child or adolescent 
with mild skeletal features, myopia but no ectopia lentis, and mitral valve prolapse but no 
definite enlargement of the aortic root has a predisposition for MFS. Because most MFS 
features are age-dependent, longitudinal observation of a patient may result in a more 
confident diagnosis. However, if major features of MFS do not emerge over time, and the 
family history reveals no close relative with the disease, an alternative diagnosis may be 
more appropriate. Faced with such diagnostic challenges in an era before a molecular 
understanding of MFS existed, Glesby and Pyeritz defined MASS ‘phenotype’ (OMIM 
604308),300 which took into account the observed mitral valve prolapse, myopia, aortic 
root dilatation (that is at most borderline and nonprogressive), mild skeletal 
abnormalities, and striae atrophicae. MASS was not termed a ‘syndrome’ because of its 
genetic and pathogenic heterogeneity; however, it clearly forms a phenotypic continuum 
with MFS.80 MASS can be either a highly variable, autosomal dominant trait that runs in 
a family, or it can be sporadic. Although careful prospective studies have not been 
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performed, major aortic and ocular problems rarely develop. Notwithstanding this, these 
patients and families require cardiovascular follow-up.  
Mitral valve prolapse (MVP) is usually associated with valve thickening and a 
tendency to progress to mitral regurgitation. The echocardiographic finding of MVP is 
the most common abnormality of the human heart.301 Up to 5 percent of young adults 
possess MVP (particularly females),302 while the condition and factors that are associated 
with it are legion.303 In the absence of contributory systemic illness or thickening of the 
valve (which would point towards an underlying connective tissue defect), it is often of 
little significance. MVP has long been known to be familial (OMIM 157700), and the 
majority of studies point towards autosomal dominant inheritance with reduced 
penetrance.304 Probands with MVP have also shown a higher proportion than expected 
with long arms, joint hypermobility, pectus excavatum, reduced thoracic kyphosis, and 
spontaneous pneumothorax.305,306 This extended phenotype has been shown to segregate 
in families, leading to the designation ‘MVP syndrome.’  
Etiology and Pathogenesis 
Mutations in FBN1 have been identified in patients with MASS 
phenotype,280,277,278,307 although too few mutations have been described to determine 
whether the mild manifestations are determined by the FBN1 genotype or by the 
influence of modifier genes. MASS phenotype breeds true in large kindreds, and 
mutations causing the phenotype often create PTCs that lead to degradation of the mutant 
transcript, both of which are supportive of the former hypothesis. In addition, individuals 
possessing mutation R1170H in FBN1 present with dolichostenomelia, with or without 
MVP, but no evidence of lens dislocation or aortic root dilatation.301,308 This and similar 
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mutations may cause a relatively modest decrease in fibrillin-1 abundance (above the 
threshold needed to cause MFS) and/or a decrease in some (but not all) fibrillin-1 
functions. In keeping with this hypothesis, one patient who presented with MVP and 
subtle skeletal manifestations was shown to possess somatic mosaicism for a FBN1 
mutation, which when inherited through the germline, caused classic and severe MFS.301   
Familial MVP is a genetically heterogeneous disorder, with linkage to FBN1 in a 
number of large pedigrees excluded. One form of familial myxomatous valvular 
dystrophy was mapped to Xq28,309 and later shown to be caused by mutations in the gene 
encoding filamin-A (FLNA).310 Other loci for familial MVP have also been mapped (e.g. 
16p11.2-p12.1, 13q31.3-q32.1, 11p15.4),311 although causal genes are not yet identified. 
Familial Aortic Aneurysm, Familial Aortic Dissection, BAV with Aneurysm 
The term “annuloaortic ectasia” was coined in the 1950s to describe enlargement 
of the aortic root that is typical of MFS. However it can also be found in isolation 
(OMIM 132900). The term is something of a misnomer, because the aortic annulus rarely 
shows primary enlargement; regurgitation through an otherwise-normal aortic valve is 
actually due to stretching of the commissures at the sinotubular junction following 
aneurysm expansion. Indeed, with the marked decrease in prevalence of rheumatic 
valvular disease, so-called idiopathic annuloaortic ectasia has become the most common 
cause of isolated aortic regurgitation.312 Except in cases of inflammatory or infectious 
aortic disease, the histopathology of the aortic wall invariably shows the same medial 
degeneration that is found in MFS.199,202 
The phenotypes fall into three classes, which have much overlap. Familial 
thoracic aortic aneurysm (FTAA) shows all the hallmarks of proximal aortic disease seen 
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in MFS.313 Whether this phenotypic designation should be used for patients and families 
that show mild skeletal features typical of MFS, such as anterior chest deformity, remains 
controversial. Aortic root dilatation shows autosomal dominant inheritance with marked 
variability,314 and management usually follows that for MFS.  
Familial aortic dissection is characterized by a susceptibility to dissection of the 
proximal aorta with little or no preceding dilatation.315,316,317 This is an extremely rare 
autosomal dominant disorder, in which it can be difficult to identify members of a family 
who have inherited the susceptibility.318 To date, no family possessing familial aortic 
dissection has shown linkage to FBN1.40 The condition needs to be distinguished from the 
vascular form of Ehlers-Danlos syndrome (OMIM 130050). 
An association between coarctation of the aorta, bicuspid aortic valve (BAV), 
aneurysm of the proximal aorta, and aortic dissection has long been recognized.319,320 As 
a result, individuals identified with one or more of these features should also be screened 
for the others. Furthermore, since BAV is one of the defects in the ‘left-sided flow’ 
spectrum of congenital heart abnormalities,321 which shows relatively high recurrence 
risk,322 echocardiographic screening of close relatives, reproductive genetic counseling, 
and fetal echocardiography (since hypoplastic left heart exists in this spectrum) are 
warranted. While it was initially thought that aortic dilatation occurred as a consequence 
of turbulent blood flow through a bicuspid valve, some individuals in affected families 
with no discernible valve dysfunction still develop dilatation, suggesting that there is an 
inherent defect in the aortic wall.323 Unlike MFS, maximal aortic dilatation in BAV with 
aneurysm often occurs in the more distal ascending aorta. Of note, all of the involved 
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structures derive from neural crest. With rare exceptions (see below) affected individuals 
do not show systemic connective tissue findings or widespread vascular disease.   
Valve replacement or removal of an aneurysm does not preclude subsequent 
involvement of other aortic segments (e.g. proximal aortic root), mandating routine 
follow-up. The Ross procedure should be used with caution as it can be problematic to 
place a structurally predisposed segment of the pulmonary artery into the high-pressure 
arterial system. Finally, relatives of probands with BAV and aneurysm can have isolated 
aortic dilatation and dissection. Hence a negative screen for BAV does not eliminate the 
risk for significant vascular disease, and is an indication for indefinite follow-up. 
Etiology and Pathogenesis 
A number of genes have been shown to cause FTAA, including FBN1 (although 
rarely). A G1127S mutation was found in a large family exhibiting late-onset dilatation of 
the aortic root.324 Some individuals in the kindred also showed fragile ocular zonules 
and/or skeletal manifestations, but none met the diagnostic criteria for MFS. This glycine 
residue is conserved in cbEGF-like domains, but has not been implicated in calcium 
binding or hydrophobic interactions. However, NMR analysis demonstrated defective 
domain folding.325 Mutations D1155N and P1837S have also been identified in 
individuals with ascending aortic aneurysm, and skeletal involvement that failed to meet 
diagnostic criteria for MFS.326 No affected family members were available for analysis. 
Interestingly, many mutations in cbEGF-like domains at analogous positions to D1155N 
have been associated with classic MFS. In addition, cells harboring mutations G1127S 
and D1155N show diminished ECM fibrillin-1 deposition by pulse-chase analysis.407,409  
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Mutations in TGFBR2 (and rarely TGFBR1) have also been shown to cause 
FTAA. Mizaguchi and colleagues identified a 3p24.1 chromosomal breakpoint that 
disrupted the TGFBR2 gene in a Japanese individual with ascending aortic aneurysm.359 
The G1524A mutation that the patient possessed caused a synonymous amino acid 
substitution (Q508Q) that led to abnormal splicing. The authors also identified 3 other 
missense mutations in TGFBR2 in 4 unrelated probands. Other mutations in TGFBR2 
have since been identified in 4 unrelated families with familial TAAD who did not 
possess MFS.327 Atypically for this diagnosis, affected members also possessed 
descending aortic disease and aneurysms of other arteries. Strikingly, all 4 mutations 
affected an arginine residue at position 460 in the intracellular domain of TGFBR2, 
suggesting a mutational hot spot for familial TAAD. Despite identical mutations in the 
families, assessment of linked polymorphisms suggested they were not distantly related. 
Structural analysis of the TGFBR2 serine/threonine kinase domain revealed that R460 is 
located within a highly conserved region, and that the amino acid substitutions resulting 
from these mutations appear to interfere with the receptor's ability to transduce signals. 
Downstream effectors of TGFβ have more recently been shown to also cause 
FTAA. Van der Laar et al. described a family who presented with aneurysms, dissections 
and tortuosity throughout the arterial tree, in association with mild craniofacial, skeletal 
and cutaneous anomalies, and early-onset osteoarthritis.328 They mapped the genetic 
locus to chromosome 15q22.2-24.2 and consequently showed that a mutation in SMAD3 
was the cause. The SMAD3 mutation led to increased aortic expression of several key 
players in the TGFβ pathway, including SMAD3 itself. A novel frameshift mutation was 
subsequently described in SMAD3 in a family with autosomal dominant inheritance of 
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TAAD with intracranial and abdominal aortic aneurysms.329 The authors also sequenced 
181 probands with familial TAAD and identified 3 additional SMAD3 mutations in 4 
families that were absent in 2300 controls. Of note, none of these patients possessed any 
osteoarthritic abnormalities. There is also recent data describing likely pathogenic 
variants in SMAD2 in 3 families with arterial aneurysms and dissections.330 
Other recent work identifying genes associated with isolated FTAA has directly 
implicated perturbation of the contractile apparatus in its pathogenesis. Heterozygous 
mutations in MYH11, which encodes smooth muscle myosin heavy chain 11 (MYH11), 
cause ascending aortic aneurysm in association with patent ductus arteriosus and rarely 
bicuspid aortic valve.331,332 By contrast, heterozygous mutations in ACTA2, which 
encodes α-smooth muscle actin (α-SMA), cause a high but incomplete penetrance of 
ascending aortic aneurysm and dissection, with a lower incidence of descending aortic 
aneurysm and dissection, patent ductus arteriosus and bicuspid aortic valve.333 Many 
patients also show a purplish discoloration of the skin in a network pattern, caused by 
altered tone in deep dermal capillaries (livedo reticularis) and pigmented cysts of the iris 
(iris flocculi). VSMCs isolated from patients with MYH11 mutations showed high 
proliferative rates, and upregulation of insulin-like growth factor 1 (IGF-1) signaling and 
components of the angiotensin II signaling cascade.415 More recently, aortic tissue from 
patients with MYH11 mutations was shown to have high VSMC expression of the 
calcium-binding protein S100A12, which is linked to high TGF-β expression and 
signaling in mice.334 
Given that mutations in the two major components of the contractile apparatus in 
VSMCs causes FTAA, an investigation was performed to assess whether mutations in the 
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kinase that controls VSMC contractile function, namely myosin light chain kinase 
(MYLK), also causes the disorder. Wang and colleagues sequenced MYLK in 193 
affected probands from unrelated FTAA families.335 One nonsense and 4 missense 
variants were identified in MYLK that were not present in matched controls. Two 
variants, p.R1480X (c.4438C>T) and p.S1759P (c.5275T>C), segregated with aortic 
dissections in two families. Both families demonstrated a similar phenotype characterized 
by acute aortic dissection with little enlargement of the aorta. The p.R1480X mutation 
leads to a truncated protein lacking the kinase and calmodulin binding domains, and 
p.S1759P alters amino acids in the α-helix of the calmodulin binding sequence, which 
disrupts kinase binding to calmodulin and reduces kinase activity in vitro. Furthermore, 
mice with SMC-specific knockdown of Mylk show medial degeneration of the aorta.  
Recent progress has also been made in understanding the genetic basis of BAV, 
either in isolation or in association with aneurysm. Garg et al. identified a 5 generation 
European-American family with linkage to a single locus on chromosome 9q34-35.336 
Direct sequencing of all coding exons of the NOTCH1 gene revealed a heterozygous C-
to-T transition of nucleotide 3322 that leads to a PTC at position 1108 (p.R1108X). 
Additionally, in a second smaller Hispanic family, a single base pair deletion was 
identified at position 4515 that segregated with aortic valve disease, but was not found in 
1,138 ethnically diverse controls.418 This deletion resulted in a frameshift mutation 
(H1505del) that predicted a severely altered protein containing 74 incorrect amino acids 
at the carboxy terminus of the extracellular domain, followed by a premature stop codon.  
There is also recent evidence to suggest that abnormalities in components of the 
ECM that are involved in proteoglycan synthesis can cause BAV with aneurysm. 
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Baasanjav and colleagues analyzed 5 patients with BAV and aortic root aneurysm, who 
also had recessive joint dislocations and congenital heart defects.337 They identified 
linkage to chromosome 11 and detected a mutation (c.830G>A, p.Arg277Gln) in 
B3GAT3, the gene coding for glucuronosyltransferase-I (GlcAT-I). This enzyme 
catalyzes an initial step in the synthesis of glycosaminoglycan side chains of 
proteoglycans. Patients' cells, as well as recombinant mutant protein, showed reduced 
enzyme activity, while patient fibroblasts demonstrated decreased levels of dermatan 
sulfate, chondroitin sulfate, and heparan sulfate proteoglycans, indicating that the defect 
in linker synthesis affected all three lines of O-glycanated proteoglycans. Further studies 
demonstrated that GlcAT-I resides in the Golgi apparatus and is expressed in all the 
affected tissues (i.e. heart, aorta, and bone). This indicates that reduced GlcAT-I activity 
results in variable combinations of heart malformations, including mitral valve prolapse, 
ventricular septal defect, and BAV.  
Loeys-Dietz Syndrome 
Loeys Dietz Syndrome (LDS) is an aortic aneurysm syndrome that has some 
systemic features of MFS, but other unique features.358 As in MFS, patients with LDS 
show malar hypoplasia, high-arched palate, retrognathia, pectus deformity, scoliosis, joint 
laxity, dural ectasia, and aortic root aneurysms and dissection. Although their fingers tend 
to be long, overgrowth of the long bones can be subtle and is often absent. These patients 
do not show ectopia lentis. Unique features include a high frequency of hypertelorism, 
broad or bifid uvula, arterial tortuosity, and aneurysms with dissection throughout the 
arterial tree. Other less consistent features include blue sclerae, translucent skin, easy 
bruising, craniosynostosis, cleft palate, Chiari type I malformation of the brain, learning 
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disability, congenital heart disease (patent ductus arteriosus, atrial septal defect, 
bicommissural aortic valve), clubfoot deformity and cervical spine instability. 
Approximately 75% of LDS patients present with typical facial dysmorphic 
features (cleft palate, craniosynostosis or hypertelorism) termed LDS type 1. LDS type 2 
was used to describe a subset without major craniofacial involvement (although some 
patients have isolated bifid uvula or hypertelorism), but with cutaneous manifestations 
(velvety and translucent skin, easy bruising and atrophic scars). The current belief is that 
both types of LDS form a clinical continuum.338 The natural history of both types of LDS 
is characterized by aggressive arterial aneurysms and an increased risk of pregnancy-
related complications such as uterine rupture and death. The major source of early 
mortality in LDS is progressive dilatation of the aorta, usually maximal at the level of the 
sinuses of Valsalva, leading to aortic dissection and rupture. The arterial involvement is 
widespread and arterial tortuosity, specifically of the head and neck vessels, is present in 
most individuals with LDS. Important considerations when managing cardiovascular 
features of LDS include the fact that tearing of the aorta often occurs at younger ages and 
smaller diameters than in MFS, vascular disease is not limited to the root of the aorta, and 
blood vessel dilations are amenable to early and aggressive surgical intervention.  
Etiology and Pathogenesis 
LDS is associated with heterozygosity for mutations in either TGFBR1 or 
TGFBR2.358 Most causal mutations are missense mutations in or near the serine-threonine 
kinase domain of either receptor subunit. More than 95% of individuals with features 
strongly suggestive of LDS have a mutation in one of these genes. No differences in 
clinical characteristics are observed between individuals with mutations in TGFBR1 or 
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TGFBR2. Despite evidence that receptors derived from selected mutated alleles cannot 
support TGF signal propagation, tissues derived from affected individuals show 
increased expression of both collagen and connective tissue growth factor, as well as 
nuclear accumulation of pSmad2, indicative of increased TGF signaling.358 The 
mechanism by which this paradoxical increase in TGF signaling occurs is not yet 
known. Patients with heterozygous loss of function mutations in SMAD3 have phenotypic 
overlap with LDS, with or without the potential added manifestation of osteoarthritis. 
Congenital Contractural Arachnodactyly 
In general, congenital contractural arachnodactyly (CCA) is a milder phenotype 
than MFS. It primarily affects the skeleton, with contractures of the digits, elbows and 
knees evident at birth. These joint contractures tend to improve with age, especially with 
physical therapy.339 Long bone elongation and kyphoscoliosis usually develop during 
childhood and then progress. In a small number of individuals, scoliosis has been found 
to be rapidly progressive and resistant to bracing. A distinct anomaly of the external ear, 
namely a ‘crumpling’ of the pinna, is present in most individuals with CCA.15,16,340,341 
Cardiovascular involvement in the form of MVP can occur,20,422,423,342 although the 
presence of aortic dilatation and dissection, or ectopia lentis, is more suggestive of 
MFS.343,344,345 Although its incidence has not been estimated, CCA is much less common 
than MFS. As with MFS, CCA is inherited as an autosomal dominant trait, with a large 
proportion of cases being sporadic, indicative of a new mutation in a parental germ cell. 
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Etiology and Pathogenesis 
All families studied show linkage to the FBN2 gene on chromosome 5.37,226 Thus 
far, all of the mutations associated with CCA occur in a region of the gene bounded by 
exons 24 to 34. Interestingly this corresponds to the region of FBN1 in which mutations 
cause the most severe variant of MFS. As well as location, the types of FBN2 mutations 
seen in CCA are similar to the FBN1 mutations of MFS, including splicing mutations and 
cysteine substitutions in cbEGF-like domains.346,347,348,349,350,351 A number of mutations 
with more nebulous functional consequence also precisely correspond to FBN1 mutations 
causing MFS.432 As only a small number of mutations have been identified, it remain 
unclear whether this clustering of mutations is influenced by selection bias. Alternatively, 
mutations occurring outside of this region may be either phenotypically neutral or result 
in a milder or different phenotype. Interestingly, a fetus with an interstitial deletion of 
chromosome 5 encompassing the FBN2 gene showed certain features of CCA,352 
suggesting that loss-of-function may be an important pathogenetic mechanism. 
Shprintzen-Goldberg Syndrome 
Shprintzen-Goldberg syndrome (SGS) is a rare disorder with features of MFS, 
along with craniosynostosis, characteristic dysmorphic facial features, neonatal hypotonia 
and mental retardation. The phenotype seems heterogeneous, both genetically and 
clinically. The most important clinical features for diagnostic purposes include 
craniosynostosis and exophthalmos, arachnodactyly and camptodactyly, hernias, and 
muscular hypotonia. While the vast majority of early described cases showed 
developmental delay,353,354 it now appears that intelligence can be variable.355 Rarely 
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patients also have cardiovascular involvement characteristic of MFS.356 Greally and 
colleagues suggested that in addition to craniosynostosis and other craniofacial features, 
the presence of dysplasia of the first and second cervical vertebrae, dilatation of the 
lateral ventricles and a Chiari I malformation define SGS.438 By contrast, others have 
suggested that SGS type I should be limited to those patients with mental retardation, 
craniosynostosis, and skeletal changes characteristic of MFS, while SGS type II should 
include those with normal intelligence and aortic root dilatation.357 
Etiology and Pathogenesis 
While most individuals have no affected relatives, autosomal dominant and 
recessive inheritance has been reported.358 Dietz and colleagues reported an FBN1 
mutation in a 7-year-old girl with typical ocular, skeletal, and cardiovascular features of 
MFS, who also had hypotonia, scaphocephaly with craniosynostosis, low-set anomalous 
ears, hyperelastic skin, diastasis recti, and mental retardation.359 She was found to have a 
3668G-A transition in FBN1, resulting in a cys1223-to-tyr substitution (C1223Y) in one 
of the EGF-like domains. More recently, a 3662G-A transition, which results in a 
cys1221-to-tyr (C1221Y) substitution in FBN1, was identified in a Japanese boy with 
clinical findings consistent with SGS.360 To date, no mutations in genes other than FBN1 
have been identified in patients with SGS. 
Weill-Marchesani Syndrome 
Weill-Marchesani syndrome (WMS) is a rare connective tissue disorder first 
described by Weill in 1932,361 and further delineated by Marchesani.362 The patients 
present with short stature, short and stubby hands and feet, and may have stiff joints and 
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thick skin, especially in the hands. Ophthalmic complications include dislocation of 
microspherophakic (i.e. small) lenses, severe myopia, acute and/or chronic glaucoma, and 
cataract. Both autosomal dominant (AD),363,364,365 as well as autosomal recessive 
inheritance (AR) with occasional brachymorphism in heterozygotes,366 have been 
described. In a literature review of 128 cases of WMS, including 57 AR cases, 50 AD 
cases, and 21 sporadic cases, Faivre and colleagues found no significant differences in 
mode of inheritance for short stature, brachydactyly, thick skin, mild mental retardation 
(13% of all patients), myopia, or glaucoma.367 They found some differences for 
microspherophakia (94% in AR, 74% in AD), ectopia lentis (64% in AR, 84% in AD), 
joint limitations (49% in AR, 77% in AD), and cardiac anomalies (39% in AR, 13% in 
AD), while some heterozygotes with AR inheritance presented with milder clinical 
manifestations.449 The authors concluded that there is general clinical homogeneity 
despite genetic heterogeneity in WMS.  
Etiology and Pathogenesis 
Clinical similarities with MFS prompted Wirtz and colleagues to consider FBN1 
as a candidate gene for WMS.447 Interestingly, two large AD WMS families showed 
linkage to chromosome 15q21.1,447 but linkage to this region was excluded for AR 
WMS.368 Faivre and colleagues subsequently reported a 24nt in-frame deletion in exon 
41 (5074_5097del) of FBN1 in a large AD WMS family.369 The deletion involved one of 
the LTBP motifs in fibrillin-1, and cosegregated with disease in the family. 
Immunohistochemical analysis of skin sections of WMS patients showed an apparent 
decrease in fibrillin-1 staining when compared to controls.447 Interestingly, one family 
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has been described in which patients were affected with either MFS or WMS,370 
suggesting that modifiers can influence the clinical expression of selected FBN1 alleles. 
The AR form of WMS appears to be genetically distinct from the AD form. 
Faivre et al. performed a genomewide search in 2 large affected consanguineous families 
of Lebanese and Saudi origin with AR WMS.371 The disease gene was mapped to 
19p13.3-p13.2, with homozygous mutations in the ADAMTS10 gene subsequently being 
identified in these families.372 A total of 3 distinct mutations were identified in the 2 
families and in 1 sporadic WMS case, consisting of 1 nonsense and 2 splice mutations. 
Homozygosity for 2 different missense mutations in ADAMTS10 in 2 consanguineous 
Saudi Arabian families with AR WMS,373 and compound heterozygosity for mutations in 
ADAMTS10 in an 86-year-old man with AR WMS,374 has since been described.  
ADAMTS10 is a member of the large ADAMTS (A Disintegrin-like And 
Metalloproteinase with Thrombospondin type 1 repeats) family of zinc-dependent 
proteases. There are at least 19 ADAMTS enzymes, all of which share the same 
organization, namely a signal sequence, a propeptide domain, a metalloproteinase domain 
containing a zinc-binding active-site motif (similar to that of the ADAM proteases), a 
disintegrin-like domain, a cysteine-rich region, and a variable number of thrombospondin 
type 1 (THBS1) repeats. It is believed the ADAMTS proteins are anchored to the ECM 
through interactions with aggregan or other matrix components by their THBS1 motifs. 
ADAMTS10 differs from other members of the family by the presence of 5 THBS1 
domains and a unique C-terminal PLAC (protease and lacunin) domain. ADAMTS10 
appears to be expressed in skin, fetal chondrocytes, and the fetal and adult heart. 
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A WMS-like syndrome in which affected individuals exhibit key features of 
WMS including lenticular myopia, ectopia lentis, glaucoma, spherophakia, and short 
stature, but do not display brachydactyly or decreased joint flexibility, was recently 
shown to be caused by mutations in the ADAMTS17 gene, located at 15q24.455 In 4 
affected sibs from a consanguineous Saudi Arabian family, homozygosity for a 1-bp 
insertion that fully segregated with the phenotype was found. They also identified a 
homozygous truncating mutation in 2 affected sisters from another Saudi Arabian family, 
and a homozygous splice site mutation in a sporadic case, neither of which was detected 
in 300 ethnically matched controls. Interestingly, another sporadic case (a 36-year-old 
woman with similar features), had no identified mutations in ADAMTS10, ADAMTS17, or 
FBN1, suggesting that there are yet more genetic loci to be identified in WMS.  
Familial Ectopia Lentis 
While the most common cause of ectopia lentis (EL) is trauma,76 the next most 
common cause is MFS. Non-traumatic EL is present in about 65% of MFS patients.375 
Other causes of EL include metabolic disorders with secondary effects on ciliary zonules, 
such as homocystinuria, hyperlysinemia, sulfite oxidase deficiency, and WMS. Isolated 
EL also exists, and can be inherited as a congenital AD, congenital AR, or adult-onset 
dominant trait.376 Finally, EL et pupillae exists as an AR trait (OMIM 225200).377 The 
incidence of congenital EL has been estimated to be about 0.83 per 10,000 live births.76 A 
defined cause is evident in about two-thirds of cases; MFS accounts for two-thirds of 
these, EL et pupillae accounts about 20 percent, and simple dominant EL accounts for 8 
percent. WMS, homocystinuria, and sulfite oxidase deficiency account for a further 1 
percent of cases with a defined cause.  
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Etiology and Pathogenesis 
Linkage to FBN1 has been demonstrated for some forms of dominant EL, 
including families with mild, nonspecific signs of a systemic connective tissue 
disorder.226,378 Some family members also have significant skeletal and skin involvement, 
but no aortic enlargement. One mutation (E2447K) resulted in a lysine to glutamic acid 
substitution in the calcium binding consensus sequence of a highly conserved cbEGF-like 
domain (Fig. 1-2). Interestingly, mutations in the analogous amino acid in other fibrillin-
1 cbEGF-like domains cause typical MFS.40,270,280 
Similar to WMS, the AR form of EL appears to be genetically distinct from the 
AD form. Ahram and colleagues recently identified a homozygous mutation in 
ADAMTSL4 in 15 individuals with AR EL from 4 related sibships in an inbred Jordanian 
family.379 The family showed variable degrees of lens displacement among affected 
members, in combination with deprivation amblyopia, retinal detachment and cataract, 
but no clinical manifestations in any other system. A second study identified a distinct 
ADAMTSL4 mutation in a consanguineous Turkish family affected by isolated EL.380 The 
mutation abolished the splice acceptor site in intron 4, leading to deletion of c.79 to c.344 
of exon 5 and the introduction of a PTC. ADAMTSL4 encodes ADAMTS-like 4, a 
member of the ADAMTS-like family of proteases.381 The protein comprises seven 
thrombospondin type 1 repeat domains, a cysteine-rich module, an ADAMTS-spacer 1 
domain and a PLAC domain.382  
Most recently, in 36 consecutive probands with EL who did not meet diagnostic 
criteria for MFS, causative FBN1 mutations were identified in 23/36 (64%) probands, 
while homozygous or compound heterozygous ADAMTSL4 mutations were identified in 
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6/36 (17%) probands.383 It is important to differentiate between patients with EL caused 
by FBN1 mutations versus those caused by homozygous mutations in ADAMTSL4, for 
both genetic counseling and prenatal diagnostic screening purposes. In patients with 
apparently isolated EL caused by an FBN1 mutation, it is particularly important to rule 
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TGF is secreted from cells as part of a large latent complex that binds to 
extracellular matrix (ECM) proteins including fibrillin-1,384 the deficient gene product in 
Marfan syndrome. Current models posit that ECM sequestration of TGF inhibits its 
activation, thereby limiting its ability to stimulate cell surface receptors TRI and 
TRII.385,386 In canonical signaling, the TRI/II complex phosphorylates receptor-
activated Smad2 and/or Smad3 (to pSmad2 and pSmad3, respectively), leading to 
recruitment of Smad4, translocation to the nucleus, and the transcription of Smad-
dependent genes.387 Increased Smad2/3 activation and increased expression of Smad-
responsive genes has been observed in the lung, skeletal muscle, mitral valve and aortic 
wall in humans and mice with Marfan syndrome.388,389,390,391 Treatment of Marfan mice 
with TGF neutralizing antibody (TGFNAb) ameliorates the phenotype in all these 
tissues, in association with attenuated pSmad2/3 signaling.388,389,390,391 A similar rescue is 
achieved using the angiotensin II type 1 receptor blocker losartan,388,389,390,391 which is 
known to reduce the expression of TGF ligands, receptors and activators.392,393,394 It has 
also been shown that mutations in TRI or II, which lead to a paradoxical increase in 
pSmad2/3 signaling in the aortic wall, cause Loeys-Dietz syndrome, a condition with 
considerable phenotypic overlap to Marfan syndrome, including aortic aneurysm.395,396 
Together these earlier observations suggested that canonical TGF signaling drives 
disease pathogenesis in Marfan syndrome. 
Recent work has shown that TGF also induces other (noncanonical) pathways, 
including the RhoA and mitogen-activated protein kinase (MAPK) cascades, the latter of 
which includes extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) 
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and p38.397,398,399 TGF activates these by phosphorylation to pERK, pJNK and pp38, 
respectively. We wished to assess whether these noncanonical TGF-dependent 
pathways may play a role in Marfan syndrome.  
To address this, we performed Western blot analysis on the aortic root and 
proximal ascending aorta of 12-month old Fbn1C1039G/+ (hereafter called Marfan) mice. 
Compared to wild type (WT) littermates, Marfan mice showed a significant increase in 
activation of Smad2, ERK1/2 and MEK1, the upstream activator of ERK1/2 (p<0.05, 
p<0.001 and p<0.05 respectively; Fig.2-1). In contrast, there was no difference in 
activation of Smad3, or the other MAPKs, JNK1/2 and p38.  
            
 
Fig.2-1. Western blot analysis of the aortic root and proximal ascending aorta of WT and Marfan mice. 
Only Smad2, ERK1/2 and MEK1 are activated in Marfan mice relative to WT littermates. The graphs show 
normalization to β-Actin; the same outcomes were observed with normalization to each total protein.  
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 Interestingly, activation of these proteins only occurs in the aortic root and 
proximal ascending aorta, portions of the aorta that are typically affected in Marfan 
syndrome. By contrast, the descending thoracic aorta, which is not typically affected in 
Marfan mice, did not show any evidence of activation of either canonical (Smad) or non-
canonical (i.e. MAPK) signaling cascades (Fig.2-2). 
                 
Fig.2-2. Western blot analysis of the descending thoracic aorta of WT and Marfan mice. Note that 
activation of both canonical (i.e. Smad2, Smad3) and noncanonical (ERK1/2, JNK1/2) TGFβ-dependent 
signaling cascades is the same in the descending thoracic aortas of WT and Marfan mice.  
 
Since TGFNAb and losartan attenuate aortic root growth in Marfan mice, if 
Smad2 or ERK1/2 are important mediators of aortic disease in Marfan syndrome, one 
would expect their activation to be reduced by these agents. Prior work demonstrated that 
Smad2 activation is decreased by both therapies.390 We now find that compared to 
placebo-treated littermates, Marfan mice treated with either TGFNAb or losartan also 
show a significant reduction in ERK1/2 activation (p<0.01 for both; Fig.2-3).  
70 
 
                      
Fig.2-3. Western blot analysis of WT, as well as placebo-, TGFNAb- and losartan-treated Marfan mice. 
Note the significant reduction in ERK1/2 activation following treatment with either TGFNAb or losartan. 
Plac, placebo; NAb, neutralizing antibody; Los, losartan. 
 
To confirm that ERK1/2 is a driver, rather than simply a marker, of aortic 
aneurysm progression, 2 month-old Marfan mice were treated for 2 months with the 
selective MEK inhibitor RDEA119, also known as refametinib.400 Aortic root size was 
measured by echocardiography at 2 months (baseline prior to treatment) and at 4 months 
of age (Fig.2-4). Aortic root growth was significantly greater in placebo-treated Marfan 
mice, compared to WT littermates (p<0.05). Aortic root growth in RDEA119-treated 
Marfan mice was significantly less than placebo-treated Marfan littermates (p<0.01), and 
indistinguishable from that observed in WT mice (p=0.15). Importantly, RDEA119 
therapy had no significant effect in WT mice (p=0.24), illustrating that inhibition of 
ERK1/2 activation specifically targets Marfan-associated pathological aortic root growth, 
while still allowing for normal physiological growth.  
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Fig.2-4. Aortic root growth in placebo- and RDEA119-treated WT and Marfan mice. Note that RDEA119 
therapy selectively reduced growth in Marfan mice.  
The specificity of RDEA119 was confirmed by Western Blot of the aortic root 
and proximal ascending aorta. Compared with placebo-treated Marfan littermates, 
RDEA119-treated Marfan mice showed a significant reduction in ERK1/2 activation 
(p<0.01), while Smad2, JNK1, p38 and ERK5 activation remained unchanged (Fig.2-5). 
            
Fig.2-5. Western blot analysis of placebo- and RDEA119-treated Marfan mice, showing a selective 
reduction in ERK1/2 activation in RDEA119-treated mice. Plac, placebo; RDEA, RDEA119. 
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This result also illustrates that Smad2 activation in Marfan mice is not ERK1/2-
dependent. Taken together, these data suggest that TGF-mediated ERK1/2 activation 
contributes to aortic aneurysm progression in Marfan mice and that antagonism of this 
pathway may be therapeutically useful in the disorder. 
Since ERK1/2 is a pro-proliferative intracellular mediator, the reduction in aortic 
root growth achieved in Marfan mice could simply have been a result of decreased 
somatic growth of the whole animal. We therefore weighed all mice at the end of the 2 
month trial, and found that RDEA119 therapy did not significantly affect the weight of 
either WT or Marfan mice (Fig.2-6). This supports the conclusion that the reduction in 
growth achieved by RDEA119 in Marfan mice was specific to the aorta, and was not 
simply a manifestation of reduced somatic growth.  
            
Fig.2-6. Weight of placebo- and RDEA119-treated WT (yellow) and Marfan (blue) mice at the end of the 2 
month trial. Note that RDEA119 did not significantly affect somatic growth in either WT or Marfan mice. 
This defines a critical role for noncanonical TGFβ-dependent ERK1/2 activation 
in aneurysm pathogenesis in Marfan mice. It also illustrates that inhibition of ERK1/2 
activation represents a novel therapeutic strategy for Marfan syndrome, and suggests that 
such therapies may find broader application in other aortic aneurysm syndromes.  
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Given that losartan, which selectively blocks the angiotensin-II type 1 receptor 
(AT1R), shows such good therapeutic efficacy in Marfan syndrome, this strongly 
suggests that the angiotensin pathway plays a critical role in mediating disease 
pathogenesis. Angiotensin-II can signal through both its type 1 receptor (AT1R) and its 
type 2 receptor (AT2R). AT1R signaling is known to enhance TGF signaling by 
increasing the expression of TGF ligands, receptors and activators (Fig.2-7),401,402,403  
while losartan’s therapeutic efficacy in preventing aortic aneurysm progression in Marfan 
mice is thought to be due to its ability to block this pathway.  
          
Fig.2-7. Angiotensin signaling and its effect on the TGFβ signaling cascade. Ang-II acts on the AT1R 
receptor, causing increased cellular proliferation, fibrosis and MMP2/9 activity, while decreasing apoptosis. 
Conversely, the AT2R receptor is thought to decrease proliferation, fibrosis and MMP activity, while 
increasing apoptosis. ACEi block the conversion of AngI to AngII, limiting signaling through both AT1R 
and AT2R receptors, whereas ARBs selectively block AT1R. AngI, angiotensin-I; Ang-II, angiotensin-II; 
ACE, angiotensin converting enzyme; ACEi, ACE inhibitor; ARB, angiotensin type 1 receptor blocker; 




The contribution of the AT2R to aortic aneurysm progression remains 
controversial. AT2R signaling can oppose AT1R-mediated enhancement of TGF 
signaling in some cell types and tissues (Fig.2-7).404,405 It can also induce vascular 
smooth muscle cell (VSMC) apoptosis, theoretically contributing to aortic wall damage. 
Apoptosis was observed in cultured cells derived from end-stage aneurysms in people 
with Marfan syndrome,406 but has not been found in early- or intermediate-stage aortic 
wall lesions in Marfan mice.390  
Vascular expression of the AT2R is largely limited to prenatal life, but it may 
continue to be relevant postnatally in the context of certain disease states, as evidenced 
by the acceleration of inflammatory aneurysms in AngII-infused mice treated with an 
AT2R antagonist.407 In contrast, beta-aminopropionitrile monofumarate (BAPN)-induced 
aortic aneurysm and dissection in rats, which is associated with increased expression of 
the AT2R and VSMC apoptosis, can be ameliorated by limiting Ang-II production with 
ACEi, but not by selective AT1R receptor blockade.408  
AT2R signaling has the capacity to attenuate both canonical (Smad-dependent) 
and noncanonical (MAPK) TGF-dependent signaling cascades, most notably ERK1/2, 
in some tissues.409,410 Thus, AT2R signaling can both augment and inhibit the 
pathogenesis of aneurysm in preclinical models, and the mechanistic explanation for the 
discordance is unclear. This has direct clinical relevance, as it leaves open to question the 
relative therapeutic merits of selective AT1R blockade with ARBs versus limiting 
signaling through both AT1R and AT2R with ACEi, despite small trials suggesting that 
either approach has potential in Marfan syndrome.411,412,413 
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To assess the role of the AT2R receptor in Marfan syndrome, we bred mice with a 
disrupted Agtr2 allele (encoding AT2R; AT2KO),414, with Marfan mice. Agtr2 is encoded 
on the X chromosome in humans and mice, and the AT2KO allele associates with loss of 
mRNA and protein expression, as assessed by radioligand binding, in either homozygous 
females or hemizygous males. The AT2KO mice develop normally, with no evidence of 
cardiovascular pathology or early mortality.415   
We followed the progression of aortic root aneurysm by echocardiogram until 
sacrifice of the mice at 12 months (Fig.2-8). There was a small difference in aortic root 
size between WT and AT2KO mice at 2 months (p<0.05), but this was absent thereafter.  
           
Fig.2-8. Mean aortic root diameter (+2SEM) over 12 months in WT, AT2KO, Marfan and AT2KO:Marfan 
mice. Note that AT2KO:Marfan mice had a significantly larger diameter than Marfan mice throughout.  
The aortic root diameter of AT2KO:Marfan mice was larger than that of Marfan mice at 
2 months of age (p<0.001), and this difference was maintained through to 12 months 
(p<0.05). Postnatal aortic root growth over 10 months was not different between Marfan 
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mice with or without AT2 expression (p=0.80). This could reflect postnatal waning of 
AT2R expression, attainment of an absolute threshold of aortic root growth rate in 
AT2KO:Marfan mice, and/or the accelerated death observed in AT2KO:Marfan mice that 
effectively removed the most severely affected animals from later analyses. 
Growth of the more distal ascending aorta over 10 months was significantly 
greater in AT2KO:Marfan mice compared to Marfan littermates (p<0.05), while there 
was no significant difference between WT, AT2KO and Marfan mice (Fig.2-9).  
                      
Fig.2-9. Mean ascending aortic growth (+2SEM) from 2 to 12 months of age. Note the increased rate of 
ascending aortic growth in AT2KO:Marfan mice compared to WT, AT2KO and Marfan littermates. 
Furthermore, 32% of AT2KO:Marfan mice died prior to planned sacrifice, 
compared to 12% of Marfan mice (p<0.01) and 0% of AT2KO or WT mice (Fig.2-10). 
Histological and morphometric analyses of cross sections of the aortic wall were 
performed following death or sacrifice at 12 months (representative images: Fig.2-11).  
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Fig.2-10. Kaplan-Meier survival curve demonstrating an increased rate of death in AT2KO:Marfan mice 
compared to WT, AT2KO and Marfan littermates.  
 
            
 
Fig.2-11. Verhoeff-van Gieson (VVG) staining of the aorta shows diffuse elastic fiber fragmentation and 
wall thickening in Marfan mice, which were all exacerbated in AT2KO:Marfan animals. Scale bar: 50µm. 
 
Marfan mice showed medial thickening, reduced elastin content, and increased 
elastic fiber fragmentation, compared to WT and AT2KO mice, all of which were 
exacerbated in AT2KO:Marfan mice. Of note, the aortas of WT and AT2KO mice did not 
appear to be visually different. 
78 
 
Quantitatively, there was a significant worsening of aortic architecture score in 
Marfan mice compared to WT and AT2KO littermates (p<0.001; Fig.2-12), which was 
again exacerbated in AT2KO:Marfan mice (p<0.001). There was no difference in 
architecture score between WT and AT2KO mice, suggesting that AT2KO specifically 
modulates aortic disease only in the presence of a pre-existing Fbn1 (i.e. Marfan) 
mutation. Therefore the histological changes in the aorta closely paralleled the 
echocardiography findings, supporting the conclusion that AT2R elimination exacerbates 
aortic disease in Marfan mice. 
                     
 
Fig.2-12. Mean aortic wall architecture score (+2SEM) of the proximal ascending aorta in WT, AT2KO, 
Marfan and AT2KO:Marfan mice. Note the greater aortic architecture score in Marfan mice compared to 
WT littermates, and the exacerbation in AT2KO:Marfan animals.  
 
To investigate the mechanism of protection by AT2R signaling, we monitored the 
status of both canonical and noncanonical TGF signaling in WT and Marfan mice that 
either retained or lacked the AT2R. Western blot analysis showed that Smad2 activation 
was significantly greater in the aortic root and proximal ascending aorta of Marfan mice 
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compared to WT controls (p<0.01), but there was no significant difference between 
AT2KO:Marfan and Marfan mice (p=0.30; Fig.2-13).  
        
Fig.2-13. Western blot analysis of ERK1/2 and Smad2 activation in the aortic root and proximal ascending 
aorta. Note that Smad2 activation was increased equally in AT2KO:Marfan and Marfan mice, as compared 
to WT littermates. ERK1/2 activation was significantly increased in Marfan mice when compared to WT 
littermates, and was further increased in AT2KO:Marfan animals.  
           
Fig.2-14. Western blot analysis of pJNK1 and pp38 in the aortic root and proximal ascending aorta. Note 




In contrast, ERK1/2 activation was significantly greater in Marfan mice compared 
to WT littermates (p<0.01), and was further increased in AT2KO:Marfan mice compared 
to Marfan (p<0.01), AT2KO (p<0.01) and WT littermates (p<0.001; Fig.2-13). 
Therefore, ERK1/2 (but not Smad) activation paralelled the observations seen in aortic 
root size and growth in WT, AT2KO, Marfan and AT2KO:Marfan animals. There was no 
increased activation of either JNK1/2 or p38 in AT2KO:Marfan mice, compared to 
Marfan littermates (Fig.2-14). 
To more directly assess the efficacy of ACEi and ARBs in Marfan mice, we 
performed a head-to-head trial. Marfan mice and WT littermates were treated with 
hemodynamically-equivalent doses of either the ACEi enalapril (10-15mg/kg/day) or the 
ARB losartan (40-60 mg/kg/day) from 8 weeks of age (Fig.2-15).416  
           
Fig.2-15. Mean systolic blood pressure (+2SEM) in placebo-, losartan- and enalapril-treated Marfan mice, 
and placebo- and losartan-treated AT2KO:Marfan animals.  
Aortic root growth over 7 months of treatment was significantly greater in 
placebo-treated Marfan mice compared to WT littermates (p<0.01), while losartan led to 
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a significant regression in aortic growth in Marfan mice (p<0.0001), to a rate 
significantly below that of placebo-treated WT littermates (p<0.0001; Fig.2-16). 
Importantly, losartan had no effect in WT littermates (p=0.27). Enalapril had significantly 
less effect than losartan in Marfan mice (p<0.0001), in fact being only marginally better 
than placebo treatment (p<0.05).  
           
Fig.2-16. Mean aortic root growth (+2SEM) over 7 months of treatment with either losartan, enalapril or 
placebo. Note the regression in aortic size observed in losartan-treated Marfan mice and the marginal 
(p<0.05) decrease in growth seen in enalapril-treated Marfan mice.  
 
When assessing aortic architecture, enalapril was found to be no more beneficial 
than placebo in improving aortic architecture score in Marfan mice (p=0.19), while 
losartan was significantly more beneficial than both placebo and enalapril treatment 
(p<0.05 for both; Fig.2-17). Given that the small reduction in aortic root growth in 
Marfan mice achieved by enalapril in this study was comparable to that achieved 
previously by propranolol,390 and neither drug showed any improvement in aortic 
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architecture in Marfan mice, this suggests that enalapril’s small beneficial in-vivo effect 
may well simply have been blood-pressure mediated.  
           
Fig.2-17. Mean aortic wall architecture (+2SEM) at 9 months of age, following 7 months of treatment with 
placebo, losartan or enalapril. Note that enalapril was no more effective than placebo in Marfan mice, but 
significant improvement was seen in losartan-treated animals. 
 
To assess the signaling cascades influenced by ACEi and ARBs in Marfan mice, 
we performed Western blot analyses on the aortic root and proximal ascending aortas of 9 
month old animals. Smad2 activation was significantly greater in Marfan mice compared 
to WT controls (p<0.05), and losartan treatment decreased it in Marfan mice (p<0.05), to 
levels indistinguishable from WT (p=0.31; Fig.2-18). Interestingly, enalapril reduced 
Smad2 activation in Marfan mice significantly more than both placebo and losartan 
(p<0.01), a finding that did not parallel the therapeutic effects of these agents shown by 
in-vivo echocardiography (Fig.2-16).  
83 
 
           
Fig.2-18. Western blot analysis of ERK1/2 and Smad2 activation in the aortic root and proximal ascending 
aorta of placebo-, losartan- and enalapril-treated mice. Note that Smad2 activation was decreased in both 
losartan- and enalapril-treated Marfan mice when compared to placebo-treated animals, with a more 
pronounced effect in enalapril-treated mice. In contrast, enalapril treatment failed to reduce ERK1/2 
activation, while losartan reduced it to levels indistinguishable from WT littermates. Plac, placebo; Los, 
losartan; Enal, enalapril. 
 
ERK1/2 activation was significantly greater in Marfan mice compared to WT 
controls (p<0.01), and treatment with losartan reduced it to WT levels (p=0.80; Fig.2-18). 
In contrast, enalapril treatment had significantly less effect on ERK1/2 activation than 
losartan (p<0.001), in fact being no more effective than placebo (p=0.50). JNK1/2 and 
p38 activation was similar in Marfan and WT mice (Fig.2-19); both losartan and enalapril 
caused a modest reduction in JNK1/2 activation (p<0.01), but neither had any effect on 
p38 activation. Thus, similar to the AT2KO mouse data, the biochemical status of the 
noncanonical ERK1/2 pathway, but not the canonical Smad pathway, correlated most 




           
Fig.2-19. Western blot analysis of JNK1 and p38 activation in the aortic root and proximal ascending aorta 
of placebo, losartan- and enalapril-treated mice. Note that there was no significant difference in JNK1/2 or 
p38 activation in Marfan mice compared to WT controls; losartan or enalapril did not affect p38 activation, 
but both caused a small reduction in JNK1/2 activation. Plac, placebo; Los, losartan; Enal, enalapril. 
 
We next assessed whether AT2R signaling was needed to achieve losartan’s full 
therapeutic benefit. AT2KO:Marfan mice were treated with losartan from 8 weeks of age 
to 9 months of age (total 7 months of treatment; Fig.2-20). While there was a trend for 
increased aortic root growth in AT2KO:Marfan mice compared to Marfan littermates 
(p=0.06), the decrease in aortic root growth seen in AT2KO:Marfan mice treated with 
losartan was only 40% of that seen in Marfan animals that expressed the AT2R 
(p<0.001), despite there being no difference in blood pressure between the groups (Fig.2-
15). The modest reduction in aortic root growth seen in losartan-treated AT2KO:Marfan 
mice was comparable to that previously observed with propranolol in Marfan mice,390 
suggesting that it may again have been due to a reduction in blood pressure rather than 
any modulation of cytokine signaling. 
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Fig.2-20. Mean aortic root growth (+2SEM) over 7 months of treatment with placebo or losartan in WT and 
Marfan mice. Note the diminished effectiveness of losartan in Marfan mice lacking the AT2R 
(AT2KO:Marfan), as compared to Marfan mice that retained it.  
 
Together, these data suggest that AT2R signaling protectively modifies aortic 
disease in Marfan mice, and the therapeutic efficacy of ACEi likely relates either to 
AT1R receptor blockade or an anti-hypertensive effect. In addition, we have shown that 
selective AT1R blockade using the ARB losartan is significantly more beneficial than 
ACEi in Marfan mice, with AT2R signaling needed to achieve the full potential of ARBs.  
To assess the effect of AT2R knockout on losartan’s ability to modulate ERK1/2 
signaling in Marfan mice, we again performed Western blot analysis on the aortic root 
and proximal ascending aorta of 9-month old mice. While losartan was again able to 
reduce ERK1/2 activation in Marfan mice that retained the AT2R (p<0.05), it had a 
significantly reduced ability to lower ERK1/2 activation in Marfan mice lacking the 
AT2R (Fig.2-21). By contrast, there was no change in Smad2, JNK1/2, or p38 activation 
in losartan-treated Marfan mice that did or did not express the AT2R (Fig.2-22).   
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Fig.2-21. Western blot analysis of the aortic root and proximal ascending aorta in 9-month old mice treated 
with placebo or losartan. Note losartan’s inability to decrease ERK1/2 activation in AT2KO:Marfan mice.  
              
Fig.2-22. Western blot analysis of the aortic root and proximal ascending aorta in 9-month old Marfan mice 
and AT2KO:Marfan mice treated with losartan. AT2R knockout does not influence Smad2, JNK1/2 or p38. 
In conclusion, dual blockade of AT1R-mediated ERK1/2 activation and AT2R-
mediated ERK1/2 inhibition, as occurs either with the use of ACEi in Marfan mice or the 
use of losartan in AT2KO:Marfan mice, results in no net change in ERK1/2 activation 
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status, and a very modest therapeutic benefit. By contrast, losartan treatment shows a 
much greater therapeutic benefit in Marfan mice, and this correlates with a substantial 
reduction in ERK1/2 activation. It achieves this effect via the combination of inhibiting 
AT1R-mediated ERK1/2 activation, while simultaneously shunting Ang-II signaling 
through the AT2R and driving ERK1/2 inhibition. This indicates that, in the presence of 
AT1R blockade, ongoing AT2R signaling is required for the modification of ERK1/2 
activation, and that enalapril’s lack of effect on ERK1/2 activation is attributable to the 
loss of AT2R signaling with this agent (Fig.2-23).  
         
Fig.2-23. Summary of the effects of AngII receptors on both canonical and noncanonical TGF signaling. 
AT1R signaling drives ERK1/2 activation whereas AT2R signaling inhibits it. Losartan attenuates ERK1/2 
activation by blocking AT1R signaling while simultaneously shunting signaling through the AT2R. 
 
While the concordant effects of prior manipulations and therapies on canonical 
and noncanonical TGF signaling made it impossible to dissect out their relative 
contributions, the differential effects of losartan and enalapril treatment suggest that 
TGF-mediated ERK1/2 activation is the predominant driver of aneurysm progression in 
Marfan mice, and that the therapeutic efficacy of ARBs lies in their ability to modulate 
this pathway to a greater degree than ACEi. 
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Increased ERK activation has been shown to occur in the aorta of a fibulin-4 
deficient mouse model of cutis laxa with aneurysm, although a mechanistic link remains 
to be elucidated.417 ERK activation also appears to be central to the pathogenesis of both 
cardiovascular and non-cardiovascular disease manifestations in a mouse model of 
Noonan syndrome.418,419 Although aortic aneurysm has been described in this 
condition,420,421 it is not highly penetrant, suggesting as yet undefined context specificity 
in how ERK1/2 activation may drive aortic disease progression. It is also notable that the 
combination of aortic root and ascending aortic aneurysm is seen in individuals with 
either Loeys Dietz syndrome (LDS) or bicuspid aortic valve (BAV) with aneurysm. Both 
conditions are associated with increased TGF signaling in the aortic wall,395,422 and a 
contribution of ERK1/2 activation has recently been elucidated in LDS.423 
The long-term use of MAPK antagonists could theoretically have deleterious side 
effects. It is worth noting that both erk1-/- and erk1-/- erk2+/- mice survive, with no overt 
phenotypic defect. The mechanistic basis of embryonic lethality in erk2-/- mice is not 
known, but it suggests that ERK2 is critically important during development. By contrast, 
inhibition of ERK1 and ERK2 activation by RDEA119 is well tolerated post-natally in 
mice, as well as in humans,424 and shows significant therapeutic benefit in our study. This 
appears to be analogous to TGF, where deficiency states are not tolerated during 
development, but are better tolerated and show phenotypic benefit postnatally. Finally, 
given losartan’s profound inhibition of ERK activation, it is notable that losartan has been 
used for decades in patients without any apparent long-term deleterious consequences. 
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This work also suggests that analysis of ERK1/2 activation status may permit the 
optimization of dosing regimens for losartan or other ARBs in ongoing or future clinical 
trials in people with Marfan syndrome. Furthermore, focused attention on the ERK1/2 
signaling cascade may unveil new therapeutic targets in the treatment of aortic aneurysm 
disease. Finally, this work focuses attention on noncanonical TGFβ signaling cascades in 
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Calcium channel blockers (CCBs) are a class of blood pressure lowering 
medications that block movement of calcium into cells from the extracellular space. 
There are several sub-classes of CCB based on chemical structure, including 
dihydropyridines (e.g. amlodipine) phenylalkylamines (e.g. verapamil) and 
benzothiazepines (e.g. diltiazem). CCBs are currently considered an alternative 
therapeutic strategy for Marfan patients intolerant of β-blockers, due to their ability to 
reduce contractility of the heart (negative ionotropy).425,426,427 In doing so, they 
theoretically reduce stress on the aortic wall during cardiac systole. However, there is 
limited empirical evidence for their safety or utility in patients with Marfan syndrome 
and other forms of inherited thoracic aortic aneurysm.428 To address this, we assessed the 
effect of two major classes of CCB in our Fbn1C1039G/+ Marfan mouse model.  
Animals were treated from 2 to 5 months of age with a dose of amlodipine that 
resulted in a similar reduction in blood pressure as is achieved using losartan in our 
mouse model (12mg/kg/day; Fig.3-1).  
 
          
Fig.3-1. Systolic and diastolic blood pressure in mice treated with placebo (drinking water), losartan 
(60mg/kg/day) or amlodipine (12mg/kg/day). Note the significant reduction in blood pressure in losartan- 
and amlodipine-treated mice compared to placebebo, but no difference between them. 
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The mice underwent unsedated in-vivo echocardiography at baseline (prior to 
treatment), and every month thereafter. Between 2 and 4 months of age, placebo-treated 
Marfan mice showed greater aortic root growth than wild-type (WT) littermates (p<0.01). 
Amlodipine-treated Marfan animals unexpectedly showed accelerated aortic root growth 
(p<0.05) and an even more striking dilatation of the ascending aorta (p<0.0001), an aortic 
segment just distal to the aortic root, which is less commonly affected in people and mice 
with Marfan syndrome (Fig.3-2). Two-way ANOVA confirmed that there was a 
significant interaction effect between genotype and amlodipine use (p<0.0001), 
indicating that Marfan mice are indeed significantly more susceptible to the deleterious 
effects of amlodipine than their WT littermates.  
 
           
Fig.3-2. Echocardiography data showing an exacerbation of mean aortic growth (±2SEM) in both the aortic 
root and the ascending aorta over 2 months in amlodipine-treated mice, relative to placebo. Note the greater 
effect in Marfan animals. Plac, placebo; Aml, amlodipine. 
 
Furthermore, whilst no WT or placebo-treated Marfan mice died during the 3 
month drug trial, more than 40% of amlodipine-treated Marfan mice died secondary to 
aortic rupture, as evidenced by hemothorax or hemopericardium (p<0.01; Fig.3-3).  
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Fig.3-3. Survival curve demonstrating selective premature lethality due to aortic dissection in amlodipine-
treated Marfan mice.  
 
Following death or sacrifice, latex injection of the vasculature illustrated the 
enlargement of the ascending aorta in amlodipine-treated Marfan mice (Fig.3-4).  
 
      
 
Fig.3-4. Representative latex-injected images showing increased aortic size (distance between arrowheads) 
in amlodipine-treated Marfan mice. By comparison, amlodipine only had a very modest effect in WT mice. 




Histologic analyses revealed ascending aortic wall thickening, elastic fiber 
fragmentation, reduced elastin content and increased collagen deposition in Marfan 
animals, all of which were exacerbated by amlodipine treatment (Fig.3-5).  
 
         
Fig.3-5. Verhoeff’s-van Gieson (VVG) stain (above) and Masson’s trichrome stain (below) of the proximal 
ascending aorta. VVG stains elastin (black) and extracellular matrix (pink); trichrome stains collagen 
(blue). The aortic wall thickening, elastic fiber fragmentation and loss, and increased collagen in Marfan 
mice were all exacerbated by amlodipine; there was no effect in WT mice. Scale bar: 40µm.  
 
Aortic architecture was graded quantitatively by 4 blinded observers on a scale of 
0 to 5.429 Marfan mice treated with amlodipine showed worse overall aortic wall 
architecture (Fig.3-6), as judged by observers blinded to genotype and treatment arm, 
when compared to either their placebo-treated counterparts (p<0.01) or WT littermates 
(p<0.0001). This effect was not observed in the descending thoracic aorta, an aortic 




       
 
Fig.3-6. Mean aortic wall architecture score (±2SEM) of the proximal ascending aorta, showing the 
significant exacerbation by amlodipine in Marfan mice. Again there was no effect in WT mice. Scale: 1 
(normal) to 5 (extensive damage). Plac, placebo; Aml, amlodipine. 
 
         
Fig.3-7. VVG stain (upper panel) and trichrome stain (lower panel) of the descending thoracic aorta in 
placebo- and amlodipine-treated WT and Marfan mice. Note the absence of any effect in the descending 
thoracic aorta of either WT or Marfan mice treated with amlodipine. Scale bar: 40µm. 
 
Compared to placebo-treated WT mice, amlodipine-treated WT animals showed a 
small but significant increase in aortic root (p<0.05) and ascending aortic (p<0.01) 
growth (Fig.3-2). The magnitude of this exacerbation was far less than that seen in 
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Marfan mice (p<0.05 and p<0.001, respectively), and neither mortality nor histological 
sequelae were observed in WT animals (Fig.3-4, 3-5, 3-6).  
 
          
Fig.3-8. Mean aortic wall architecture score (±2SEM) of the descending thoracic aorta in placebo- and 
amlodipine-treated WT and Marfan mice. Note the lack of difference in aortic architecture score in either 
WT or Marfan mice treated with amlodipine, relative to placebo. Scale: 1 (normal) to 5 (extensive damage). 
Plac, placebo; Aml, amlodipine. 
 
Prior studies assessing the effects of CCBs in other mouse models of aortic 
disease used lower doses of amlodipine, typically ranging from 1 to 5mg/kg/day.430,431 
We utilized a dose of 12mg/kg/day in order to obtain a similar reduction in blood 
pressure as is achieved using losartan in our Marfan mouse model, as we wished to 
eliminate blood pressure as a confounding variable when comparing the differential 
physiological and biochemical effects of the two agents. To ensure that the deleterious 
effect we observed was not simply due to toxicity of the drug, we repeated the trial using 
a dose of 3mg/kg/day (Fig.3-9). Even at this dose, amlodipine still exacerbated both 
aortic root and ascending aortic growth in WT mice (p<0.05 and p<0.01, respectively) 
and Marfan littermates (p<0.001 for both), with greater accentuation again occurring in 




            
 
Fig.3-9. Mean aortic root and ascending aortic growth (±2SEM) over 2 months in mice treated with 
amlodipine at a dose of 3mg/kg/day. This paralleled the effect of amlodipine at 12mg/kg/day (Fig.3-2). 
Plac, placebo; Aml, amlodipine. 
 
To assess the generalizability of our findings, we treated mice with verapamil 
from 2 to 6 months of age. Compared to placebo-treated Marfan mice, verapamil-treated 
animals showed enhanced growth in the aortic root (p<0.01) and ascending aorta 
(p<0.001; Fig.3-10, 3-11). Two-way ANOVA confirmed a significant interaction effect 
on aortic growth between genotype and verapamil use (p<0.01). 
 
            
 
Fig.3-10. Mean aortic growth (±2SEM) from 2 to 6 months of age in verapamil-treated WT and Marfan 
mice. Plac, placebo; Ver, verapamil.  
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Fig.3-11. Representative images of latex-injected hearts showing enlargement of the ascending aorta 
(arrowheads) in verapamil-treated Marfan mice, relative to WT. Scale bar: 2mm. 
 
                        
 
Fig.3-12. VVG staining (upper panel) and Masson’s trichrome staining (lower panel) of the proximal 
ascending aorta in placebo- and verapamil-treated WT and Marfan mice. The aortic wall thickening, elastic 
fiber fragmentation and loss, and increased collagen present in Marfan mice were all exacerbated by 
verapamil; note the absence of effect in WT mice. Scale bar: 40µm. 
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Fig.3-13. Mean aortic wall architecture score (±2SEM) of the proximal ascending aorta in placebo- and 
verapamil-treated mice. Scale: 1 (normal) to 5 (extensive damage). Plac, placebo; Ver, verapamil. 
 
As with amlodipine, verapamil induced a marked exacerbation of the histological 
phenotype seen in the aortic wall of Marfan mice (Fig.3-12, 3-13).  
 
          
 
Fig.3-14. VVG staining (upper panel) and Masson’s trichrome staining (lower panel) of the descending 
thoracic aorta in placebo- and verapamil-treated WT and Marfan mice. Note the absence of any effect in 
the descending thoracic aorta of either WT or Marfan mice treated with verapamil. Scale bar: 40µm. 
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Fig.3-15. Mean aortic wall architecture score (±2SEM) of the descending thoracic aorta. Note the lack of 
difference in either WT or Marfan mice treated with verapamil, relative to placebo. Scale: 1 (normal) to 5 
(extensive damage). Plac, placebo; Ver, verapamil. 
 
Verapamil increased ascending aortic growth in WT animals (Fig.3-10), although 
again there were no histologic changes (Fig.3-12, 3-13). Similarly, verapamil did not alter 
the architecture of the descending thoracic aorta in Marfan mice (Fig.3-14, 3-15).  
To interrogate the mechanism underlying this detrimental CCB effect in Marfan 
mice, we performed Western blot analyses on the aortas of 4-month old animals (Fig.3-
16). Treatment with amlodipine accentuated signaling changes previously observed in 
Marfan mice, including enhanced activation of both canonical (Smad) and noncanonical 
(ERK1/2) TGF-dependent signaling cascades (p<0.0001 for both).   
Concomitant treatment of Marfan mice with amlodipine and the MEK inhibitor 
RDEA119 prevented CCB-accentuated aortic enlargement (p<0.0001; Fig.3-17), 
achieving a growth rate indistinguishable from that observed in WT littermates (p=0.18). 
RDEA119 also rescued the premature lethality (p<0.05; Fig.3-18), and alterations in 
aortic wall architecture seen in amlodipine-treated Marfan mice (p<0.0001), to levels 




           
             
Fig.3-16. Western blot analysis of the aortic root and ascending aorta. Note the exacerbation of canonical 
(Smad3) and noncanonical (ERK1/2) cascades in Marfan animals. Plac, placebo; Aml, amlodipine. 
 
           
Fig.3-17. Mean ascending aortic growth (±2SEM) over 2 months, showing rescue by RDEA119 in 
amlodipine-treated mice. Plac, placebo; Aml, amlodipine; RDEA, RDEA119. 
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Fig.3-18. Survival curve over a 2-month treatment period, demonstrating that RDEA119 is able to fully 
rescue the premature lethality previously observed in amlodipine-treated Marfan mice.  
 
     
 
Fig.3-19. Representative latex-injected images, as well as VVG and trichrome staining, illustrating the 
protective effect that RDEA119 achieved in amlodipine-treated Marfan mice over a 2-month treatment 




           
 
Fig.3-20. Mean aortic architecture score (±2SEM) in amlodipine/RDEA119-treated mice. Note the full 
rescue achieved by RDEA119 in amlodipine-treated Marfan mice. Aml, amlodipine; RDEA, RDEA119.  
 
           
             
 
Fig.3-21. Western blot showing rescue of ERK1/2 activation by RDEA119 in amlodipine-treated Marfan 
mice. RDEA119 had no effect on Smad3 activation. Plac, placebo; Aml, amlodipine; RDEA, RDEA119.  
104 
 
This rescue of aortic disease by RDEA119 in amlodipine-treated Marfan mice 
correlated with full normalization of ERK1/2 activation in these animals (p<0.0001; 
Fig.3-21). By contrast, RDEA119 had no effect on Smad3 activation in these mice 
(p=0.26), illustrating that phenotypic rescue by RDEA119 can be achieved in the absence 
of Smad3 inhibition, and that Smad3 activation in amlodipine-treated Marfan mice is not 
ERK1/2-dependent. Taken together, these data suggest that ERK1/2 activation is a 
critical determinant of the deleterious effect imposed by CCBs in Marfan mice.  
ERK1/2 activation in Marfan mice is also known to be dependent upon activation 
of the angiotensin II type 1 receptor (AT1R), since the AT1R blocker (ARB) losartan 
rescues aortic root growth in Marfan mice in association with normalization of ERK1/2 
activation. Losartan was also able to prevent enhanced ascending aortic growth in 
amlodipine-treated Marfan mice (p<0.05; Fig.3-22).  
 
         
 
Fig.3-22. In-vivo echocardiography showing mean ascending aortic growth (±2SEM) over 2 months in 
placebo-, amlodipine- and combined amlodipine/losartan-treated mice. Note the rescue by losartan in 




This rescue correlated with reduced ERK1/2 activation in Marfan mice treated 
with either losartan alone (p<0.01) or losartan plus amlodipine (p<0.01; Fig.3-23). Hence 
the deleterious effect of CCBs in Marfan mice also appears to be AT1R-dependent. 
 
           
 
Fig.3-23. Western blot analysis of the aortic root and ascending aorta. Note the rescue of ERK1/2 activation 
in Marfan mice treated with losartan alone, or losartan in combination with amlodipine. Plac, placebo; Aml, 
amlodipine; Los, losartan. 
 
There is evidence that TGFβ-dependent gene expression can be mediated by 
protein kinase C (PKC) in both human fibroblasts and aortic vascular smooth muscle 
cells (VSMCs),432,433 and that PKC blockade can inhibit TGFβ-dependent phenotypes and 
gene expression in-vitro and in-vivo.434,435 Furthermore, angiotensin-II has been shown to 
activate ERK1/2 via PKC,436,437,438 with TGFβ potentially serving as an intermediary in 
this process.439 Hence we decided to assess the activation status of PKC in both placebo- 




          Western blot analysis of the aortic root and proximal ascending aorta showed that 
PKCβ activation was significantly greater in Marfan mice than WT littermates (p<0.05), 
and both TGFβNAb and losartan reduced it (p<0.05 for both), to levels indistinguishable 
from WT mice (Fig.3-24, 3-25). This closely paralleled the effects of these drugs on 
ERK1/2 activation (Fig.3-23, 3-24).  
 
                
          
 
Fig.3-24. Western blot analysis of the aortic root and proximal ascending aorta. Note the reduction in PKCβ 
and ERK1/2 activation in the aortas of TGFβ neutralizing antibody (NAb)-treated Marfan mice. Plac, 
placebo; NAb, neutralizing antibody. 
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 Furthermore, amlodipine treatment accentuated PKCβ activation in Marfan mice 
(p<0.001), in association with increased activation of phospholipase C (PLCγ), its 
upstream activator (p<0.001), both of which were rescued by treatment with losartan 
(p<0.001 and p<0.0001, respectively; Fig.3-25). These data suggest that both PKCβ and 
its upstream activator PLCγ are TGFβ- as well as AT1R-dependent in Marfan mice. 
 
                  
        
 
 
Fig.3-25. Western blot of the aorta illustrating enhanced PKCβ and PLCγ activation in Marfan mice 
relative to WT littermates. Note the exacerbation of both PKCβ and PLCγ in amlodipine-treated Marfan 




 Enzastaurin is a PKC inhibitor with relative selectivity for PKCβ, and has been 
shown to inhibit PKC-mediated ERK1/2 activation.440,441 It competes with ATP for the 
nucleotide triphosphate-binding site of PKC, thereby blocking its activation.442 In 
keeping with the hypothesis that PKCβ mediates CCB-induced aortic aneurysm 
exacerbation in Marfan mice, treatment with enzastaurin led to a significant reduction in 
ascending aortic growth in amlodipine-treated Marfan animals (p<0.01; Fig.3-26). 
 
          
 
 
Fig.3-26. Enzastaurin rescues mean ascending aortic growth (±2SEM) over 2 months in amlodipine-treated 
Marfan mice. Plac, placebo; Aml, amlodipine; Enz, enzastaurin. 
 
 Latex-injected images show the rescue achieved by enzastaurin on ascending 
aortic aneurysm progression in amlodipine-treated Marfan mice (Fig.3-27). Enzastaurin 
also significantly rescued the deleterious histological changes imposed on the Marfan 
aorta by amlodipine, both qualitatively (Fig.3-28) and quantitatively (Fig.3-29). 
Cumulatively, these data suggest that PKCβ mediates amlodipine-induced aortic 





                      
    
Fig.3-27. Representative images of latex-injected hearts, showing the protective effect of enzastaurin in 
amlodipine-treated Marfan mice. Scale bar: 2mm.  
 
        
 
Fig.3-28. VVG stain (upper panel) and Masson’s trichrome stain (lower panel) of the proximal ascending 
aorta. Note the amelioration of aortic histology in Marfan mice treated with amlodipine and enzastaurin, 
relative to amlodipine alone. Scale bar: 40µm. Aml, amlodipine; Enz, enzastaurin. 
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Fig.3-29. Mean aortic architecture score (±2SEM) of the ascending aorta in Marfan mice treated with 
placebo, enzastaurin, amlodipine, or amlodipine in combination with enzastaurin. Note the significant 
improvement in aortic architecture in Marfan mice treated with enzastaurin (relative to placebo) and 
enzastaurin in combination with amlodipine (relative to amlodipine alone). Scale: 1 (normal) to 5 
(extensive damage). Plac, placebo; Enz, enzastaurin; Aml, amlodipine. 
 
To confirm that PKCβ also mediates aortic aneurysm progression in placebo-
treated Marfan mice, aortic root growth was measured in WT and Marfan animals over a 
2 month treatment period (Fig.3-30). This showed that indeed enzastaurin was able to 
significantly rescue aortic root growth in Marfan mice (p<0.01), reducing it to a level 
indistinguishable from that of WT animals. Enzastaurin also significantly rescued the 
histological changes seen in placebo-treated Marfan mice (p<0.01; Fig.3-29). 
Western blot analysis of the aortic root and ascending aorta showed that rescue of 
aortic growth by enzastaurin correlated with a reduction in PKCβ activation in placebo- 
and amlodipine-treated Marfan mice (p<0.05 and p<0.001, respectively; Fig.3-31). 
Furthermore, enzastaurin rescued ERK1/2 activation in both placebo- and amlodipine-
treated Marfan mice (p<0.001 and p<0.0001, respectively), inferring that PKCβ mediates 
ERK1/2 activation in these animals. 
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Fig.3-30. Mean aortic root growth (±2SEM) over 2 months in WT and Marfan mice. Note the significant 
rescue of aortic growth by enzastaurin in Marfan mice. Plac, placebo; Enz, enzastaurin. 
 
                          
             
Fig.3-31. Western blot of the aorta, showing rescue of both PKCβ and ERK1/2 activation in Marfan mice 
treated with enzastaurin, with or without amlodipine. Plac, placebo; Enz, enzastaurin; Aml, amlodipine. 
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We became interested in the clinically-available antihypertensive agent 
hydralazine, not only because it reduces blood pressure (a desirable effect in Marfan 
syndrome), but also because it can inhibit PKC-mediated ERK1/2 activation in-
vivo.443,444 Therefore we performed a trial of mice treated with hydralazine from 2 to 6 
months of age (Fig.3-32). Compared to WT mice, placebo-treated Marfan animals 
showed greater aortic root growth (p<0.0001), which was fully rescued by hydralazine 
(p<0.0001), to a growth rate indistinguishable from that observed in WT mice (p=0.26).  
 
           
 
Fig.3-32. Mean aortic root growth (±2SEM) over 4 months in WT and Marfan mice treated with either 
placebo or hydralazine. Hydralazine led to a significant reduction in mean aortic root growth in Marfan 
mice, to a growth rate indistinguishable from that of WT mice. Plac, placebo; Hyd, hydralazine.  
 
Hydralazine was also able to significantly rescue the deleterious histological 
changes seen in the aortic root of Marfan mice, such that they were indistinguishable 
from placebo- and hydralazine-treated WT littermates (p<0.0001; Fig.3-33, 3-34). This 
phenotypic and histological rescue correlated with a reduction in both PKCβ and ERK1/2 
activation in Marfan mice treated with hydralazine (p<0.01 and p<0.001), to levels 




           
 
Fig.3-33. VVG staining (upper panel) and Masson’s trichrome staining (lower panel) of the aortic root in 
WT and Marfan mice treated with either placebo or hydralazine. Note the amelioration of aortic histology 
in Marfan mice treated with hydralazine relative to placebo, such that they closely recapitulate a WT 
phenotype. Scale bar: 40µm. 
 
        
 
Fig.3-34. Mean aortic wall architecture score (±2SEM) of the aortic root in WT and Marfan mice. Note the 
significant improvement in aortic architecture score in Marfan mice treated with hydralazine. Scale: 1 




           
           
Fig.3-35. Western blot analysis of the aortic root, showing that hydralazine rescues PKCβ and ERK1/2 
activation in Marfan mice. Plac, placebo; Hyd, hydralazine.  
 
Given that RDEA119 had no effect on PKCβ activation in amlodipine-treated 
Marfan mice (Fig.3-36), this suggests that PKCβ lies upstream of ERK1/2 in the 
pathogenic sequence of events that leads to aortic aneurysm in Marfan mice, and suggests 
that both enzastaurin and hydralazine achieve their beneficial effect in Marfan mice via 
inhibition of PKCβ-mediated ERK1/2 activation (Fig.3-37).           
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Fig.3-36. Western blot assessing PKCβ activation in RDEA119-treated mice. Despite fully rescuing aortic 
growth in amlodipine-treated Marfan mice, RDEA119 had no effect on PKCβ, suggesting that PKCβ lies 
upstream of ERK1/2 in Marfan disease pathogenesis. Plac, placebo; Aml, amlodipine; RDEA, RDEA119.       
   
            
 
Fig.3-37. Key nodal points in Marfan mouse aortic disease. Drugs shown in red ameliorate aortic aneurysm 
progression, while manipulations shown in blue exacerbate it. AT1R, angiotensin-II type 1 receptor; AT2R, 
angiotensin-II type 2 receptor; AT2KO, AT2R knockout; PLCγ, phospholipase C gamma; CCBs, calcium 




To determine if our observations made in a mouse model of Marfan syndrome 
have relevance for patients, we first studied the effect of amlodipine on human dermal 
fibroblasts from Marfan patients and controls (Fig.3-38).445,446 While there was no 
difference in ERK1/2 activation between Marfan and control cells at baseline (p=0.16), 
Marfan cells showed greater ERK1/2 activation than controls in response to amlodipine 
(p<0.01). Marfan cells also displayed higher TGFβ-dependent gene expression (in the 
form of COL1A1) than controls at baseline (p<0.001), and greater enhancement, 
compared to both their baseline state and to treated control cells, following treatment with 
amlodipine (p<0.01 for both; Fig.3-39).   
 
         
 
Fig.3-38. Western blot analysis assessing ERK1/2 activation in dermal fibroblasts from Marfan patients and 
controls. Technical triplicates were performed for 2 control cell lines and 4 patient cell lines to ensure 
internal consistency. There was no discernable difference in ERK1/2 activation at baseline between patient 
and control cells. By contrast, following treatment with amlodipine, Marfan patient cells showed greater 





          
 
Fig.3-39. Quantitative RT-PCR assessing TGFβ-dependent gene expression in dermal fibroblasts from 
Marfan patients and controls. COL1A1 gene expression was greater in Marfan patient cells compared to 
controls at baseline, and showed greater enhancement than controls following treatment with amlodipine.  
 
 
           
 
Fig.3-40. Analysis of circulating total TGFβ1 levels in the plasma of people treated with either placebo 
(Plac), non-dihydropyridine (non-DHP, e.g. verapamil) or dihydropyridine (DHP, e.g. amlodipine) calcium 
channel blockers. Compared to people without Marfan syndrome (controls), placebo-treated Marfan 
patients had higher circulating TGFβ1 levels. Marfan patients treated with non-dihydropyridine CCBs had 
a small but non-significant increase in TGFβ1 levels relative to placebo, while Marfan patients treated with 
dihydropyridine CCBs had roughly a 2-fold increase in circulating TGFβ1 levels relative to placebo, which 
was more than 8 times that of controls.  
 
It has been shown that Marfan patients have higher total plasma TGFβ1 levels 
than controls, which can be ameliorated by losartan.447 Using a similar dataset, we found 
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that placebo-treated Marfan patients had higher plasma TGFβ1 levels than non-Marfan 
controls (p<0.0001; Fig.3-40), while Marfan patients treated with dihydropyridine CCBs 
(e.g. amlodipine) had even higher levels (p<0.01). Marfan patients treated with non-
dihydropyridine CCBs (e.g. verapamil) showed a slight but non-significant increase. 
These findings correlated with our Marfan mouse data, in which both classes of CCB 
were detrimental, but amlodipine had a more pronounced effect (Fig.3-2, 3-10).  
In collaboration with other members of the Genetically Triggered Thoracic Aortic 
Aneurysms and Cardiovascular Conditions (GenTAC) consortium,448 we conducted a 
case-control study to assess the effect of CCBs on aortic dissection or aortic surgery in 
patients with Marfan syndrome and other forms of inherited thoracic aortic aneurysm 
(TAA; Table 3-1). The other forms of inherited TAA primarily included Loeys-Dietz, 
Turner and Ehlers-Danlos syndromes, familial thoracic aortic aneurysm, and bicuspid 
aortic valve (BAV) with aneurysm.  
Marfan patients with native aortic roots at the time of enrollment (n=531) who 
received CCBs (as compared to other antihypertensive agents) had an increased odds of 
aortic dissection (odds ratio (OR) 12.5, p=0.032). Strong trends were maintained after 
correction for either systolic blood pressure (OR 12.7, p=0.06) or aortic root size (OR 
11.2, p=0.08) at enrollment.  
A more profound detrimental effect of CCBs on aortic dissection could be masked 
by the practice of performing prophylactic aortic surgery when the aorta reaches a 
dimension that confers risk for dissection. This is generally considered correct clinical 
management, since the rate of morbidity and mortality with aortic dissection is higher 
when surgery is performed on an emergent rather than an elective basis. In such a 
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scenario, one might see an increased rate in the need for aortic surgery in the absence of 
an increased rate of aortic dissection. In keeping with this hypothesis, we found that 
CCB-treated Marfan patients had an increased odds of needing aortic surgery (OR 5.5, 
p<0.001) when compared to patients on other antihypertensive agents, which remained 
significant when corrected for either blood pressure (OR 5.4, p<0.001) or aortic size (OR 
5.0, p<0.01) at enrollment. 
 
           
 
Table 3-1. GenTAC data. Effect of calcium channel blockers (CCBs) on aortic disease in patients. Absolute 
odds (illustrated as a percentage; equals the number of patients with the event divided by the number of 
patients without the event, multiplied by 100), and odds ratio (equals the odds in CCB-treated patients 
divided by the odds in non-CCB-treated patients), for aortic dissection and aortic surgery, in patients 
treated with CCB versus other antihypertensive agents (i.e. non-CCB) are shown in the table above.  
The analysis is stratified into patients with Marfan syndrome (‘Marfan’), and other forms of inherited 
thoracic aortic aneurysm (‘Other’). The table includes odds ratio and p-values corrected for blood pressure 
(‘BP’), aortic root size (‘Aortic Size’), or β-blocker use (‘β-blocker’) at enrollment. n, number of patients 




For patients with other forms of inherited TAA and native aortic roots at the time 
of enrollment (n=1,819), there was suggestion of an increased risk for aortic dissection in 
those who had taken CCBs, although this did not reach statistical significance (OR 4.7, 
p=0.26). This was most likely secondary to prophylactic surgical intervention, given that 
these patients had an increased risk of aortic surgery (OR 2.4, p=0.004), which remained 
significant when corrected for either blood pressure (OR 2.2, p=0.016) or aortic size (OR 
2.2, p=0.017) at enrollment.  
Given that β-blocker therapy is the first-line therapy for patients with Marfan 
syndrome and other related inherited TAA syndromes, and CCBs are typically given to 
patients who cannot tolerate β-blockers, one could hypothesize that the observations 
herein may relate more to an absence of protective β-blockade rather than use of CCBs.  
This interpretation is directly at odds with our mouse model data, where disease 
acceleration occurred due to the presence of a deleterious factor (i.e. CCB therapy), not 
simply due to the absence of a protective agent (i.e. β-blockade). If the latter were the 
case, then one would expect CCB-treated Marfan mice to have shown the same growth 
rate as placebo-treated Marfan animals, which was not the case.  
To further assess this, we controlled for β-blocker use in our GenTAC analysis 
(Table 3-1), and found that it did not fundamentally alter the conclusions of the study. 
The odds of aortic dissection and aortic surgery remained significantly increased in 
Marfan patients on CCBs (OR 15.9, p=0.045; OR 5.7, p<0.01; respectively), while the 
odds of aortic surgery remained significantly increased in other inherited TAA syndrome 
patients on CCBs (OR 2.0, p=0.026).  
121 
 
Any class of drug that lowers blood pressure and/or reduces cardiac contractility 
may theoretically be beneficial in Marfan and related inherited TAA syndromes, since a 
reduction in hemodynamic stress placed upon an inherently weakened aortic wall should 
hypothetically limit aortic expansion and delay or prevent aortic dissection. Prior studies 
in mouse models of Marfan syndrome and related disorders have shown that β-blockers 
(e.g. propranolol),449 or angiotensin converting enzyme inhibitors (ACEi, e.g. enalapril), 
achieve a relatively modest inhibition of aortic aneurysm growth, and fail to preserve 
aortic wall architecture when compared to the ARB losartan, despite an equivalent 
reduction in blood pressure. Notably, in Marfan mice the extent of relative protection of 
these agents correlates closely with suppression of TGFβ-dependent canonical (Smad2/3) 
or noncanonical (ERK1/2) signaling. While these different classes of antihypertensive 
agent show varying degrees of protective effect in Marfan mice, they do at least all confer 
some degree of protection against aneurysm progression.   
To our knowledge, this is the first time that a class of clinically-available blood 
pressure lowering agents has been shown to exacerbate aortic aneurysm and cause 
dissection in a mouse model of Marfan syndrome. This is despite the fact that amlodipine 
lowered blood pressure equally as much as losartan, an effect which should provide some 
degree of protection against aneurysm growth. This deleterious effect was not limited to 
the dihydropyridine amlodipine, but also extended to another class of CCB, namely the 
phenylalkylamine verapamil. Given that a significant number of patients with Marfan 
syndrome and related conditions are prescribed CCBs, a previously-unidentified 
deleterious role for these drugs has important clinical ramifications. 
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It is interesting to note that amlodipine and verapamil showed the same trend, 
namely a small deleterious effect in WT mice and a much greater accentuation of growth 
in Marfan animals, with the effect being greater in the ascending aorta than the aortic 
root. In terms of absolute growth, amlodipine had a significantly greater effect than 
verapamil, even at its lower dose. While the two drugs both target L-type calcium 
channels on the cell membrane, verapamil is generally considered to have greater 
selectivity for cardiac tissue, while amlodipine is considered to have stronger tropism for 
aortic vascular smooth muscle cells. It may be for this reason that amlodipine has a 
relatively greater detrimental effect on the aorta compared to verapamil.  
We have further elucidated that PKCβ-mediated ERK1/2 activation contributes to 
the deleterious effect of CCBs in Marfan mice, while inhibition of this TGFβ- and AT1R-
dependent pathway using either a PKC inhibitor (enzastaurin) or the clinically available 
antihypertensive agent hydralazine is able to prevent aortic aneurysm progression in 
Marfan mice, in association with blunted PKCβ and ERK1/2 activation. While ARBs 
such as losartan and ACE inhibitors such as enalapril are teratogenic and hence not 
appropriate for use in pregnancy, hydralazine is well-tolerated, making it an appealing 
alternative therapeutic strategy for Marfan syndrome, particularly in pregnant women.  
It is also notable that while CCBs accelerate growth of the aortic root in Marfan 
mice, they have an even more pronounced effect on the more distal ascending aorta, an 
aortic segment that is less frequently affected in Marfan syndrome. The molecular basis 
of regional predisposition for aortic aneurysm is not yet fully understood, but may relate 
to the distinct developmental origins of the two aortic segments. While vascular smooth 
muscles cells in the aortic root primarily derive from the second heart field (SHF), those 
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in the more distal ascending aorta derive from the cardiac neural crest (CNC). Prior work 
has shown that L-type calcium channel function is critical for correct CNC migration, 
differentiation and morphogenic patterning, as well as maintenance of an appropriate 
post-developmental differentiated state.450 Furthermore, mutations in L-type calcium 
channels result in cellular hypertrophy and hyperplasia in neural-crest derived tissues.451 
This may explain why CCBs appear to have a greater deleterious effect on the ascending 
aorta compared to the aortic root.  
Interestingly, the ascending aorta is characteristically involved in patients with 
bicuspid aortic valve (BAV) with aneurysm. Despite being the most common 
developmental cardiovascular abnormality in humans, the genetic cause(s) and molecular 
mechanisms underlying BAV and the associated aortopathy are not well understood. This 
work provides rationale and incentive to elucidate whether altered calcium, PKC and/or 
ERK1/2 signaling may play a role in this condition. 
There is only one prior study assessing the effect of CCBs on aortic growth in 
Marfan patients.452 The number of CCB-treated patients was small (n=6), and the study 
combined data on patients treated with either CCBs or β-blockers. Given that β-blockers 
are known to confer protection against aortic growth in Marfan patients,453,454,455  and 
nearly 80% of patients in the study were on β-blockers but not CCBs, a detrimental effect 
of CCBs could easily have been masked. Interestingly in the study, the complication rate 
was more than twice as high in CCB-treated patients as compared to those on β-blockers 
(33% vs 15%), although numbers were too small to draw firm conclusions.  
While randomized double-blinded prospective clinical trials are the preferred 
approach to analyze the therapeutic efficacy of a drug, this is not really feasible for agents 
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that are found to be severely detrimental in pre-clinical models, since ethical approval for 
a prospective human trial is unlikely to be granted. Retrospective analyses of large 
datasets are a more realistic solution in such scenarios. An inherent limitation to any 
analysis of rare Mendelian disorders is the number of patients available. This is even 
more challenging when stratifying patients based on drugs that have been prescribed. The 
GenTAC consortium was established to try to overcome some of these challenges.  
However, it needs to be recognized that the human data contained herein is still 
limited by relatively small sample size (more so for aortic dissection than aortic surgery) 
and an inability to control for the dose or number of medications that patients were 
receiving. We were able to control for aortic size at the time of enrollment, which is an 
indicator of baseline aortic disease severity and a predictor of future risk of aortic 
dissection and/or need for aortic surgery. We were also able to control for blood pressure, 
which is a known risk factor for aneurysm progression. Hence while the conclusions that 
can be drawn are not definitive, the data suggest that CCBs should be used with caution 
in Marfan patients. They also suggest that CCBs may be deleterious in other Marfan-
related conditions, although a larger sample size will be needed to assess risk after 
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Loeys-Dietz syndrome (LDS) is a systemic disorder of connective tissue with 
both overlapping and distinguishing features with Marfan syndrome (MFS), and is most 
often caused by mutations in the genes encoding either subunit of the TGF receptor, 
TGFBR1 and TGFBR2.456,457 Rare mutations in the gene encoding the intracellular 
signaling effector Smad3 have also been described in patients with phenotypic 
manifestations of LDS.458 Three TGF ligand isoforms exist in mammals (TGF1, -2, 
and -3), but their relative contribution to aortic aneurysm in the context of connective 
tissue disorders has not been explored.  
In association with collaborators in Belgium, we identified eight families with an 
autosomal dominant aortic aneurysm phenotype with variable clinical expression. 
Features shared with Marfan syndrome and Loeys-Dietz syndrome included pectus 
deformity, arachnodactyly, scoliosis, and skin striae. Features that were atypical for 
Marfan syndrome but that are observed in Loeys-Dietz syndrome included bifid uvula, 
bicuspid aortic valve, arterial tortuosity, club feet, and thin skin with easy bruising. 
Ectopia lentis, which is routinely described in Marfan syndrome, was not observed.  
Microarray analysis in two patients with these features in addition to mild 
developmental delay, revealed two de novo microdeletions in the 1q41 region. Both 
deletions encompassed the TGFB2 gene, making it an obvious candidate gene for this 
aneurysm phenotype with Marfan syndrome-like features.  
All exons and intron-exon boundaries of the TGFB2 gene were subsequently 
screened by Sanger sequencing in a cohort of 86 aneurysm patients who were negative 
for FBN1 and TGFBR1/2 mutations. A total of six heterozygous mutations in TGFB2 
were identified, including one nonsense mutation, three missense mutations and two 
127 
 
intragenic deletions, one in-frame and one causing a frameshift. The three missense 
mutations, p.Arg327Trp, p.Arg330Cys and p.Pro366His, substituted evolutionarily 
conserved residues and were categorized as probably damaging by Polyphen,459 
deleterious by SIFT,460 and disease-causing by MutationTaster.461 In addition, these 
mutations were not observed in the 1000 Genomes Project,462 and were not present in 
over 10,000 exomes listed in the NHLBI (USA) Exome Variant Server.  
Since two whole gene deletions were found in addition to two mutations predicted 
to lead to nonsense-mediated mRNA decay (p.Tyr99* and p.Tyr369Cys*), 
haploinsufficiency appeared to be the mechanism. The TGFβ family members, including 
TGFβ2, are generated as latent pre-pro-proteins. Generation of active cytokine requires 
cleavage by furin or furin-like proteases at a dibasic cleavage site (RXXR motif). In 
human TGFβ2, the cleavage site spans from amino acids 327 to 331 (RKKRA). Of note, 
two missense mutations, p.Arg327Trp and p.Arg330Cys, were predicted to prevent 
proper cleavage and activation of the TGFβ2 peptide. While this was all consistent with a 
loss-of-function mechanism, functional studies were necessary to fully explore the 
putative inactivating nature of the missense mutations and the in-frame deletion. 
In order to model this condition and to assess the role of TGFB2 mutations in 
aortic wall homeostasis we examined the effect of Tgfb2 haploinsufficiency in gene-
targeted mice. Homozygous knockout (Tgfb2-/-) mice exhibit late embryonic lethality 
secondary to congenital heart disease including double outlet right ventricle, persistent 
truncus arteriosis, and atrioventricular valve abnormalities.463 In contrast, the phenotype 
of heterozygous mice (Tgfb2-/+) had not been examined in detail. Patients with Loeys-
Dietz syndrome demonstrate aortic aneurysm in a characteristic anatomic distribution 
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with predominant dilation of the aortic root at the level of the sinuses of Valsalva.456 This 
pattern is similar in patients with Marfan syndrome,464 and in Marfan mice harboring a 
heterozygous Fbn1 mutation (Fbn1C1039G/+).465 Interestingly, by 8 months of age, Tgfb2-/+ 
mice showed dilation of the aortic annulus and root, but normal more distal ascending 
aortic dimensions, which closely parallels the phenotype seen in Marfan mice (Fig.4-1). 
This demonstrates that loss of function of a single allele of Tgfb2 is sufficient to cause 
aortic root aneurysm in mice.  
 
            
 
Fig.4-1. Parasternal long axis echocardiographic systolic images of the aortic root of 8 month old wild type 
(WT), Tgfb2-/+ and Fbn1C1039G/+ (Marfan) mice. Arrows denote the aortic root dimension. Scale bar: 
0.75mm. Echocardiographic quantification of dimensions at the aortic valve (AoV), aortic root (AoR), 
sinotubular junction (STJ), and ascending aorta (AscAo) in WT, Tgfb2-/+ and Fbn1C1039G/+ Marfan mice.  
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To investigate TGF signaling activation in Tgfb2-/+ mice, we performed Western 
blot analysis on the aortic root of 8-month old mice. As seen previously, Marfan mice 
showed increased activation of Smad2 (p<0.05) and ERK1/2 (p<0.01) relative to WT 
controls,466,467 while Tgfb2-/+ mice showed increased activation of Smad2 (p<0.05), 
Smad3 (p<0.05), and ERK1/2 (p<0.01; Fig.4-2). This suggests that the signature of 
upregulated canonical Smad and noncanonical ERK1/2 activation appears to be present 
in Loeys-Dietz syndrome-like phenotypes in mice.  
 
                                                                                              
 
 
Fig.4-2. Western blot analysis of the aortic root demonstrating increased activation of Smad2, Smad3 and 
ERK1/2 in 8-month old Tgfb2-/+ mice, with increased Smad2 and ERK1/2 activation in Marfan mice. 
 
Interestingly, Tgfb2-/+ mice demonstrated greater Smad3 activation (p<0.05), but 
significantly lower ERK1/2 activation (p<0.01), than Marfan littermates. While Marfan 
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syndrome and Loeys-Dietz syndrome do show overlapping clinical features, they also 
show a number of unique manifestations. Whether these subtle differences in downstream 
TGFβ-dependent signaling cascades play a role remains to be elucidated. 
An excess of canonical TGF-β signaling has also been demonstrated in the aortic 
wall of patients with Loeys-Dietz syndrome.468 However, this has been difficult to 
reconcile with the location and character of the underlying mutations. Loeys-Dietz 
syndrome is predominantly caused by heterozygous missense substitutions in the kinase 
domains of either TβRI or TβRII (encoded by the TGFBR1 and TGFBR2 genes, 
respectively).468,469 When mutant proteins are expressed in cells naïve for the 
corresponding receptor subunit, there is failure to propagate Smad-dependent TGFβ 
signaling.461 More rarely, Loeys-Dietz syndrome-like phenotypes can be caused by 
haploinsufficiency for Smad3, which is also a positive effector of TGFβ signaling.462,470 
Notably, these heterozygous loss-of-function mutations in SMAD3 also result in high 
TGFβ signaling in the aortic wall of patients and mouse models.462,470 
In addition, some phenotypic features of Loeys-Dietz syndrome, such as cleft 
palate, have historically been attributed to a low TGFβ signaling state on the basis of cell 
type-specific targeting of genes encoding TGFβ effectors in mice.471,472 Furthermore, 
organ culture experiments have implicated a specific deficiency of TGFβ3 activity in the 
pathogenesis of premature skull fusion.463,464 Conditional targeting experiments expected 
to attenuate or abrogate TGFβ signaling in mice have also shown altered vessel wall 
homeostasis, while pharmacologic antagonism of TGFβ signaling has been shown to 
exacerbate the inflammatory aneurysm phenotype observed following angiotensin II 
infusion in genetically-predisposed mouse backgrounds.465,467,473 Taken together, these 
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apparently contradictory data have engendered considerable controversy regarding the 
precise role of TGFβ in the pathogenesis of aortic aneurysm.  
In this case, loss of function of a positive regulator of TGFβ signaling, namely 
TGFβ2 isoform, would again lead one to assume that there should be a downregulation of 
downstream TGFβ-dependent pathways. The question in this scenario was how this may 
occur. One hypothesis posits that it is a result of excessive, nonproductive compensatory 
mechanisms, most likely proximately-induced by an imbalance of the various signaling 
cascades (e.g. canonical vs. noncanonical pathways) supported by TGF receptors in a 
given cell type, or an imbalance of TGF signaling in general between distinct but 
neighboring cell populations.474 
A pathogenic model focused on excessive and nonproductive compensatory 
events would also explain the so-called ‘TGF paradox,’ in which loss of function 
mutations in TGF-related signaling factors drive increased TGF tissue activity and 
disease progression, analogous to current concepts in cancer biology. Such tenets, if true, 
would support current therapeutic strategies for Marfan syndrome and related disorders 
aimed at a global, or at least ‘balanced’ antagonism of TGF signaling. However, further 
work is required to elucidate the answer to this potentially complex conundrum. 
Another approach to tackle this question is to try to identify the genetic causes of 
other Marfan-related conditions, in the hope that this provides further insight into the 
molecular mechanisms driving syndromic presentations of aortic aneurysm. Shprintzen-
Goldberg syndrome is a systemic connective tissue disorder of unknown etiology that 
includes virtually all the craniofacial, skeletal, skin and cardiovascular manifestations of 
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Marfan syndrome and Loeys-Dietz syndrome, with the additional findings of mental 
retardation and severe skeletal muscle hypotonia.  
Substitution of two cysteine residues (p.C1223Y and p.C1221Y) in the epidermal 
growth factor-like domain of fibrillin-1, encoded by exon 29 in FBN1, have been 
reported in association with a Shprintzen-Goldberg syndrome-like phenotype, including 
all features of Marfan syndrome, as well as Shprintzen-Goldberg syndrome-specific 
features such as craniosynostosis and developmental delay.475,476 It remains to be 
determined if this tentative phenotype-genotype correlation manifests a predominant 
consequence of FBN1 genotype, modifier loci or chance. 
Phosphorylated Smad2 and Smad3 form a complex with the Co-Smad protein 
Smad4, translocate to the nucleus and mediate TGFβ dependent transcriptional responses 
through direct Smad-DNA binding, as well as interactions with other DNA-binding 
proteins. The ability of nuclear R-Smad/Co-Smad complexes to precisely regulate gene 
transcription is modulated by the recruitment of transcriptional co-activators such as p300 
and CREB binding protein (CBP), and co-repressors such as SKI.477 
The SKI (Sloan Kettering Institute) proto-oncoprotein family of proteins, which 
also includes the SKI-like protein SKIL, negatively regulate Smad-dependent TGFβ 
signaling at multiple cellular locations by impeding R-Smad phosphorylation, preventing 
nuclear translocation of the R-Smad/Co-Smad complex, and inhibiting TGFβ target gene 
output by competing with p300/CBP for Smad binding and by recruitment of 
transcriptional repressor proteins, such as mSin3A and HDAC1.478,479,480 While TGFβ 
can also induce noncanonical TGFβ signaling cascades, a role for SKI in modulating 
these noncanonical cascades has not previously been described.481,482 
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To further explore this, whole exome sequencing was performed for a single 
affected Shprintzen-Goldberg syndrome child-unaffected parent trio. This revealed only 
one variant, a heterozygous missense change in exon 1 of the SKI gene (c. 347G>A, p. 
Gly116Glu), which was not present in SNP databases, was predicted to be damaging 
(PolyPhen-2 score: 0.999; SIFT score: 0.05), was not present in either parent, and was a 
strong functional candidate based upon the role of SKI in TGFβ signaling.483,484 
11 other sporadic Shprintzen-Goldberg syndrome patients were sequenced and 
heterozygous variants in 9 were identified, including 8 missense mutations and one 9 
base pair deletion. These mutations were absent from dbSNP 134, the 1000 genomes 
project and over 10,000 exomes reported on the NHLBI Exome Variant Server, and 
confirmed to be de novo when testing of the unaffected parents was possible (5/9). 
Collectively, 10 mutations in 10 patients with Shprintzen-Goldberg syndrome were 
identified in SKI by a combination of whole exome and Sanger sequencing. Each 
mutation substituted or deleted residues that show complete evolutionary conservation 
among members of the SKI gene family.485 
The mutations in SKI clustered in two distinct regions at the N-terminus of the 
protein. The first region is located in the Smad2/3 binding domain of SKI (residues 17-
45), while the second region localizes to a portion of the Dachshund-homology domain 
(DHD) of the SKI protein that mediates binding to SNW1 and N-CoR, proteins that are 
essential to the transforming activity of SKI and to the recruitment of transcriptional co-
repressors such as histone deacetylases, respectively.485,486,487 
One of the mutations (L21R) substituted an amino acid that was previously shown 
to be essential for SKI-Smad3 interaction.488 Two of the mutations substituted 
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immediately adjacent glycine residues at positions 116 and 117 that contribute to an 
exposed type 1 prime β hairpin loop in the DHD.489 Interestingly, residues 125-131, 
which lie immediately distal to the β-turn defined by glycines 116-117, influence binding 
of Smad2 and Smad3 to their more proximal N-terminal binding site.489,490 
In order to assess the functional consequence of SKI mutations identified in 
Shprintzen-Goldberg syndrome, we monitored TGFβ signaling in primary dermal 
fibroblasts derived from 2 Shprintzen-Goldberg syndrome patients and 2 controls. 
Western blot analysis showed greater activation of Smad2 (p<0.01, p<0.05), Smad3 
(p<0.05, p<0.05), and ERK1/2 (p<0.01, p<0.01) in patient cells compared to controls, 
both at baseline and after acute (30 minute) stimulation with exogenous TGFβ2 (Fig.4-3). 
This implies loss of suppression of TGFβ-dependent intracellular signaling cascades in 
Shprintzen-Goldberg syndrome cells relative to controls.  
We also observed a significant increase in mRNA expression for TGFβ-dependent 
genes in Shprintzen-Goldberg syndrome fibroblasts, including COL1A1, COL3A1, FN1, 
VIM and CDKN1A (encoding types I and III collagen, fibronectin, vimentin and p21, 
respectively; Fig.4-4). This is in keeping with prior work showing that transcription of 
these genes is normally negatively regulated by SKI.491 
TGFβ also induced transcription of genes encoding negative regulators of itself, 
including SKI, SKIL, and SMAD7, as part of an autoregulatory loop. We observed 
increased mRNA expression for each of these genes in Shprintzen-Goldberg syndrome 
cells compared to controls, suggesting that SKI normally suppresses the expression of 
itself as well as other negative regulators of TGFβ signaling. Interestingly, the SKI- 
regulated target genes CTGF and SERPINE1 (also known as PAI-1) showed equal 
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expression in Shprintzen-Goldberg syndrome and control cells, suggesting either gene-
specific differences in their sensitivity to attenuation of SKI function or to the regulatory 








Fig.4-3. Western blot analysis of dermal fibroblasts at steady state (baseline) and in response to acute (30 
minute) TGF-β2 stimulation. Representative Shprintzen-Goldberg syndrome and control blots are shown (1 
SGS patient and 1 control, with 3 biological replicates for each). Graphs display quantification of 3 
biological replicates for 2 SGS patients and 2 controls. All data were normalized to β-Actin. The control 
baseline value for each graph was set to 1.0; all other values represent a fold ratio change compared to this.  
 
          These data show that the manifestations of Shprintzen-Goldberg syndrome are 
caused by primary mutations in a prototypical repressor of TGFβ signaling, and that this 
associates with a cell-autonomous increase in Smad2/3 and ERK1/2 activation at steady-
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state and in response to TGFβ ligand, as well as with increased transcriptional output of 
TGFβ-responsive genes. It remains to be determined whether the increased ERK1/2 
activation seen in Shprintzen-Goldberg syndrome cells in response to TGFβ manifests 
loss of a previously unrecognized primary function of SKI or secondary cellular events.  
 
             
Fig.4-4. Relative mRNA expression for TGFβ target genes (normalized to β-Actin), as assessed by 
quantitative RT-PCR analysis. Quantification was again performed on 3 biological replicates in each of 2 
Shprintzen-Goldberg syndrome patients and 2 controls.  
 
It is interesting to note that the signaling changes herein observed in Shprintzen-
Goldberg syndrome patient cells directly parallel previous findings in the aortas of both 
patients and mouse models of Marfan syndrome, Loeys-Dietz syndrome and the Loeys-
Dietz syndrome-like phenotype generated by mutations in TGFβ2, suggesting that 
combined TGFβ-dependent canonical (Smad2/3) and noncanonical ERK1/2 signaling 
cascade activation may represent a common molecular signature of multiple syndromic 
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It is well-recognized that the severity of aortic disease and other systemic 
manifestations in patients with Marfan syndrome (MFS) is highly variable. While the 
causes for this are not well understood, there is clearly a strong genetic component, since 
members of the same family often share similar manifestations and outcomes. Despite 
this, there is very limited correlation between the type or location of a patient’s mutation 
in the FBN1 gene and their disease. This implies that there may be other major modifier 
genes which determine the penetrance and/or severity of a patient’s disease.  
Prior work has shown that the C57BL6 and Sv129 mouse backgrounds have 
strain-specific modulatory effects on TGFβ deficiency phenotypes, and this may relate to 
their influence on downstream TGFβ signaling.492,493 With this in mind, we sought to 
determine whether the 129 background could exacerbate our Marfan mouse phenotype, 
with the intention of trying to elucidate the gene(s) involved in this process, and 
hopefully identifying novel therapeutic strategies for the disorder as a result. 
Therefore, we backcrossed our Fbn1C1039G/+ mouse model (hereafter termed 
Marfan mice), from a pure C57BL/6J (hereafter termed BL6) background, greater than 10 
generations onto a 129S6/SvEvTac (hereafter termed 129) background. Aortic size and 
growth in both wild type (WT) and Marfan mice on the two background strains was then 
compared in a head-to head in-vivo echocardiography trial. Data was collected initially at 
2 months of age, and then every 2 months thereafter until death or sacrifice.  
At 2 months of age, Marfan mice on both BL6 and 129 backgrounds had larger 
aortic roots than their respective WT littermates (p<0.0001 and p<0.00001, respectively; 
Fig.5-1), while 129 Marfan mice had significantly larger aortic roots than their BL6 
Marfan counterparts (p<0.0001). Of note, there was no difference in aortic root size 
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between WT mice on the two background strains, suggesting that aortic root size was 
modified by the 129 background only in the presence of a mutant Fbn1 allele (i.e. in a 
disease-specific manner).  
While Marfan mice on both BL6 and 129 backgrounds had a modest but 
significantly greater ascending aortic size at 2 months of age compared to their respective 
WT littermates (p<0.0001 and p<0.001, respectively; Fig.5-1), there was no accentuation 
of this portion of the aorta in 129 Marfan mice. In fact, both WT and Marfan mice on the 
129 background had a significantly smaller ascending aorta than their BL6 counterparts 
(p<0.0001 for both). Hence the 129 background augmented growth in the portion of the 
aorta that is most classically affected in Marfan syndrome (i.e. the aortic root), rather than 
simply inducing hypertrophy or hyperplasia of the entire aorta.  
 
           
Fig.5-1. In-vivo echocardiography data, showing mean aortic root and ascending aortic size (±2SEM) at 2 
months of age. There is an exacerbation of aortic root size in 129 Marfan mice, compared to BL6 
counterparts. Note the absence of a difference in aortic root size in WT mice on the 2 background strains, 
implying disease-specific modification. Also note the lack of exacerbation of the ascending aorta in 129 




The difference in mean aortic root size between BL6 and 129 Marfan mice was 
even more pronounced at 6 months of age (p<0.0001; Fig.5-2), with 129 Marfan mice 
having an aortic root size that was nearly 1.5 times that of their BL6 Marfan counterparts. 
This was due to the striking difference in post-natal aortic root growth. While the aortic 
root of BL6 Marfan mice grew only slightly more than WT littermates from 2 to 6 
months of age (p<0.05; Fig.5-2), the aortic root of 129 Marfan animals grew more than 3 
times as much as their BL6 counterparts (p<0.0001).  
There was no difference in aortic root size at 6 months, or growth from 2 to 6 
months, in WT mice on the two background strains (Fig.5-2). Furthermore, ascending 
aortic size at 6 months was barely greater in 129 Marfan mice than in 129 WT littermates 
(p<0.05; Fig.5-3), and actually less than in BL6 Marfan mice (p<0.001), again implying 
aortic root-specific accentuation of post-natal disease progression in 129 Marfan animals. 
 
           
 
Fig. 5-2. Mean aortic root size (±2SEM) at 6 months of age, showing increased size in Marfan mice on a 
129 background, compared to their BL6 counterparts. When looking at post-natal aortic root growth from 2 
to 6 months of age, the effect of 129 background on Marfan mice becomes even more apparent, with 
growth in Marfan animals on a 129 background being roughly 3-fold that of their BL6 counterparts. 
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Fig.5-3. Mean ascending aortic size (±2SEM) at 6 months of age, showing that both WT and Marfan mice 
on a 129 background again had smaller ascending aortas than their BL6 counterparts. When looking at 
post-natal ascending aortic growth between 2 and 6 months of age, WT mice on the two backgrounds grew 
the same amount as eachother and 129 Marfan mice. Only BL6 Marfan mice showed a small but significant 
increase in ascending aortic growth relative to the other groups.   
 
These differences were also apparent when looking at representative 
echocardiography images of the aorta in 6-month old mice (Fig.5-4). While aortic root 
size (yellow arrowheads) was greater in BL6 Marfan mice than their WT littermates, 
there was a clear accentuation of aortic root size in 129 Marfan mice. By contrast, the 
ascending aorta (red arrowheads) was actually slightly smaller in both WT and Marfan 
mice on a 129 background, compared to their BL6 counterparts.  
Given the lack of difference of aortic root size in WT mice on the two background 
strains, the absence of an exacerbation of ascending aortic size in 129 Marfan mice, and 
no difference in weight between the two mouse strains (Fig.5-5), cumulatively these data 
infer that the exacerbation of aortic root aneurysm seen in Marfan mice on a 129 
background is due to Marfan-specific disease modification, and not simply due to greater 
growth of either the whole aorta or the whole animal. 
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Fig.5-4. Representative parasternal long-axis images of the aortic root (yellow arrowheads) and ascending 
aorta (red arrowheads). Note the increased aortic root size in Marfan mice on a 129 background, compared 
to a BL6 background. By contrast, WT and Marfan mice on a 129 background appear to have slightly 
smaller ascending aortas than their BL6 counterparts. Scale bar: 1mm.  
 
           
 
Fig.5-5. Mean weight (±2SEM) in grams at 2 months of age in WT and Marfan mice on BL6 and 129 
backgrounds. Note the absence of a difference in weight between either WT or Marfan mice on the two 





This accelerated aortic root growth in 129 Marfan mice resulted in increased 
mortality from aortic dissection and/or aortic rupture in these animals, as evidenced by 
hemothorax or hemopericardium (Fig.5-6). While no WT mice, nor any BL6 Marfan 
mice, died by 10 months of age in the study, nearly 40% of 129 Marfan mice had died by 
this timepoint (p=0.007). Larger aortic root size at last echocardiography timepoint was a 
strong predictor of premature lethality from aortic dissection during the subsequent 
follow-up period in 129 Marfan mice, similar to what is seen in Marfan patients. 
 
          
Fig.5-6. Survival curve demonstrating selective premature lethality due to aortic dissection in 129 Marfan 
mice. By 10 months of age, nearly 40% of mice had died. By contrast, at 10 months of age, no BL6 Marfan 
mice, nor any WT mice, had died. 
 
Given that increased blood pressure is known to influence the rate of aortic 
aneurysm growth and incidence of aortic dissection and premature lethality in humans, 
while drugs used to reduce blood pressure slow aortic growth and reduce mortality in 
Marfan patients, we assessed whether there were any blood pressure differences in mice 
on the two background strains. We found no significant difference in blood pressure in 
WT or Marfan mice on either background strain (Fig.5-7), eliminating this as a potential 
variable driving greater aortic root growth and premature lethality in 129 Marfan animals. 
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This is further supported by the observation that ascending aortic growth was not 
increased in 129 Marfan mice compared to their BL6 counterparts; if blood pressure were 
driving aortic disease in 129 Marfan mice, one would anticipate that ascending aortic 
growth would likely also be increased in these animals, which it was not.  
 
          
 
Fig. 5-7. Systolic blood pressure in WT and Marfan mice on both BL6 and 129 pure backgrounds. Note the 
lack of difference in blood pressure between any of the groups.  
 
To assess whether phenotypic modification by the 129 background in Marfan 
mice was restricted to the aorta, we assessed tissues outside of the cardiovascular system 
that are known to be affected in mice and humans with MFS. Marfan mice have 
previously been shown to possess developmental emphysematous dilation of the distal 
alveolar air spaces in the lungs,494 which can be quantified by calculating a mean linear 
intercept (MLI). The larger the MLI, the more severe the disease phenotype. Following 
death or sacrifice of the animals at 10 months of age, their lungs were infused with 
molten agar under constant low pressure, and sectioned as described previously.495 While 
there was no significant difference in MLI between BL6 and 129 WT mice (Fig.5-8), 
BL6 Marfan mice had a significantly greater MLI than their WT littermates (p<0.001), 




         
 
Fig.5-8. Representative cross-sectional images showing H&E staining of the lungs in WT and Marfan mice 
on BL6 and 129 backgrounds. Note the enlargement of the distal airways in BL6 Marfan mice compared to 
both BL6 and 129 WT mice, which was further exacerbated in Marfan mice on a 129 background. 
Quantitatively, this is measured by mean linear intercept (MLI), which confirms the significant 
exacerbation of the Marfan phenotype by the 129 background. Scale bar: 50um. 
 
Marfan mice also possess severe skeletal deformity, including rib overgrowth and 
spine kyphosis.496 This parallels the phenotypic manifestations seen in patients, including 
rib cage deformities (e.g. pectus excavatum or carinatum) and severe scoliosis, which can 
cause restrictive lung disease and may necessitate major surgical intervention. Spine 
kyphosis in mice can be quantified using a kyphosis index (KI),497 which is analogous to 
the Cobb’s angle that can be used to quantity the degree of human scoliosis.498 While 
there was no difference in KI between WT mice on the two backgrounds (Fig.5-9), BL6 
Marfan mice showed a significantly greater KI than their WT littermates (p<0.0001), 




           
 
 
Fig.5-9. Representative spinal x-rays in BL6 and 129 WT and Marfan mice. Kyphosis index (KI) is 
measured by drawing a line between the anterior superior iliac spine and the point of maximal cervical 
lordosis (orange line). Thoracic kyphosis is then measured by drawing a line perpendicular from this to the 
point of maximal thoracic kyphosis (yellow line with arrowheads). Note the increased kyphosis in BL6 
Marfan mice compared to WT littermates, which is exacerbated in 129 Marfan animals. Scale bar: 1mm. 
 
These data indicate that the 129 background modifies not only the aortic 
phenotype seen in Marfan mice, but also other highly penetrant systemic manifestations. 
Interestingly, there was a significant correlation between aortic root size and both lung 
MLI (r2=0.75, p=0.012) and spine KI (r2=0.30, p=0.013) in 129 Marfan mice. However, 
the amount of phenotypic exacerbation in 129 Marfan mice compared to their BL6 
Marfan counterparts was substantially greater for the aorta (45%), compared to both the 
lung (20%) and the spine (10%), suggesting that while the 129 background strain 




Given that aortic and other systemic phenotypes (e.g. lung, myxomatous mitral 
valve disease, skeletal myopathy) in Marfan mice have been shown to be driven by 
TGFβ,494,495,499,500 we assessed whether enhanced TGFβ signaling might underlie the 129 
background-mediated phenotypic exacerbation seen in Marfan mice.  
We therefore performed Western blot analysis on the aortas of 6-month old mice 
(Fig.5-10 and 5-11). There was no significant difference in activation of any of the tested 
proteins between BL6 and 129 WT mice. Compared to BL6 Marfan mice, 129 Marfan 
animals showed increased activation of ERK1/2 (p<0.0001; Fig.5-10), as well as its 
upstream activators RAF (p<0.0001), MEK1 (p<0.001) and PKCβ (p<0.001). 129 
Marfan mice also showed increased activation of Smad2 (p<0.01; Fig.5-11) and Smad3 
(p<0.0001), relative to BL6 Marfan counterparts.  
Interestingly, 129 Marfan animals also showed increased activation of p38 
(p<0.0001; Fig.5-11), which has not previously been observed in Fbn1C1039G/+ Marfan 
mice, but has been seen in Fbn1-null (mgN/mgN) mice.501 By contrast, there was no 
increase in JNK1/2 activation in 129 Marfan animals, suggesting that these mice show 
selective ERK1/2 and p38 upregulation, rather than global upregulation of all MAPK 
signaling pathways. 
 Given that AT1R blockade using the ARB losartan, or selective inhibition of 
ERK1/2 activation using RDEA119, can rescue aortic aneurysm progression in BL6 
Marfan mice,495,502 we wished to assess whether they could also rescue the more severe 
aortic disease observed in 129 Marfan animals (Fig.5-12). Interestingly, both losartan and 
RDEA119, at doses previously used in BL6 Marfan mice, achieved a full rescue of aortic 
root growth in 129 Marfan mice (p<0.00001 and p<0.01, respectively), to growth rates 
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indistinguishable from that of placebo-treated WT mice in the case of RDEA119, or 
below that of placebo-treated WT mice in the case of losartan (p<0.001). These data 
suggest that both classes of agent may prove to be clinically useful in treating even severe 
forms of the disorder. 
  
         
          
 
Fig.5-10. Western blot analysis of the aortic root in BL6 and 129 WT and Marfan mice. Note the increased 
activation of ERK1/2, as well as its upstream activators RAF, MEK1 and PKCβ, in 129 Marfan mice 
relative to their BL6 Marfan counterparts. Also note the lack of difference in activation in 129 and BL6 WT 
mice, suggesting disease-specific modification.  
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Fig.5-11. Western blot analysis of the aortic root in BL6 and 129 WT and Marfan mice. Note the increased 
activation of Smad2, Smad3 and p38 in 129 Marfan mice, relative to their BL6 Marfan counterparts. By 
contrast, note the lack of increase in JNK1/2 activation in 129 Marfan mice, and the absence of a difference 
in activation status of any of the molecules in BL6 and 129 WT animals.  
 
While a 2-month treatment duration was too short a time period to obtain a 
significant rescue of premature lethality using RDEA119 in 129 Marfan mice, over a 6-
month treatment duration, losartan was able to significantly rescue the premature lethality 
from aortic dissection observed in 129 Marfan mice (p<0.05; Fig.5-13). 
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Fig.5-12. Mean aortic root growth (±2SEM) in placebo- and losartan-treated 129 WT and Marfan mice 
from 2 to 6 months of age (left graph), and placebo- and RDEA119-treated 129 WT and Marfan mice from 
2 to 4 months of age (right graph). Note the significant rescue of aortic root growth in 129 Marfan mice by 
both losartan and RDEA119. Both drugs also reduced aortic root growth in WT mice, but the magnitude of 
effect was substantially less than that observed in Marfan animals. 
 
         
 
Fig.5-13. Survival curve for placebo- and losartan-treated 129 WT and Marfan mice, showing significant 





The full rescue achieved by both losartan and RDEA119 in 129 Marfan mice 
suggests that the aortic root aneurysm exacerbation seen in 129 Marfan mice is likely a 
result of exacerbation of known drivers of disease progression (namely TGFβ and 
angiotensin), rather than new drivers not previously identified in BL6 Marfan mice. This 
is supported by the Western blot data, showing enhancement of both canonical (Smad2 
and Smad3) and noncanonical (ERK1/2) TGFβ-dependent signaling cascades in the 
aortas of 129 Marfan mice. Whether increased p38 activation plays a significant role in 
driving aortic root growth in 129 Marfan animals, and whether it lies in parallel, upstream 
or downstream of ERK1/2 and/or Smads 2 and 3 in this process, remains to be elucidated.  
Losartan may have shown a greater degree of rescue than RDEA119, given that it 
not only inhibits ERK1/2 activation, but also reduces blood pressure, which is known to 
provide a degree of protection from aortic aneurysm progression in Marfan syndrome. 
Whether there is a role for p38 in driving aortic disease in 129 Marfan mice, and whether 
losartan’s superior efficacy in abrogating aortic root growth in 129 animals may also be 
due to its ability to also inhibit p38 activation,503,504 is an area of ongoing investigation.  
Next, we wished to try to identify genetic modifiers in the 129 background strain 
that might lead to exacerbation of the aortic root disease seen in Marfan mice. The first 
question to address was whether any modifiers are located on the X chromosome, since 
this can be easily assessed by stratifying our existing BL6-129 aortic data by gender. 
Stratification of aortic root size at 6 months of age showed no evidence of a gender effect 
in Marfan mice on either a pure BL6 (p=0.11) or a pure 129 (p=0.98) background (Fig.5-
14), arguing against the existence of any X-linked modifier on either background that 
influences post-natal aortic size in Marfan mice.  
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Fig.5-14. Mean aortic root size (±2SEM) at 6 months of age in BL6 and 129 Marfan mice, stratified by 
gender. Note the absence of a significant difference in aortic root size between male and female Marfan 
mice on either background strain. 
 
Once we had eliminated the X chromosome as a source of possible 129-related 
genetic modification in Marfan mice, we turned our attention to the autosomes. In order 
to map modifier loci on the 129 background strain, we first bred BL6 Marfan mice to 129 
WT animals, and 129 Marfan mice to BL6 WT animals (F0 generation), to create an F1 
generation cohort. To assess whether this cohort developed an intermediate aortic 
phenotype, we measured aortic root size in the F1 generation mice. At 6 months of age, 
F1 Marfan mice possessed an aortic root size that was intermediate between the two pure 
strains (Fig.5-15); it was significantly larger than that of pure BL6 Marfan mice 
(p<0.001), but significantly smaller than that of pure 129 Marfan animals (p<0.0001). 
This argued against the existence of a single dominant locus on either background. Had 
this been the case, all F1 generation Marfan mice would have had an aortic root size that 
was indistinguishable from either pure BL6 or pure 129 Marfan animals (depending on 
which background possessed the dominant locus). 
153 
 
         
 
Fig.5-15. Mean aortic root size (±2SEM) at 6 months of age in pure BL6, pure 129 and F1 mixed 
generation BL6/129 WT and Marfan mice. Note the intermediate size of the F1 Marfan mice, being 
significantly bigger than pure BL6 Marfan mice, but significantly smaller than pure 129 Marfan animals. 
 
To try to assess whether there was a large or small number of modifier loci 
driving the aortic root exacerbation seen in 129 Marfan mice, we bred F1 mice together 
to create an F2 generation. These F1 matings were random, since we wished to assess the 
distribution of aortic root size at 6 months of age in F2 generation mice in a non-biased 
fashion. We then graphed the frequency of mice with aortic root sizes ranging from 
1.8mm to 3.2mm in 0.1mm increments at 6 months of age, separately for pure BL6, pure 
129 and mixed F1 BL6/129 Marfan mice (Fig.5-16, upper panel).  
This generated three overlapping but distinct distribution curves for the three 
backgrounds strains. Only pure BL6 Marfan mice had an aortic root size at 6 months that 
was less than 2.2mm, while only pure 129 Marfan mice had an aortic root size at 6 
months that was 2.7mm or greater. Only mixed F1 BL6/129 mice had an aortic root size 
at 6 months that was in the 2.3-2.49mm range. This means that for any mice of unknown 
background strain, they can be classified as ‘pure BL6-like,’ ‘mixed F1-like,’ or ‘pure 
129-like’ if their aortic root size at 6 months of age falls within one of these three ranges.  
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There was also some overlap in aortic root size between the backgrounds. A few 
mice from the pure BL6 and mixed F1 backgrounds had an aortic root size at 6 months in 
the 2.2mm to 2.29mm range. A few mice from the mixed F1 and pure 129 backgrounds 
had an aortic root size at 6 months in the 2.5mm to 2.69mm range. Hence any mice of 
unknown background with an aortic root size at 6 months that falls in one of these ranges 
cannot be classified into one of the three backgrounds with any degree of certainty.  
 
          
 
Fig.5-16. Upper panel: Distribution showing the number of Marfan mice (Y-axis) with a given aortic root 
size at 6 months of age (X-axis), stratified by strain background (pure BL6, F1 mix, pure 129). The mean 
aortic root size for each of the 3 backgrounds is written above the graph in the corresponding color. Aortic 
root size on the X-axis is rounded to 1 decimal place (i.e. the 1.8s column equates to an aortic root size 
from 1.80mm to 1.89mm; the 1.9s column equates to an aortic root size from 1.90mm to 1.99mm).  
Lower panel: Distribution showing the number of Marfan mice (Y-axis) with a given aortic root size at 6 
months of age (X-axis) in the interbred F2 generation. Mice were categorized as ‘pure BL6-like’, ‘mixed’ 
or ‘pure 129-like,’ based on aortic root size (shown in the appropriate color). Mice that fell into the overlap 
ranges (2.20mm to 2.29mm, and 2.50mm to 2.69mm) were colored in black. 
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We then graphed this same distribution of aortic root size at 6 months of age for 
Marfan mice in the F2 generation (Fig.5-16, lower panel). If the 129 background contains 
a large number of modifier loci, all of which only possess a small effect on aortic root 
size, one would anticipate that random assortment of the chromosomes would result in a 
normal distribution (i.e. a bell-shaped curve) in the F2 generation of Marfan mice. 
Instead, as can be seen from the graph, there was segregation into 3 discrete peaks, which 
closely correlated with the peaks observed previously in the pure BL6, pure 129 and 
mixed F1 generation mice (Fig.5-16, upper panel). First, this suggested that there are only 
a small number of major loci driving the aortic root size exacerbation seen in 129 Marfan 
mice. Second, this illustrated that the majority of F2 generation Marfan mice (33 out of 
36 mice = 95%) naturally fall into one of the three main background categories, based on 
their aortic root size at 6 months of age (‘pure BL6-like’ if  less than 2.20mm, ‘mixed’ if 
2.30-2.49mm, or ‘pure 129-like’ if greater than 2.70mm).  
In light of this, we selectively bred F2 generation Marfan mice that possessed 
small and large aortic root dimensions to create 5 further generations of interbred 
BL6/129 animals. This resulted in a 7 generation pedigree of related Marfan mice (Fig.5-
17). These mice underwent echocardiography at 6 months of age, and based on their 
aortic root size, were categorized as ‘pure BL6-like,’ ‘mixed F1-like,’ and ‘pure 129-
like.’ We then selected 35 ‘pure BL6-like’ mice (using the conservative aortic root size 
range of 1.90mm to 2.10mm), and 41 ‘pure 129-like’ mice (aortic root size 2.70mm or 
greater), and sent them for linkage analysis. In total, genotyping was performed using 862 
SNPs that differed between the BL6 and 129 parental strains (mean number of SNPs per 




Fig.5-17. Seven generation pedigree of interbred BL6 and 129 Marfan mice that were used to identify 35 
‘pure BL6-like’ (red asterix) and 41 ‘pure 129-like’ (blue asterix) Marfan mice, based on aortic root size at 
6 months of age. These mice were then used to perform the genome wide linkage analysis.  
 
Whole genome mapping revealed 2 quantitative trait loci (QTLs) on 
chromosomes 5 and 11 that strongly linked with ‘pure 129-like’ aortic phenotype, both of 
which exceeded the LOD Score threshold of 3.82 for genome wide significance (Fig.5-
18). The individual loci possessed LOD scores of 4.76 and 4.78, respectively (Figs.5-19, 
5-20), both of which were highly significant (p=0.008). Furthermore, there was evidence 
of additive epistasis between the 2 loci (MfLOD=12.8, p=0.0006; Fig.5-21). While each 
locus individually modifies aortic root size in Marfan mice, a greater effect is achieved 
by a combination of the 2 loci. In fact, when the number of 129 alleles across the 2 loci is 
plotted against aortic root size of Marfan mice at 6 months of age, one can see a clear 
dose-response, with an increasing number of 129 alleles (from 0-4; up to 2 at each locus)  
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resulting in an incremental increase in aortic root size of the animals (Fig.5-21).  
 
            
Fig.5-18. Genome-wide linkage analysis comparing aortic root size at 6 months of age in ‘pure BL6-like’ 
and ‘pure 129-like’ F2-F7 generation Marfan mice. This revealed 2 loci, on chromosomes 5 and 11, which 
exceeded the LOD score genome wide significance threshold of 3.82.  
         
           
Fig.5-19. The chromosome 5 locus consisted of a 20cM peak, with a LOD Score of 4.76, which was highly 




          
 
Fig.5-20. The chromosome 11 locus consisted of a 10cM peak, with a LOD Score of 4.78, which was 
highly significant (p=0.008). The region of the peak highlighted in red also reached genome-wide 
significance by association analysis. 
 
          
 
Fig.5-21. Evidence of epistasis between the chromosome 5 and 11 loci. When the dosage of 129 alleles 
(from 0-4, up to 2 from each locus) is plotted against aortic root size of Marfan mice at 6 months of age, 
one can see a clear dose-response, with an increasing number of 129 alleles resulting in an incremental 
increase in aortic root size of the animals. 
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The limits of the regions of interest in the 2 peaks were defined as those areas 
achieving significance by both genome wide linkage and association (red boxes in Fig.5-
19 & 5-20). This included a 14.7Mb region on chromosome 5 (128,433,315-143,149,098 
bp) and an 8.9 Mb region on chromosome 11 (106,799,515-115,722,120 bp).  
We identified a number of potential candidate genes within the regions of interest 
in the 2 peaks. The peak on chromosome 5 contains 211 genes, 4 of which are obvious 
candidates. Mmp17 encodes an indirect activator of latent TGFβ and is involved in 
extracellular matrix homeostasis; Rabgef1 encodes an integrator of TGFβ and Ras-Raf-
MEK-ERK signaling; Eln encodes elastin, a major component of elastic fibers which is 
known to interact directly with fibrillin-1; Rasa4 encodes a calcium-dependent Ras 
GTPase-activator, which can inhibit the Ras-Raf-MEK-ERK pathway. The peak on 
chromosome 11 contains 89 genes, 3 of which are obvious candidates. PKC alpha 
encodes a calcium-activated protein kinase that can influence the ERK cascade; Map2k6 
encodes a protein that is activated by Map3k4, and itself can activate p38; Grb2 encodes 
an adapter protein that links growth factor receptors to the RAS signaling cascade. All of 
these molecules represent strong possible functional candidates, the relative expression of 
which is currently being assessed in the aortic roots of BL6 and 129 animals.  
Another approach we used to identify candidate genes in the 2 regions of interest 
was to search for causal genetic variation using the mouse genome project online 
repository.505 Of the 211 genes in the peak on chromosome 5, 207 exonic or splice site 
variants were identified; 55 of these were missense or indel variants; 8 of these were 
predicted to be deleterious by either SIFT or PROVEAN; only 1 variant was in a strong 
functional candidate gene. This was a missense point mutation in Mmp17 (rs29636438; 
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c.A1737G; p.X579W). MMP17 (also known as MT4-MMP) is one of two members of 
the MMP family, which along with MMP25, is anchored to the plasma membrane via a 
GPI anchor. This appears to confer upon these enzymes a unique set of regulatory and 
functional mechanisms that separates them from the rest of the MMP family. The 
identified variant is predicted to alter the C-terminal region of the protein, modifying its 
attachment to the GPI anchor, and possibly affecting its cell surface expression. 
Interestingly, screening of patients with inherited thoracic aortic aneurysms led to 
the recent identification of a missense mutation (R373H) in MMP17 that prevented its 
expression in human transfected cells.506 Furthermore, elimination of Mmp17 in mice 
resulted in dysfunctional VSMCs, altered vessel wall extracellular matrix, and increased 
susceptibility to angiotensin II induced thoracic aortic aneurysm. There is also evidence 
that MMP17 can directly interact with the epidermal growth factor receptor (EGFR), and 
positively regulate its activation.507 This is of particular interest, given that angiotensin II 
infusion in mice has been shown to lead to upregulation of EGFR activation in the 
abdominal aorta, while treatment with the EGFR inhibitor erlotinib has been found to 
inhibit the development of abdominal aortic aneurysm and reduce the rate of lethality 
from aortic dissection in these mice, in association with decreased EGFR activation.508 
Given the predicted deleterious variant in Mmp17 that we identified in our linkage 
peak on chromosome 5, we hypothesized that 129 Marfan mice may possess greater 
EGFR activation than their BL6 counterparts. To test this, we performed Western blot 
analysis on the aortic root of 6 month old mice, and found that EGFR activation was 
significantly increased in 129 Marfan mice relative to their BL6 counterparts (p<0.01; 
Fig.5-22). Furthermore, treatment from 4 to 6 months of age with the EGFR inhibitor 
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erlotinib significantly reduced aortic root growth in 129 Marfan mice (p<0.001; Fig.5-
23), to a growth rate indistinguishable from that of WT mice (p=0.88). This suggests that 
EGFR activation is increased in more severe aortic disease in Marfan mice, while 
inhibition of EGFR activation represents a novel therapeutic strategy for the disorder. 
 
         
 
Fig.5-22. Western blot analysis of EGFR activation in the aortic root of 6-month old BL6 and 129 WT and 
Marfan mice. Note the significant increase in EGFR activation in 129 Marfan mice, relative to their BL6 
counterparts. Plac, placebo; Erlo, erlotinib. 
 
           
 
Fig.5-23. Mean aortic root growth (±2SEM) from 4 to 6 months of age in placebo- and erlotinib-treated 129 
WT and Marfan mice. Note the significant rescue of aortic root growth achieved by erlotinib in 129 Marfan 
animals. Plac, placebo; Erlo, erlotinib. 
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Of the 89 genes in the peak on chromosome 11, 118 exonic or splice site variants 
were identified; 47 of these were missense or indel variants; 13 of these were predicted to 
be deleterious by SIFT or PROVEAN; only 1 of these was in strong functional candidate 
gene. The identified variant is a missense point mutation in Map2k6, also known as 
Mek6, Mkk6, and Mapkk6 (rs51129320; c.G227A; p.G76E).  
In the Mapk signaling cascade, receptor phosphorylation activates a conserved 
cascade of three serine-threonine protein kinases. A specific Map3k phosphorylates and 
activates a specific Map2k, which itself phosphorylates and activates a specific Mapk. As 
a member of the Map2k family, Map2k6 is a strong functional candidate for several 
reasons. First, it can be activated by both angiotensin II and TGFβ,509,510 both of which 
play a critical role in disease pathogenesis in Marfan mice. Second, it directly influences 
p38,511,512,513 the activation of which is increased in 129 Marfan mice relative to BL6 
counterparts (Fig.5-11). Third, the direct upstream activator of Map2k6 is Map3k4,514 
which has recently been identified as a strong functional candidate as a major genetic 
modifier of aortic aneurysm growth in humans with MFS,515 while haploinsuffiency for 
Map3k4 leads to a significant rescue of aortic root growth in Marfan mice (Fig.5-24).  
The p.G76E variant is located in the N-terminal lobe of the protein, which 
consists of a coiled region, five anti-parallel β-sheets and an α-helix.516 It substitutes a 
small, non-polar glycine residue, located in an exposed β-hairpin loop between the 2nd 
and 3rd β-sheets, with a large, polar glutamate residue. The alteration is not predicted to 
dramatically disrupt the β-hairpin loop, presumably because the glutamate residue is on 
an exposed surface.517 However, amino acid residue 76 forms part of a cluster of amino 
acids, which are conserved across all Map2k proteins. It sits between the phosphate-
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binding ribbon of the protein, which binds ATP and is necessary for catalytic activity, 
and the catalytic domain of the protein.509,518 It also falls within the dimerizing domain of 
the protein.519 Taken together, these data suggest that the p.G76E alteration could 
influence the binding of ATP, its catalysis, or the dimerization of Map2k6, any of which 
could feasibly alter the function of the protein.  
 
 
         
 
Fig.5-24. Mean aortic root growth (±2SEM) from 2 to 10 months of age in WT and Marfan mice that retain 
either one or two normal copies of Map3k4. Note the significant rescue of aortic root growth in Map3k4 
haploinsufficent Marfan mice. Data courtesy of Alex J. Doyle (MD-Res Thesis, 2014). 
 
 By generating stably-transfected cell lines that contain copies of either the BL6 or 
129 Mmp17 and Map2k6 variants, ongoing work is exploring whether there are 
identifiable signaling differences that result from expression of the alternate alleles. 
Furthermore, we are currently generating 129 Marfan mice that are haploinsufficient for 
either Mmp17, Map2k6, or both, to assess whether haploinsuffiency for either of these 
proteins does indeed rescue aortic root growth in 129 Marfan mice, and whether there is a 
synergistic effect when both proteins are in a haploinsufficient state. 
There is work published after the initiation of this project that claims to show the 
129 background influences disease severity in Marfan mice.520 It used a modified version 
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of a previously-described Marfan mouse model (mgΔ), which has a 6kb portion of the 
Fbn1 gene between exons 19-24 replaced by a neomycin-resistance expression (neoR) 
cassette.521 In the new study, the cassette was flanked by lox-P sequences (mgΔloxPneo) to 
allow Cre-recombinase-mediated deletion of the cassette. However, all analyses in the 
paper appear to have been performed in mice that retained the cassette, making the direct 
link to human relevance debatable.  
In this prior study, it was concluded that, compared to the BL6 background, the 
129 background increased the severity of the Marfan mouse phenotype in the aorta, lung 
and spine. However, there was no direct statistical comparison made between Marfan 
mice on the two backgrounds in any of the three organ systems. Furthermore, visual 
assessment of both the lung MLI and the aortic wall thickness data at 6 months of age in 
the paper suggests that there was no significant difference in phenotypic severity in either 
system between Marfan mice on the 2 background strains.  
It was also stated that the 129 background resulted in an earlier onset of disease in 
Marfan mice, although again no statistical comparisons were made to support this. 
Furthermore, 129 Marfan mice were reported to have a normal lifespan, indicating that 
the apparent earlier onset and greater severity of disease had no effect on clinical 
outcome. It was also stated that the 129 background caused a greater degree of variability 
in the Marfan phenotype. For example, when assessing aortic disease, 60% of 129 
Marfan mice were classed as ‘asymptomatic’ at 3 months of age, while 33% fell into this 
category at 6 months. Asymptomatic was defined as being no different to WT mice.  
Since the mice were back-crossed 14 times onto a 129 background, it was 
concluded that genetic heterogeneity could not be the source of this clinical variability. It 
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was therefore stated that epigenetic modification by the 129 background strain was the 
likely mechanism of action, although there was no evidence shown for this. By contrast, 
we find that not only did every 129 Marfan mouse have more severe aortic disease than 
their WT littermates at both 2 and 6 months of age, but that every 129 Marfan mouse had 
more severe aortic disease than all of their BL6 Marfan counterparts. Hence we find a 
fully penetrant phenotype that did not show any significant degree of variability. 
The prior work explained that the severity of the phenotype in 129 Marfan mice 
correlated between the different systems (i.e. those mice with more severe pulmonary 
manifestations also had more severe aortic or bone disease), and that this inversely 
correlated with the degree of total Fbn1 expression (i.e. the more Fbn1 expression, the 
more mild the phenotypes). This is relatively unsurprising, since the mechanism by which 
the mgΔ mouse model is thought to induce a phenotype is via neoR casette-mediated 
disruption of Fbn1 expression. It is hence likely that both the phenotypic manifestations 
and the clinical variability of the mice in the study could be explained by neoR casette-
mediated disruption of Fbn1 expression in a non-allele-specific manner (since total Fbn1 
expression varied, while the mutant/normal ratio remained constant). Whether this 
explains the proposed difference in the Marfan phenotype between the 2 background 
strains, and whether this has any relevance to human disease, remains open to question. 
Certainly there was no evidence provided in the paper to show how the 129 background 
strain was thought to be causing an alteration in Fbn1 expression. 
By contrast, through genome-wide linkage analysis, we have identified 
chromosomal loci and sequence-specific polymorphisms in candidate genes on the 129 
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background that may influence phenotypic exacerbation in Marfan mice, with direct 
evidence of altered molecular signaling and the potential for therapeutic rescue.   
MFS has traditionally been considered a monogenic disorder, as to date only 
mutations in FBN1 have been shown to cause it. However, it is well recognized that there 
is considerable heterogeneity between patients in terms of which tissues are affected, and 
the severity of their symptoms in those tissues. Given that both of these tend to track in 
families, this suggests that there is heritability of these modifying variables, with modifier 
genes being one obvious possible mechanism. This work suggests that it is indeed 
feasible to map modifier chromosomal loci in post-natally progressive, continuous, 
phenotypes in mice, with the ultimate aim of identifying candidate genes and designing 
novel therapeutic strategies as a result.  
This work also suggests that there may be a role in the future for genetic testing of 
candidate modifier genes in patients to provide additional prognostic information. 
Analogous to the data herein, which shows that the 129 background modifies disease 
severity in multiple organ systems, but has a proportionally greater effect in one (i.e. the 
aorta), genetic testing of modifier genes in patients in the future may need to be stratified 
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Our Understanding about Marfan Syndrome Prior to This Work 
 
In 1896, French pediatrician Antonine Bernard-Jean Marfan described a 5-year-
old girl, Gabrielle P.,522 who was tall for her age, had disproportionately long limbs and 
fingers, and joint contractures of her fingers and knees. 6 years later, Mery and 
Babonneix added scoliosis to the list of skeletal abnormalities,523 while the French 
clinician Achard coined the term ‘arachnodactyly’ to explain the long, spidery fingers 
seen in another similar patient.524  Ectopia lentis and mitral regurgitation were later added 
to the list of features.525,526 In 1938, Apert proposed the name ‘Marfan syndrome,’527 and 
in 1943, one year after Marfan’s death, aortic dilatation, regurgitation, and dissection 
were added to the list of features.528,529 In 1949, Lutman and Neel examined segregation 
of the skeletal and ocular symptoms,530 interpreted it as autosomal dominant inheritance, 
and concluded it likely represented the pleiotropic effects of a single gene.  
It was another 42 years before Dietz and colleagues first identified mutations in 
FBN1 as the genetic cause of the disorder. Even though it has been nearly 120 years since 
the syndrome was first described, and nearly 25 years since the causal gene was first 
identified, it is only relatively recently (in the past decade) that major significant 
advances in our understanding of the molecular mechanisms underlying Marfan 
syndrome (MFS) and related disorders has come to light. 
It was long thought that fibrillin-1 containing microfibrils were required for 
elastic fiber integrity in the extracellular matrix. This led to the belief that individuals 
with MFS had an obligate predisposition to tissue structural weakness and failure. This 
was thought to explain the reason why the aorta in MFS dilates at blood pressures that do 
not typically have any deleterious consequence. Since fibrillin-1 is only expressed until 
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early childhood, and many patients are diagnosed with MFS after this age, this boded 
poorly for the development of novel therapeutic strategies for the disorder.   
However, it was evident that certain manifestations of MFS, such as bone 
overgrowth, mitral valve elongation and thickening, and skeletal muscle hypoplasia, were 
difficult to reconcile with a pathogenic model that invoked compromised tissue structural 
integrity; they were more suggestive of altered cellular performance. The degree of 
homology between the fibrillins and the latent TGF binding proteins (LTBPs) prompted 
the hypothesis that perhaps abnormal or insufficient fibrillin-1 containing microfibrils in 
the tissues of MFS patients might lead to altered TGF activation. Whether this was true, 
and whether TGF was driving disease pathogenesis in MFS, remained to be determined. 
There was a paradigm shift in our thinking about the disorder when mice 
heterozygous for a missense mutation in the gene encoding fibrillin-1 (Fbn1C1039G/+ 
hereafter referred to as Marfan mice) were found to show excess TGF signaling, as 
evidenced by increased nuclear accumulation of phosphorylated Smad2/3 (pSmad2/3) in 
the aortic root, lung, skeletal muscle and mitral valves.531,532,533 Furthermore, the fact that 
treatment with systemically-administered TGF-neutralizing antibody (TGF NAb) was 
able to rescue these phenotypes in Marfan mice, in association with blunted Smad2/3 
activation, highlighted the potential for post-natally administered therapeutic 
interventions to influence the outcome of the disorder. 
While TGFNAb is not yet approved for human use (it remains in clinical trials), 
further advancement in the potential for therapeutic opportunites in MFS came with the 
recognition that the angiotensin II (AngII) type 1 receptor (AT1R) blocker (ARB) 
losartan, which is known to attenuate TGF signaling in other disease states, by reducing 
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the expression of TGF ligands, receptors, and activators,534,535,536,537 could fully rescue 
of aortic root aneurysm progression, aortic wall thickness and aortic wall architecture in 
Marfan mice.527 Not only that, but it was significantly more efficacious than either 
placebo or a hemodynamically-equivalent dose of the beta-blocker propranolol. A similar 
phenotypic rescue by losartan was also observed in the skeletal muscle and lungs of MFS 
mice, tissues in which blood pressure changes have no relevance.533,538 Notably, rescue in 
all tissues correlated with reduced Smad2/3 activation, suggesting that losartan was 
achieving its therapeutic effect through antagonism of TGF signaling. 
There is preliminary evidence to suggest that these findings hold promise for 
patients with MFS. The effect of add-on ARB therapy was assessed in a small cohort of 
pediatric MFS patients who had severe aortic root enlargement despite previous medical 
therapy. This study found that add-on ARB therapy significantly slowed the rate of aortic 
root and sinotubular junction dilatation, whereas the distal ascending aorta (which does 
not normally dilate in MFS) remained unaffected.539 In light of this growing body of 
evidence, a number of prospective clinical trials to assess the therapeutic potential of 
ARBs in MFS have been initiated.540 Given the subtle nuances of each, they will likely 
address distinct but complimentary clinical questions. Several have now yielded data, 
while some are yet to be completed. 
Losartan has been assessed as an add-on therapy in other more recent trials.541,542 
Chiu and colleagues assessed the efficacy of losartan add-on to existing β-blockade in 28 
patients with MFS (39% males; mean±SD age, 13.1±6.3 years), with recognized aortic 
root dilation (z score >2.0), who were receiving β-blockers (atenolol or propranolol) at 
baseline. Follow up was 35 months. They found that the annual aortic root dilation rate 
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was significantly lower in the losartan add-on group (0.10 mm/yr vs 0.89 mm/yr; 
p=0.02), with 5 of the patients (33%) actually having regression in aortic root size over 
the treatment period. The absolute aortic diameters at the sinus of Valsalva, annulus, and 
sinotubular junction showed similar results (p=0.02, p=0.03, and p=0.03, respectively).  
The COMPARE study was a large multicenter, open-label, randomized controlled 
trial with blinded assessments, comparing losartan add-on to no additional treatment in 
233 operated and unoperated adults with MFS.543 Patients who were already on β-
blockers or calcium channel blockers (CCBs) were continued on their existing 
medication, while those who were already on ARBs or angiotensin converting enzyme 
inhibitors (ACEi) were excluded from the study. Aortic root dilatation after 3.1±0.4 years 
of follow-up was significantly lower in the losartan add-on group than in controls 
(0.77±1.36mm vs. 1.35±1.55mm, p=0.014). Furthermore, in patients with prior aortic 
root replacement, aortic arch dilatation was significantly lower in the losartan add-on 
group than in controls (0.50±1.26mm vs. 1.01±1.31mm, p=0.033). 
Losartan has also been compared to placebo as a monotherapy. One study was 
conducted in an unselected cohort of 20 pediatric and adolescent patients aged from 1.7 
to 21.6 years, all of whom had genotype-confirmed MFS.543 Follow-up was 33±11 
months. A significant reduction in normalized aortic dimensions was observed with 
losartan in the valve, root, sinotubular junction, and ascending aorta (p=0.008, p<0.001, 
p=0.012, and p=0.001, respectively). A significant correlation between greater 
improvement and younger age at onset (r2=0.643, p=0.002) and longer therapy duration 
(r=2-0.532, p=0.016) was also noted, although no correlation between therapeutic 
response and the type of mutation or clinical presentation was found.  
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More recently, the results from a randomized trial conducted in 608 children and 
young adults with MFS, comparing losartan monotherapy with atenolol monotherapy, 
were published.544 There was no significant difference in the baseline-adjusted rate of 
change in aortic-root z score between the two treatment arms (atenolol -0.139±0.013, 
losartan -0.107±0.013 standard-deviation units per year, respectively; p=0.08). 
Interestingly, both growth rate slopes were significantly less than zero, indicating a 
decrease in aortic root diameter relative to body surface area with either treatment. This 
degree of rescue by a β-blocker was substantially more than had been seen in previous 
studies, and may relate to the fact that the trial used a dose that was significantly higher 
than is generally used in regular clinical practice.  
Hence while the majority of the data so far suggest that ARBs offer therapeutic 
benefit in patients with MFS, there are still some conflicting results. In an attempt to 
more definitively address this issue further, a prospective, collaborative meta-analysis 
using individual patient data from all the randomized trials in MFS for ARBs versus 
placebo (or open-label control), and ARBs versus β-blockers, has been proposed.545 This 
aims to address the effects of ARBs on aortic root enlargement and a range of other end 
points in MFS patients. The logic is that if individual participant data from all of the trials 
are combined, a meta-analysis of the resulting data, totaling approximately 2,300 
patients, would allow estimation across a number of trials of the treatment effects both of 
ARBs and β-blockade. Such an analysis may also allow estimation of treatment effects in 
particular subgroups of patients on a range of end points of interest, and would likely 
allow a more powerful estimate of the effects of these treatments on a composite end 
point of several clinical outcomes than would be available from any individual trial.  
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The Implications of this Work for Marfan Syndrome and Related Conditions 
 
A Role for ERK Signaling in MFS and its Therapeutic Implications 
 
Following aberrant matrix-dependent activation of TGF and subsequent 
interaction with its cell surface receptor, it remained to be determined what the critical 
TGF-dependent intracellular mediators were driving disease pathogenesis in MFS. Until 
this work, much of the focus in both MFS and other TGF-dependent disease states had 
been placed on so-called canonical (i.e. Smad) pathways. However it was becoming 
increasingly recognized that TGF can also stimulate other (noncanonical) cascades, 
including the phosphatidylinositol-3-OH kinase (PI3K)/AKT, Rho-associated protein 
kinase (ROCK), and mitogen-activated protein kinase (MAPK) cascades, the latter of 
which includes extracellular signal-regulated kinase (ERK), Jun N-terminal kinase (JNK) 
and p38.546,547,548 While Smad2/3 activation had been shown to correlate with both 
disease progression and therapeutic rescue by TGF NAb and losartan in Marfan mice, a 
cause-and-effect relationship had yet to be determined.  
In Chapter 2, we show that both Smad and ERK1/2 are activated in the aortas of 
Marfan mice, and both are inhibited by TGF NAb and losartan. Furthermore, treatment 
with the orally-bioavailable selective inhibitor of ERK1/2 activation RDEA119 abrogated 
aortic root growth in Marfan mice. ERK1/2 activation, but not Smad activation, was 
reduced in RDEA119-treated Marfan animals, confirming the specificity of the drug and 
illustrating that Smad activation in Marfan mice is not ERK-dependent. Furthermore, 
RDEA119 had no effect on aortic root growth in WT mice, indicating that it selectively 
targets Marfan-associated pathological aortic growth, rather than simply inducing aortic 
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hypoplasia. This work suggests that the noncanonical TGF-dependent ERK1/2 cascade 
plays a critical role in driving aortic disease progression in Marfan mice. 
There is considerable evidence in the literature linking the TGF and angiotensin 
signaling pathways. It is well recognized that AngII can mediate progression of aortic 
aneurysm, but the relative contribution of the angiotensin-II type 1 receptor (AT1R) and 
the angiotensin-II type 2 receptor (AT2R) remained unknown in MFS. Given losartan’s 
therapeutic efficacy via inhibition of the AT1R, this receptor appeared likely to play a 
role in disease pathogenesis in MFS. The contribution of the AT2R to aortic aneurysm 
progression in MFS remained controversial. On the one hand, AT2R signaling has been 
shown to oppose AT1R-mediated enhancement of TGF signaling in some cell types and 
tissues,549,550 which would suggest it should provide protection in MFS. By contrast, 
AT2R signaling can also induce vascular smooth muscle cell (VSMC) apoptosis, 
theoretically contributing to aortic wall damage.551 This has direct clinical relevance, as it 
left open to question the relative therapeutic merits of selective AT1R blockade with 
ARBs versus limiting signaling through both the AT1R and the AT2R using an 
angiotensin-converting enzyme inhibitor (ACEi). 
In Chapter 2, we show that genetic elimination of the AT2R results in accelerated 
aortic growth and rupture in Marfan mice, indicating that AT2R signaling provides 
protection within this context. Furthermore, losartan’s efficacy is reduced in AT2R-
deficient Marfan mice, indicating that ARBs achieve their effect through selective AT1R 
blockade in combination with continued signaling through the protective AT2R. To 
directly assess the efficacy of ARBs versus ACEi, a head-to-head trial of 
hemodynamically-equivalent doses of the ARB losartan and the ACEi enalapril was 
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performed in Marfan mice. Enalapril was less effective than losartan in reducing aortic 
root growth. Both agents attenuated canonical TGF (i.e. Smad2) signaling in the aortas 
of Marfan mice, but losartan uniquely inhibited ERK1/2 activation. Although concordant 
effects of prior therapies on canonical and noncanonical TGF signaling cascades made it 
impossible to dissect out their relative contributions, the differential effects of losartan 
and enalapril in this work suggested that noncanonical TGF signaling (specifically 
ERK1/2) is the predominant driver of aneurysm progression in Marfan mice.  
Notwithstanding this, there is evidence in patients with MFS that ACEi therapy 
may be beneficial. Enalapril treatment was shown in a small cohort of MFS patients to be 
favorable over -blocker therapy,552 although no biochemical analysis was performed and 
no comparison to ARBs was made. Another study suggested that treatment with the 
ACEi perindopril is beneficial in patients with MFS,553 although the analysis period was 
relatively brief (6 months), ACEi therapy was not prescribed in isolation (but rather was 
used in combination with -blockers), and no comparison to ARBs was made. However, 
the study did show that combined ACEi/-blocker therapy led to a significant reduction 
in circulating latent and active TGFβ, as well as total matrix metalloproteinase (MMP)-2 
and -3 levels. Hence there is still some question as to the relative therapeutic merits of 
ARBs versus ACEi in patients with MFS, an issue that is further clouded by the fact that 
some ACEi such as perindopril may have a number of pleitropic effects.554 
Chapter 3 discusses the accentuation of the Marfan aortic phenotype by calcium 
channel blockers (CCBs), while Chapter 5 explores the exacerbation of aortic root growth 
observed in Marfan mice on a 129 background. In both of these scenarios, the severity of 
the disease phenotype correlated with the degree of ERK1/2 activation, with both CCB-
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treated BL6 Marfan mice and 129 Marfan mice showing enhanced activation of ERK1/2, 
relative to BL6 Marfan counterparts. Hence ERK1/2 activation not only appears to be 
increased in Marfan mice, but it also appears to show a dose-response relationship; the 
greater the degree of ERK1/2 activation, the greater the degree of aortic growth. 
Furthermore, treatment with RDEA119 leads to rescue of aortic growth in both CCB-
treated BL6 Marfan mice, and in 129 Marfan animals, indicating that the exacerbation of 
ERK1/2 activation seen in both of these disease contexts is a driver of aortic disease 
pathogenesis, rather than simply a marker or secondary response to disease progression. 
More recent work by Cook and colleagues suggests that enhanced ERK1/2 
activation may also underlie other phenotypic manifestations in Marfan mice.555 They 
have shown that mice homozygous for a hypomorphic allele of Fbn1 display spontaneous 
emergence of an enlarged and dysfunctional heart, typical of dilated cardiomyopathy 
(DCM). They went on to show that the hearts of these mice had significantly increased 
ERK1/2 activation, with both the cardiomyopathy and the ERK1/2 activation being 
rescued by either losartan treatment or AT1 receptor elimination. Similar to our work, 
they also found that treatment with either the ACEi enalapril or the β-blocker propranolol 
was significantly less efficacious than losartan, although their effect on ERK1/2 
activation in the setting of DCM was not reported. 
The work by Cook at el. also concluded that the DCM phenotype and ERK1/2 
activation in Marfan mice is AT1R-dependent but AngII-independent (i.e. AT1R 
activation occurs in a ligand-independent manner). This raises the question of whether 
this is also true for other manifestations of the disorder, including aortic aneurysm. There 
are a number of reasons why this may not be the case. First, they used a different mouse 
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model of MFS, namely the Fbn1MgR/MgR model, which has no direct human correlate. 
This differs from the Fbn1C1039G/+ mouse model which we have used throughout our 
work, which is heterozygous for the most common class of missense mutation causing 
MFS in people. Furthemore, they solely focused on DCM, and did not address the 
phenotypic consequences of angiotensinogen gene knockout in any other tissues.  
It is also notable that the critical figure in their paper that assesses the phenotypic 
consequence of deletion of the angiotensinogen gene (Agt-/-) is incomplete. For the first 
2 physiological parameters used to define DCM in their paper (LVIdD and %FS), there is 
a break in the horizontal axis between the previously mentioned manipulations and the 
Fbn1MgR/MgR, Agt-/- analysis, presumably because these data were obtained at a later time 
point from the original manipulations. It would be most appropriate to compare the 
Fbn1MgR/MgR, Agt-/- mice to newly generated littermates. While new WT control data was 
included in the Fbn1MgR/MgR, Agt-/- analysis, there was no new Fbn1MgR/MgR control data 
included. Therefore it is hard to know whether or not the Fbn1MgR/MgR, Agt-/- manipulation 
represented a failed rescue for either LVIdD or %FS. For the 3rd parameter used to define 
DCM in their paper, namely HW/BW ratio, no data at all was included for the 
Fbn1MgR/MgR, Agt-/- manipulation. Finally, there was no mention of the effect of the 
Fbn1MgR/MgR, Agt-/- manipulation on ERK1/2 activation, making it impossible to know 
whether there was any associated biochemical correlation.  
Hence the only conclusion that can be reached from this aspect of their work is 
that Marfan mice lacking angiotensinogen have some degree of left ventricular dilatation 
and dysfunction, compared to WT mice. This falls far short of suggesting that all aspects 
of MFS relate to an AT1R-dependent but AngII-independent mechanism. It is also 
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notable that there is no mention of any mechanism beyond a vague reference to stretch 
and integrin signaling to explain ligand-independent AT1R activation in this work. 
By contrast, we have shown that elimination of the AT2R in Marfan mice reduces 
the therapeutic efficacy of AT1R blockade with losartan in these animals, and that this 
correlates with a lack of rescue of ERK1/2 activation in losartan-treated AT2R-knockout 
Marfan mice. This suggests that the protective effect of AT1R blockade in MFS is, at 
least in part, dependent on AT2R signaling. Given that AngII is the major ligand for the 
AT2R, this suggests that AngII signaling (via the AT2R) plays a significant role in 
modulating disease pathology in Marfan mice. Since ARBs work predominantly (if not 
exclusively) as a competitive inhibitor of the AT1R, these data suggest that the 
therapeutic effect of ARBs relates to displacement of AngII and shunting of signaling 
through the AT2R. While we have not assessed the effect of angiotensinogen knockout 
on aortic growth in Marfan mice, this would seem a reasonable avenue for future work. 
 
A Role for ERK Activation in Other Marfan-Related Conditions 
 
Since our initial discovery about the role of ERK1/2 activation in MFS, there is a 
growing body of evidence that increased ERK1/2 activation may be present in a number 
of Marfan-related conditions. Loeys Dietz syndrome (LDS) is a related connective tissue 
disorder that is characterized by a high risk for aneurysm and dissection throughout the 
arterial tree. It is caused by heterozygous missense mutations in either TGFβ receptor 
gene (TGFBR1 or TGFBR2). Two knock-in mouse strains with LDS mutations in either 
Tgfbr1 or Tgfbr2 have been genereated, both of which recapitulate the aortic 
manifestations seen in LDS patients.556   
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Analysis of the aortic wall in LDS mice has revealed increased activation of both 
Smad2 and ERK1/2, as well as increased TGFβ target gene output.556 Analogous to what 
was observed in Marfan mice, treatment of LDS mice with losartan led to a significant 
rescue of aortic root growth, in association with blunted Smad2 and ERK1/2 activation, 
as evidenced by immunofluorescence. By contrast, treatment of LDS mice with the β-
blocker propranolol showed an inferior rescue of aortic growth, and no effect on ERK1/2 
activation, which further parallels our work in Marfan animals.  
Chapter 4 discusses our identification of heterozygous mutations or deletions in 
the gene encoding TGFβ2 ligand as the cause of an LDS-like condition. Tgfb2 
haploinsufficient mice show evidence of aortic root aneurysm, along with increased 
activation of both Smad and ERK1/2 in the aorta. No therapeutic rescue trial using 
RDEA119 was attempted in these mice, but this would be something to consider in the 
future to further delineate a role for ERK1/2 activation in this mouse model. 
Chapter 4 also discusses the identification of SKI, a prototypical repressor of 
TGFβ signaling, as the genetic cause of Shprintzen-Goldberg syndrome (SGS), a 
condition with considerable phenotypic overlap with both MFS and LDS. The SKI (Sloan 
Kettering Institute) proto-oncoprotein family of proteins, which also includes the SKI-
like protein SKIL, are known to negatively regulate Smad-dependent TGFβ signaling at 
multiple cellular locations. This includes impeding R-Smad phosphorylation, preventing 
nuclear translocation of the R-Smad/Co-Smad complex, and inhibiting TGFβ target gene 
output by competing with p300/CBP for Smad binding, and by recruiting transcriptional 
repressor proteins, such as mSin3A and HDAC1.557,558,559 By contrast, a role for SKI in 
modulating ERK1/2 activation has not previously been described.547,560 
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Interestingly, we found evidence of increased activation of both Smad2/3 and 
ERK1/2 in primary dermal fibroblasts from SGS patients compared to controls, both at 
baseline and after acute stimulation with TGFβ. We found no difference in the activation 
of JNK1/2 or p38 between SGS and control cells at baseline or in response to TGFβ. This 
selective upregulation of Smad and ERK1/2 activation in SGS patient cells directly 
parallels previous findings in the aortas of Marfan, Loeys-Dietz, and TGFB2 
haploinsufficient mice. The mechanism by which SKI may influence ERK1/2 activation 
remains to be determined. Furthermore, in the absence of a mouse model, it was not 
possible to assess whether inhibition of ERK1/2 activation could rescue the phenotypic 
manifestations of SGS. However, with the creation of a mouse model of SGS in the near 
future, this is a question that will hopefully be answered in the not-too-distant future.   
The fibulins are a family of proteins that are thought to function as intermolecular 
bridges within the ECM. Both fibulin-4 and fibulin-5 bind to fibrillin-1 and elastin, and 
play a role in elastic fiber assembly and function. While fibulin-5 appears to promote 
elastin fiber assembly through the recruitment of tropoelastin to microfibrils, fibulin-4 
appears to recruit lysyl oxidase (LOX), which crosslinks elastin molecules.561 Fibulin-4 
deficiency causes autosomal recessive cutis laxa in association with arterial tortuosity and 
aortic aneurysm in both humans and mice,562,563 while fibulin-5 deficiency causes cutis 
laxa with arterial tortuosity but not aneurysm.  
Evidence for increased canonical TGF signaling has been found in both humans 
and mice deficient in fibulin-4. Increased Smad2 activation and CTGF expression were 
observed in the aortas and lungs of patients with fibulin-4 mutations,564 while analysis of 
aortic tissue from mice heterozygous or homozygous for a fibulin-4 hypomorphic allele 
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revealed a graded increase in Smad2 activation and nuclear translocation, CTGF 
expression and collagen deposition compared to WT animals.565 There is also evidence 
that ERK1/2 activation is increased in the aortas of mice that are either globally- or 
smooth muscle cell selectively-deficient in fibulin-4. The exact mechanism by which 
fibulin-4 deficiency leads to this increased activation remains to be determined, although 
failure of abnormal or absent fibulin-4 to recruit LOX, which can directly inactivate 
TGF ligand,566 is one proposed mechanism.    
There are a number of genetic conditions that result from mutations in genes 
encoding proteins in the Ras-Raf-MEK-ERK pathway, the so-called ‘ras-opathies.’ These 
disorders include gain-of-function mutations in PTPN11 (encoding a protein tyrosine 
phosphatase) which causes Noonan syndrome (NS), and loss-of-function mutations in 
NF1 (encoding a Ras GTPase-activating protein) which causes neurofibromatosis Type 1 
(NF1). In mouse models of NS, multiple manifestations of the disease, including cardiac, 
craniofacial, skeletal, heart valve deformities, and cognitive impairment, appear to be 
ERK-dependent, while treatment with either a selective MEK inhibitor or lovastatin can 
rescue these phenotypes, in association with reduced ERK1/2 activation.567,568,569,570,571  
While pulmonary valve stenosis and hypertrophic cardiomyopathy are known to 
be prevalent in NS, aortic aneurysm was previously considered to be a rare manifestation. 
In light of our work showing the prominent role that ERK1/2 signaling plays in driving 
aortic disease in Marfan mice, Cornwall and colleagues assessed the prevalence of aortic 
aneurysm in NS patients.572 They undertook a retrospective study of thoracic ascending 
aortic anatomy in 37 patients with NS who did not have any confounding medical 
conditions. The patients’ ages ranged from 0.6 to 32 years.  
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Based on their most recent echocardiogram, patients showed both aortic annulus 
and aortic root dilation (mean z scores of 1.14 and 0.98, respectively, p<0.005) although 
the sinotubular junction and the ascending aorta were normal (mean z scores of 0.05 and 
0.19, respectively). The aortic root was aneurysmal (>2 z scores) in 8 of the 37 subjects, 
which constituted 21.6% of the cohort. PTPN11 mutations were present in 14 subjects, 
whose aortic status was similar to the cohort overall. Among 13 subjects with multiple 
imaging studies over an average of 6.8 years, the average z score increased by 0.78 and 
0.39 for the aortic annulus and aortic root, respectively, while multivariate analysis 
indicated that age accounted for 7-11% of the total variance in the aortic annular and root 
diameters, respectively. This work showed for the first time that a significant number of 
NS patients do indeed possess aortic annular and aortic root dilation, which is often 
present in childhood and progresses over time. 
Despite this, aortic aneurysm prevalence, severity and complications (dissection 
and death) are more prevalent in MFS than NS. One explanation for this may be that 
PTPN11 is not highly expressed, or is of minor significance to ERK1/2 signaling, in the 
aorta. Another possibility is that ERK1/2 activation alone is not sufficient for aneurysm 
to develop; while there is overlap in the intracellular cascades activated in MFS and NS 
(ERK1/2), other pathways appear to be MFS-specific (Smad2/3, and possibly p38 in 
certain contexts). Furthermore, ERK1/2 activation appears to be TGF-dependent in 
MFS but may be TGF-independent in NS. Whether it is the nature or number of 
intracellular signaling pathways involved, the manner by which they are activated, their 
degree of activation (which itself may be magnitude- or threshold-based), the relative 
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balance of different signaling pathways (e.g. Smad, ERK1/2 and/or p38 cascades), or 
some other variable, is yet to be determined. 
Stiff skin syndrome (SSS) is a rare autosomal dominant fibrillinopathy 
characterized by thickened fibrotic skin throughout the entire body that is present at birth, 
as well as secondary joint contractures. Patients are also shorter than normal, with a mean 
adult male and female height of <15th and <5th percentile, respectively. Roughly 40 cases 
have been documented; one report identified 4 families with dominant SSS that was 
caused by heterozygous missense mutations in exon 38 of FBN1 that either created or 
destroyed cysteine residues in the N-terminal portion of the fourth TB domain. This 
domain harbours an Arg-Gly-Asp (RGD) motif that is needed to mediate cell–matrix 
interactions by binding to cell-surface integrins. Gerber and colleagues have shown that a 
mouse model of SSS (Fbn1D1545E/+) recapitulates the aggressive skin fibrosis seen in 
patients.573 Interestingly, treatment with either TGFβ NAb or integrin-modulating 
therapies achieved phenotypic rescue in these mice.  
The authors also found that fibroblasts from patients with systemic sclerosis 
(SSc), which shows phenotypic overlap with SSS, had normal TGFβ-dependent Smad3 
activation that was not influenced by integrin-modulating therapies, but uniquely showed 
TGFβ-dependent ERK1/2 activation that was normalized by treatment with integrin-
modulating therapies. ERK1/2 activation in SSc fibroblasts was seen within 5 minutes of 
stimulation with TGFβ1 and was inhibited by pretreatment with SD208, suggesting a 
relatively direct response. Interestingly, treatment of SSc fibroblasts with the MEK 
inhibitor U0126 decreased collagen expression in SSc fibroblasts. Furthermore, SSS mice 
showed increased ERK1/2 activation in CD317+ plasmacytoid dendritic and other dermal 
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cells, while treatment with RDEA119 prevented skin stiffness, accumulation of dermal 
collagen and the loss of subcutaneous fat that is typical of the disorder. This work directly 
implicates ERK1/2 activation in the pathogenesis of SSS. It also raises the question of 
whether ERK1/2 activation may be modulated by integrin signaling in MFS, and whether 
integrin-modulating therapies may represent a novel therapeutic strategy for the disorder. 
In summary, there is a growing body of evidence that ERK1/2 activation may be 
present in a number of Marfan-related conditions, while its inhibition has been shown to 
represent a productive therapeutic strategy in a growing number of them.   
 
Possible Downstream Effectors of ERK Activation in MFS 
 
Matrix metalloproteinases (MMPs) are a group of ECM proteins that have 
received much attention in MFS. Both MMP2 and MMP9 are upregulated in the aortas of 
Marfan mice.574,575 Furthermore, doxycycline, a nonspecific MMP inhibitor, has been 
shown to attenuate elastic fiber degeneration and improve vasomotor function in the 
aortas of Marfan mice. This was in association with augmented expression ratios of tissue 
inhibitors of MMPs (TIMPs) to MMPs and suppression of TGF in the aortas of these 
mice. Doxycycline has also been shown to reduce the rate of aortic dissection and 
improve survival in a more severe mouse model of MFS (MgR/MgR), in association with 
reduced MMP2 and MMP9 expression. Given that losartan can also reduce MMP2 and 
MMP9 expression and activation in the aortas of Marfan mice,576 a trial assessing the 
therapeutic potential of combined doxycycline/losartan treatment was performed. In 
comparison to the two agents used in isolation, combination therapy led to a greater 
rescue of aortic diameter and aortic wall architecture in Marfan mice.577  
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There is substantial evidence linking TGF, ERK1/2 and MMP signaling. 
ERK1/2 has been shown to increase MMP9 expression in cultured aortic smooth muscle 
cells, while selective inhibition of ERK1/2 activation can reduce this expression.578 
MMP2 and MMP9 have been shown to cleave latent TGFβ, with the protease-sensitive 
hinge region of the LAP complex being an obvious potential target for their activity. 
Furthermore, both MMP2 and MMP9, as well as other MMPs, have been shown 
to mediate Ang-II dependent transactivation of the epidermal growth factor receptor 
(EGFR) and consequent ERK1/2 activation in both vascular and renal cells.579,580 This 
suggests that a feed-forward loop could develop in MFS, whereby increased TGF-
dependent ERK1/2 activation drives MMP2/9 expression and/or activation; MMP2/9 
could in turn augment TGF activation and/or Ang-II mediated EGFR-transactivation, 
leading to enhanced or prolonged canonical or noncanonical TGF signaling. Given the 
permissive role of Ang-II in this process, the efficacy of ARBs in MFS may at least in 
part derive from their ability to intervene in this potentially detrimental feed-forward 
loop. It also represents one mechanism by which EGFR activation could occur in MFS, 
and may in part explain why treatment with the EGFR inhibitor erlotinib is able to rescue 
aortic root growth in 129 Marfan mice (Fig.5-23). However, it should be noted that the 
AT1R-dependence of EGFR activation in 129 Marfan mice is yet to be determined. 
ERK1/2 activation has also been shown to mediate Ang-II infusion driven 
abdominal aortic aneurysm (AAA) formation in apolipoprotein E-knockout mice through 
the modulation of MMP2/9. Furthermore, selective inhibition of ERK1/2 activation using 
CI1040, or treatment with the HMGCoA reductase inhibitor simvastatin, led to 
amelioration of AAA progression in this disease model, in association with reduced 
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ERK1/2 and MMP2/9 activation.581 In light of this, the potential therapeutic efficacy of 
statins was assessed in Marfan mice. Compared to placebo-treated Marfan mice, 
simvastatin-treated animals showed a significant reduction in aortic root size and a 
significant improvement in elastin fiber preservation.582 Since no biochemical analysis 
was performed in this study, it remains to be determined whether the effects of statin 
therapy in Marfan mice are TGF-, ERK1/2- and/or MMP2/9-related.  
Finally, an increase in MMP9 expression has also been observed in fibulin-4 
deficient mice,583 although whether this is ERK1/2-dependent, and whether there is any 
potential therapeutic benefit of doxycycline and/or other MMP inhibitors in autosomal 
recessive cutis laxa remains to be elucidated. 
 
A Role for Other Noncanonical TGF Signaling Cascades in MFS 
 
In Chapter 2, we found no evidence of increased JNK, p38 or RhoA activation in 
the aortas of BL6 Marfan mice. Furthermore, an in-vivo trial of fasudil, an inhibitor of 
the RhoA/ROCK pathway, previously failed to attenuate aortic root growth in these 
animals.584 However, more recent evidence suggests that other noncanonical TGF 
signaling cascades may contribute to aortic disease in MFS in certain select settings. 
Carta and colleagues found that p38 is activated in fibrillin-1 null mice.585 In-vitro 
elimination of fibrillin-1 deposition was shown to result in activation of Smad2, p38 and 
its upstream activator TGF-activated kinase 1 (TAK1). Furthermore, Western blot 
analysis of the aortic wall in fibrillin-1 null (MgN/MgN) mice showed increased Smad2 
and p38 activation relative to WT animals, although it remains to be seen whether 
selective p38 inhibition influences aortic disease progression in these animals. 
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Furthermore, it is yet to be determined why in the aortas of mice haploinsufficient for a 
missense mutation in Fbn1, selective ERK1/2 and Smad2 activation occurs, with Smad2 
activation being ERK1/2-independent; yet in the aortas of mice null for fibrillin-1, 
selective p38 and Smad2 activation occurs, with Smad2 activation perhaps being partially 
p38-dependent. Whether these differences relate to the animal models used, the timing of 
the analyses or some other aspect of TGF signaling is not yet known. 
Chapter 5 discusses activation of canonical and noncanonical TGFβ-dependent 
signaling cascades in BL6 and 129 WT and Marfan mice. Compared to BL6 Marfan 
mice, 129 Marfan animals showed increased activation of Smad2 and Smad3, as well as 
ERK1/2, and its upstream activators Raf, MEK1, and PKCβ. Interestingly, 129 Marfan 
animals also showed a significant increase in p38 activation, which had not previously 
been observed in BL6 Fbn1C1039G/+ Marfan mice. By contrast, there was no increased 
activation of JNK1/2 in 129 Marfan animals, suggesting that there is selective ERK1/2 
and p38 upregulation in 129 Marfan mice, rather than simply global upregulation of all 
MAPK signaling pathways. We also have recent evidence to suggest that CCB-treated 
BL6 Marfan mice show a similar profile relative to placebo-treated littermates (i.e. 
enhanced p38 activation, but no change in JNK1/2 activation; data unpublished).  
One explanation for this is that p38 activation is uniquely elevated in more severe 
forms of the disorder. An alternative explanation could be that in more mild phenotypes, 
its magnitude of activation is simply too subtle to detect, or the variability in its activation 
prevents achievement of statistical significance. It is also unknown whether p38 
activation represents a primary driver of disease pathogenesis, or simply a secondary 
response; future work assessing the effect of p38 inhibitors in 129 Marfan mice and/or 
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CCB-treated BL6 Marfan mice should help to address this question. Given that increased 
p38 activation is seen in inflammatory states, it remains to be determined whether these 
more severe forms of the disorder show signs of inflammation; this is something that has 
not been observed in the more mild disease seen in BL6 Marfan mice. Finally, it is 
unknown whether p38 activation in Marfan mice lies in parallel, upstream or downstream 
of ERK1/2 and/or Smad2/3 activation in aortic disease pathogenesis, although Western 
blot analysis of Smad2/3 and ERK1/2 activation following p38 inhibitor treatment, and 
p38 activation following RDEA119 treatment, should help answer this. 
Our work to date has failed to show any evidence of JNK1/2 activation in Marfan 
mice on either a BL6 or 129 background, or in the presence of CCB treatment. This begs 
the question of how and why does one see activation of two of the three major MAPK 
signaling pathways in the aortas of Marfan mice, while the third remains unaffected. One 
possibility is that there are unique activators or integrators upstream of ERK1/2 and p38 
that have not effect on JNK1/2. Whether Map2k6 in mice and/or MAP3K4 in humans 
prove to be such molecules remains to be ascertained. Certainly both are known to drive 
p38 activation; whether they also influence ERK1/2 in MFS is yet to be determined. 
Another possibility is that ERK1/2 and p38 are activated by separate mechanisms 
in Marfan mice. ERK1/2 activation has been shown to be TGF-dependent in BL6 
Marfan animals, while evidence of this for p38 is yet to be ascertained. Trials assessing 
the effect of TGF NAb in 129 Marfan mice and in CCB-treated BL6 Marfan mice, and 
whether it can rescue p38 activation in these disease contexts, have been delayed due to 
difficulties acquiring the drug from the manufacturer. However once they can be 
performed, this question should hopefully be resolved.  
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Interestingly, prior work has implicated JNK1/2 activation as a driver of aortic 
aneurysm in Marfan mice under certain genetic manipulations. Smad4 haploinsufficiency 
was shown to exacerbate aortic disease and cause premature lethality in Marfan mice, in 
association with enhanced JNK1/2 activation, while a JNK antagonist ameliorated aortic 
growth in Marfan mice that both lacked or retained full Smad4 expression.585 This 
suggests that manipulation of TGF-dependent signaling cascades (i.e. Smad4) that cause 
JNK1/2 activation may contribute to aortic aneurysm progression in MFS, and that 
JNK1/2 inhibition may be a potential therapeutic strategy for MFS. This observation is 
consistent with prior work showing that JNK1/2 inhibition could ameliorate abdominal 
aortic aneurysm (AAA) induced by the periaortic application of calcium chloride.586  
Given that mutations in the genes encoding SMAD4 and SMAD3 have been 
found to cause LDS-like phenotypes in humans,587,588 it remains to be seen whether 
JNK1/2 activation is increased in these disease states, and whether JNK1/2 antagonism 
represents a novel therapeutic strategy for them. Finally, Mmp17-mediated osteopontin 
cleavage has been shown to affect VSMC maturation in murine aortic wall development, 
in association with increased JNK1/2 activation. Again, whether JNK1/2 is critical to this 
process, and how JNK1/2 antagonism might influence it, are yet to be explored. 
 
Pharmacological Exacerbation of Disease Progression in MFS 
 
Chapter 3 discusses the surprising observation that calcium channel blockers 
(CCBs) exacerbate aortic disease pathology, progression and complications in both mice 
and humans with MFS. This appears to hold true for more than one class of CCB, and in 
the case of the human data, it seems to extend to other Marfan-related conditions.  
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To our knowledge, this is the first time that a class of clinically-available blood 
pressure lowering medications has been shown to exacerbate aortic aneurysm and cause 
dissection in MFS or any of its related conditions. This is despite the fact that CCBs 
lower blood pressure, an effect which should provide some degree of protection against 
aneurysm growth. Given that a significant number of patients with MFS and related 
conditions are prescribed CCBs, a previously-unidentified deleterious role for these drugs 
has important clinical ramifications. 
The aortas of patients with MFS have been shown to possess an increased amount 
of type 1 collagen,589 and increased tissue stiffness.590,591,592,593 Prior publications,532,585,594 
as well as the work herein, has shown that placebo-treated Marfan mice also possess 
increased collagen in their aortas, relative to WT littermates. Furthermore, there is a 
significant increase in collagen deposition in the ascending aortas of Marfan mice treated 
with CCBs. This suggests that disease severity in both placebo- and CCB-treated Marfan 
mice correlates with the degree of collagen deposition in the aorta. 
Intuitively, one would assume that increased collagen deposition in the aorta 
might be protective against aneurysm progression, by providing greater resistance to 
hemodynamic stress. However, there is evidence that this increased collagen deposition 
in MFS may not be productive in nature. Lindeman and colleagues used 3D confocal 
imaging to show that in normal vessel walls, adventitial collagen fibers are organized into 
a loose braiding of ribbons, which encage the vessel, allowing it to dilate easily but 
preventing overstretching.595 By contrast, in Marfan-associated aortic aneurysm, they 
found dramatically altered collagen architecture. Through atomic force microscopy, they 
showed that the Marfan aortic wall was unable to function as a coherent network, with 
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mechanical forces being unevenly loaded on individual fibers, and not distributed over 
the whole tissue. It may be that this uneven distribution of tension leads to repetitive and 
progressive structural compromise of the aorta in MFS, ultimately resulting in aneurysm 
and/or dissection. To more formally assess the effect of higher collagen content in the 
Marfan aorta, one could post-natally knock out individual collagen isoforms in the aorta 
of Marfan mice. However, this was beyond the scope of our current work. 
Gingival overgrowth (GO) is a well-documented side effect that can occur with 
all CCBs.596,597,598 Histologically, drug-induced GO is virtually indistinguishable from 
other types of GO; all show enlargement of gingival tissue secondary to ECM 
accumulation. Pisoschi and colleagues have shown that there is upregulation of TGFβ1 
and CTGF in CCB-induced GO, and that this involves activation of fibroblasts with a 
synthetic phenotype.599 This parallels prior work in MFS, in which VSMCs in the aortas 
of Marfan mice have been shown to develop an abnormal synthetic repertoire.600  
This indicates that CCBs can drive TGFβ-mediated ECM accumulation in disease 
contexts other than MFS. Interestingly, not all patients taking CCBs incur clinically-
significant GO; hence there appears to be some predisposition that is needed to 
precipitate it. Postulated factors include age, genetic, pharmacokinetic, inflammatory and 
immunological. Given that we have not observed CCB-induced histological changes in 
the aortas of WT mice, this suggests that abnormal fibrillin-1 and/or aberrant activation 
of TGFβ and its downstream signaling cascades is required to precipitate CCB-mediated 
pathological aortic changes. Whether there is further mechanistic overlap between CCB-
mediated GO and CCB-induced aortic disease in MFS remains to be determined, but it 
offers an interesting avenue of future exploration.   
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It is notable that while CCBs accelerate growth of the aortic root in Marfan mice, 
they have an even more pronounced effect on the more distal ascending aorta, an aortic 
segment that is typically less frequently and less severely affected in MFS. The molecular 
basis of regional predisposition for aortic aneurysm is not yet fully understood, but may 
relate to the distinct developmental origins of the two aortic segments. While VSMCs in 
the aortic root primarily derive from the second heart field (SHF), those in the ascending 
aorta largely derive from the cardiac neural crest (CNC).  
Prior work has shown that neural crest cells develop L-type calcium channels 
during migration and differentiation, while blockade of these channels by CCBs, both in 
vivo and in vitro, leads to a dramatic and reversible inhibition of neural crest 
migration.601 Furthermore, CCB treatment of whole embryos, even after neural crest cells 
have already migrated and differentiated, still causes a significant change in individual 
cell shape and morphogenic patterning, suggesting that maintenance of a differentiated 
state in neural crest cells may be regulated at least in part by L-type calcium channels. 
Other work has shown that mutations in L-type calcium channels result in cellular 
hypertrophy and hyperplasia in neural-crest derived tissues, such as the mandible.602 
Hence it may well be the developmental origin of the cells that causes the ascending aorta 
to be particularly predisposed to the influence of L-type calcium channel blockade. 
It should be noted that the doses of the drugs used in our studies are much higher 
than those used in humans, which raises the questions of if and how these murine doses 
are relevant to human therapeutics. Furthermore, both amlodipine and verapamil, which 
have been used in humans for many years without evidence of striking aortic pathology, 
increase aortic growth in WT mice by several-fold. Given these apparent discordant 
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effects in mice and humans that do not have MFS, it begs the question of whether our 
findings hold relevance to humans that do have the disorder. 
Germane to this is the fact that rodents are rapid metabolizers of drugs compared 
to humans, and so the half-life of a drug tends to be shorter in rodents. This is especially 
true for drugs whose half-life is influenced by volume of distribution, as is the case for 
CCBs. Hence the half-life of amlodipine in rodents has been shown to be approximately 
one-third to one-tenth as long as humans,603 necessitating use of significantly higher 
doses of the drug in rodent studies.  
Prior work in mouse models of cardiovascular disease have shown phenotypic 
rescue using doses of amlodipine in the range of 1-10mg/kg/day, with the greatest 
therapeutic effect being seen at the highest dose.604 We therefore chose to use a dose that 
maximized our chance of seeing a therapeutic effect, while simultaneously reducing 
blood pressure equally as much as losartan in our mouse model. Hence we used a dose of 
12mg/kg/day. Fig.3-1 illustrates that both losartan and amlodipine induced approximately 
a 25% reduction in systolic and diastolic blood pressure in the mice. This allowed us to 
eliminate blood pressure as a variable when considering the discordant phenotypic and 
biochemical responses of Marfan mice to the two drugs. We further confirmed our 
findings using a significantly lower dose of amlodipine (3mg/kg/day). 
Baseline growth of the ascending aorta is minimal in placebo-treated mice, and so 
any CCB-induced aortic growth exacerbation seems like a dramatic effect. Relative to its 
overall diameter (about 1.6mm), even growth of 0.12mm/2mo only represents a 6-7% 
increase in overall ascending aortic diameter in CCB-treated WT mice. Furthermore, this 
never progressed to a clinically relevant outcome such as death in WT mice. It is feasible 
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that modest increases in ascending aortic size could occur in humans on CCBs, but may 
not be of sufficient magnitude to have led to detection by in-vivo imaging, or to any 
clinically relevant outcome such as dissection or premature lethality. Contrary to the 
question of whether our CCB data has relevance to humans with MFS, one might argue 
that our findings in WT mice warrant further investigation in humans without MFS who 
are taking or have taken CCBs.  
While randomized double-blinded prospective clinical trials are the preferred 
approach to analyze the therapeutic efficacy of a drug, this is not really feasible for agents 
that are found to be severely detrimental in pre-clinical models, since ethical approval for 
a prospective human trial is unlikely to be granted. Retrospective analyses of large 
datasets are a more realistic solution in such scenarios. An inherent limitation to any 
analysis of rare Mendelian disorders is the number of patients available. This is even 
more challenging when stratifying patients based on drugs that have been prescribed. The 
GenTAC consortium was established to try to overcome some of these challenges.  
However, it needs to be recognized that the GenTAC human data contained 
herein was still limited by relatively small sample size (more so for aortic dissection than 
aortic surgery) and an inability to control for the dose or number of medications that 
patients were taking. We were able to control for aortic size at the time of enrollment, 
which is an indicator of baseline aortic disease severity and a predictor of future risk of 
aortic dissection and/or need for aortic surgery. We were also able to control for blood 
pressure at the time of enrollment, which is a known risk factor for aneurysm 
progression. Hence while the conclusions that can be drawn from the GenTAC data are 
not definitive, they suggest that CCBs should be used with caution in Marfan patients.  
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The identification of an unrecognized, potentially deleterious, effect in mice for a 
class of medications that have been used in humans for many years, with subsequent 
retrospective evaluation of human data suggesting it is clinically valid, speaks volumes to 
the importance of mouse models of disease in guiding future investigation in humans.  
One reason that a possible deleterious effect of CCBs in Marfan patients may not 
have been noted previously is that only a minority of patients are on them. In the 
GenTAC cohort, about 8-12% of patients were on CCBs (unpublished data). Hence in an 
average size clinic, even if an unusually high percentage of patients taking CCBs had 
incurred a dissection or required aortic surgery to prevent dissection, this total number 
may not have been outside the realm of expectation in a disorder in which a significant 
percentage of patients incur such events. This highlights the critical role that nationwide 
databases such as GenTAC play for diseases such as MFS and related conditions, as they 
allow pooling of rare event data and statistically significant results to be obtained, even 
following stratification for genetic, demographic, therapeutic, and/or other variables.  
Another reason that CCBs may not have had a more striking effect in humans 
with MFS is the use of concomitant therapies. Patients may be on 3 or more different 
antihypertensive agents. Our mouse data shows that losartan significantly rescues the 
deleterious effect of amlodipine in Marfan mice. Hence use of other agents by Marfan 
patients may have at least partially abrogated any deleterious CCB effect. Given that 
most patients with MFS are on β-blockers, we controlled for β-blocker use as part of the 
GenTAC analysis. Indeed, this led to a small increase in the odds ratio for both aortic 
dissection and need for aortic root surgery in Marfan patients, supporting the conclusion 
that β-blockers may indeed provide some protection in CCB-treated patients.   
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GenTAC also possesses aortic imaging data, such as echocardiography, CT and 
MRI. To further strengthen the argument that CCBs exacerbate aortic pathology in 
patients with MFS and related conditions, future work aims to assess aortic root growth 
over time by in-vivo imaging in patients on CCBs, compared to those who are not. 
Evidence of enhanced aortic growth in humans on CCBs would further support our 
existing binary outcome data (dissection, surgical intervention). Given the time and effort 
needed to acquire and analyze such data, it may be some time before this is available.   
It is also apparent from the GenTAC human data that CCBs appear to have a 
more deleterious effect in patients with MFS than ‘other’ related conditions. Part of the 
challenge with this interpretation is that this ‘other’ category includes a range of 
conditions, such as Loeys-Dietz, Ehlers-Danlos and Turner syndromes, bicuspid aortic 
valve (BAV) with aneurysm, and familial thoracic aortic aneurysm. These have 
overlapping but distinct phenotypic manifestations and severity. For example, while 
patients with BAV and aneurysm show a mild ascending aortic phenotype that slowly 
progresses during post-natal life and generally does not lead to dissection, patients with 
Loeys-Dietz syndrome can show vascular changes throughout the arterial tree that dissect 
even in the absence of significant aneurysmal dilatation.  
Given that sufficient sample size to permit risk stratification by individual 
disorders is always going to be challenging in any human studies of relatively rare 
genetic disorders, one approach may be to do as we have done for MFS – test the effect 
of CCBs in mouse models of these other diseases (e.g. Loeys-Dietz mice), and use the 
data from these experiments to help guide us on which disorders may need particular 
attention when considering the possible deleterious effects of CCBs in humans. 
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Mechanistically, our work has shown that CCBs exert their effect on aortic 
growth in Marfan mice in an AT1R- and ERK1/2-dependent manner. This raises the 
question of what downstream mediators of ERK1/2 activation may be driving pathology 
within the context of CCB-induced aortic disease in MFS.  
Interestingly, there is evidence that treatment with nanomolar concentrations of 
multiple CCBs, including amlodipine, felodipine, manidipine, verapamil, or diltiazem, 
can significantly increase MMP2 activity in the ECM formed by cultured human aortic 
VSMCs and fibroblasts, in association with reduced transcription of tissue inhibitor of 
metalloproteinases-2 (TIMP2).605 Futhermore, amlodipine treatment of cultured porcine 
aortic segments has been shown to significantly increase MMP9 activity, in association 
with greater elastin destruction in the aortic wall, compared to placebo-treated control 
segments.606 Hence CCB-induced enhancement of ERK1/2-mediated MMP2 and MMP9 
activation could hypothetically contribute to aortic disease pathogenesis in Marfan mice. 
Ongoing work is assessing whether MMP2 and MMP9 are upregulated in the aortas of 
CCB-treated Marfan mice, and whether dual treatment with CCBs and either selective 
inhibitors of MMP2 and MMP9, or the broad-spectrum MMP inhibitor doxycycline, may 
rescue the CCB-induced aortic disease exacerbation seen in Marfan mice.  
Our work also implicates PKCβ as a driver of disease progression in placebo- and 
CCB-treated Marfan mice, with the data suggesting that it lies upstream of ERK1/2 in the 
disease process. Furthermore, inhibition of PKCβ activation by either the selective 
inhibitor enzastaurin, or the clinically-available but infrequently-used antihypertensive 
agent hydralazine, appears to rescue aortic disease progression in Marfan mice, in 
association with blunted PKCβ and ERK1/2 activation. While ARBs such as losartan and 
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ACE inhibitors such as enalapril are teratogenic and hence not appropriate for use in 
pregnancy, hydralazine is well-tolerated, making it an appealing alternative therapeutic 
strategy for MFS, particularly in pregnant women.  
Interestingly, hydralazine-mediated ERK1/2 inhibition has been implicated in one 
of its rare but recognized side effects, drug-induced lupus. Given that this is thought to be 
an autoimmune-driven process, Mazari and colleagues assessed the effect of hydralazine 
on receptor editing, a chief mechanism of B lymphocyte tolerance to self-antigens.607 
Using mice expressing transgenic human Igs, they found that hydralazine impaired up-
regulation of RAG-2 gene expression and reduced secondary Ig gene rearrangements. 
Receptor editing was also partially abolished in a dose-dependent manner by a MEK 
inhibitor, while adoptive transfer of bone marrow B cells pretreated with hydralazine or a 
MEK inhibitor to naïve syngeneic mice resulted in autoantibody production.  
It appears that changes in DNA methylation may underlie this process.608,609 More 
specifically, reduced ERK1/2 activation in T cells decreases DNA methyltransferase 
expression, which leads to DNA hypomethylation and overexpression of methylation-
sensitive genes, such as CD70. Furthermore, hydralazine appears to reduce ERK1/2 
activation in this context via inhibition of PKC, while pharmacological blockade of PKC 
or transfection with a dominant negative PKC mutant causes demethylation of the CD70 
promoter and CD70 overexpression, similar to lupus and hydralazine-treated T cells. 
Hence hydralazine may cause drug-induced lupus via inhibition of PKC-mediated 
ERK1/2 activation, while selective blockade of either PKC or ERK1/2 in T cells appears 
to be sufficient to cause the methylation changes and autoantibody production that are 
characteristic of the disorder. 
199 
 
This raises the question of whether the multiple pharmacological agents that we 
have found rescue aortic disease in Marfan mice, in association with inhibition of 
ERK1/2 activation (losartan, RDEA119, hydralazine, enzastaurin) do so by influencing 
DNA methylation. If so, this could open up an entirely new avenue of future exploration 
into the therapeutic potential of modulators of DNA methylation in MFS. Furthermore, 
drug-induced lupus does not appear to be a common side effect in patients treated with 
losartan, RDEA119 or other MEK inhibitors; why this is the case is yet to be elucidated. 
The work by Gerber et al. in stiff skin syndrome (SSS) has implicated autoantibody 
production in both SSS and systemic sclerosis, which could be rescued by integrin-
modulating therapies. In contrast to drug-induced lupus, ERK1/2 inhibition in mouse 
models of both MFS and SSS has been shown to rescue disease, rather than exacerbate it. 
This suggests that there is as yet undefined context-specificity to the effect that ERK1/2 
inhibition has in different cells, different tissues, and different disease states.  
Finally, while MEK inhibitors such as RDEA119 have shown therapeutic 
potential for a number of cancers, a pattern of ocular adverse events has followed them 
through clinical trials.610 Patients receiving MEK inhibitors appear to have high rates of 
multifocal serous retinal detachments, as well as retinal vein occlusions. The mechanism 
of these adverse events is still unclear, although oxidative stress and blood retinal barrier 
breakdown have been proposed. Fortunately most ocular adverse events appear to be self-
limited and do not require discontinuing the drug, although this may be necessary for 
cases of severe sight-threatening ocular toxicity. Whether changes in DNA methylation 
and/or autoantibody production play a role in this process remains to be determined, but 
this could offer an interesting avenue for future exploration. 
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Genetic Exacerbation of Disease Progression in MFS 
 
As well as attempting to elucidate pharmacological modifiers of disease 
progression in Marfan mice, this work has also tried to identify genetic modifiers. The 
data herein suggest that it is feasible to map modifier chromosomal loci in post-natally 
progressive, continuous, phenotypes such as aortic growth in mice, with the ultimate aim 
of identifying candidate genes and designing novel therapeutic strategies as a result.  
Comparison of the 129 and CCB stories provides valuable insight. As discussed 
previously, both CCB- and 129-induced aortic disease exacerbation in Marfan mice 
correlates with upregulation of previously known canonical (Smad2/3) and noncanonical 
(ERK1/2) TGFβ-dependent pathways. Both of these severe modifier states also show a 
selective increase in p38 activation, which had not been observed previously in the milder 
aortic disease seen in our Fbn1C1039G/+ Marfan mouse model (i.e. placebo-treated mice on 
a BL6 background). Furthermore, they both show increased PKCβ activation, leading us 
to currently explore whether hydralazine can provide significant phenotypic rescue in 129 
Marfan mice and in CCB-treated BL6 Marfan animals. These data cumulatively suggest 
that there is commonality in the mechanisms underlying severe modifier states in Marfan 
mice, and raise the question of whether this might extend to other Marfan-related 
disorders which show more aggressive aortic growth and/or a higher predisposition to 
dissection (e.g. Loeys-Dietz and/or vascular Ehlers-Danlos syndromes).  
It is also interesting to note that while CCBs show a proportionally greater effect 
in the ascending aorta than in the aortic root, the 129 phenotypic exacerbation of aortic 
aneurysm in Marfan mice shows the opposite regional effect (i.e. selective exacerbation 
of aortic root size with relative protection of the ascending aorta). Furthermore, while the 
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129-mediated exacerbation of the aortic root was genotype-specific (i.e. aortic root size 
relative to BL6 counterparts was increased in 129 Marfan mice but not in 129 WT mice), 
the 129 protective effect on the ascending aorta was not (i.e. ascending aortic size was 
significantly smaller than BL6 counterparts in both 129 WT and 129 Marfan animals). 
Whether it turns out that the regional basis for this background effect is due to 
modifier genes on the 129 background showing selective expression or influence in 
different regions of the aorta (i.e. root versus ascending), or in cells of different 
embryological origin (i.e. SHF versus CNC), remains to be determined. One approach to 
address this will be to look for differential regional or cellular expression of our candidate 
modifier genes, via lineage-tracing. The challenge with this is the current lack of adult 
markers of VSMC lineage in mice, necessitating a complex breeding strategy that 
introduces lineage-specific marker alleles, which was beyond the scope of this work. 
These data are all the more interesting, given that the 2 modifier states appear to 
show upregulation of the same molecular pathways (Smad2/3, ERK1/2, p38, PKCβ). 
This suggests that there is commonality in the molecular mechanisms driving aortic 
growth in different regions of the aorta, and argues against activation of differential 
downstream signaling cascades as the mechanism underlying regional aortic growth 
patterns. While this appears to hold true for ascending thoracic aortic disease within the 
context of Marfan mice, it remains to be determined whether this can be extrapolated to 
other regions of the aorta (e.g. the descending abdominal aorta) and other disease states 
(e.g. the Ang-II infusion model). Certainly, the data in Chapter 2, which show a lack of 
upregulation of any TGFβ-dependent pathways in the descending thoracic aorta of 
Marfan mice, cautions against unfettered broader generalizations from our work. 
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While there is some evidence for mechanistic overlap between the Ang-II 
infusion model and our data, there are clear differences between the two mouse models, 
both phenotypically and biochemically. While losartan reduces aortic aneurysm size and 
premature lethality from aortic dissection in both mouse models, this is not surprising in 
the case of the Ang-II infusion model, given that the drug blocks the dominant receptor 
for the very molecule that is being infused. Beyond this the parallels seem to end.  
Ang-II infusion mice develop prominent abdominal aortic aneurysm (AAA) from 
which they die prematurely, while TAA is less penetrant. ERK1/2 activation appears to 
play a prominent role in the aorta of both placebo- and CCB-treated Marfan mice, but has 
not been assessed in TAA progression in Ang-II infused mice. While TGFβ NAb 
achieves phenotypic rescue in Marfan mice,532 it appears to exacerbate Ang-II infusion 
driven disease progression,611 for reasons already discussed.612 While AT2R signaling 
plays a prominent role in Marfan mouse aortic disease progression,613 it appears to play 
no role in Ang-II infused mice.614 While MMP inhibition using doxycycline ameliorates 
aortic disease and premature lethality in Marfan mice,615,616 it has no effect on AAA in 
Ang-II infused mice, while its effect on Ang-II associated TAA was not assessed.617  
There is even recent work to suggest that CCBs are protective in Ang-II infused 
mice.618 However, this was conducted in LDL receptor knockout mice fed a saturated fat-
enriched diet, in order to induce atherosclerosis. The degree of atherosclerosis correlated 
with both disease progression and CCB-mediated TAA phenotypic rescue. Given that 
atherosclerosis appears to play no role in disease progression in placebo- or CCB-treated 
Marfan mice, and given all the other mechanistic distinctions between the two models, 
the relevance of this work to genetically-inherited TAA syndromes appears to be unclear.   
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The current data also raises the intriguing question of what effect CCB treatment 
will have in mice on a 129 background. On the one hand, the highly deleterious CCB 
effect may overcome the relative protection provided by the 129 background on the 
ascending aorta, and lead to a significant accentuation of growth in both the aortic root 
and ascending aorta of 129 Marfan mice. Alternatively, the 129 background may prevent 
CCB-induced ascending aortic growth in WT and Marfan mice, while permitting some 
degree of accentuation of the already-dilated aortic root in 129 Marfan animals.  
Should the latter scenario play out, this would infer that genetic modifiers of 
aortic disease can overcome the deleterious effects of CCBs in Marfan mice. Should such 
parallels exist in humans, this may offer another explanation as to why a deleterious CCB 
effect is not more apparent in patients with MFS and related disorders. Given that 129 
Marfan mice have larger aortic roots (AR) but smaller ascending aortas (AA) than their 
BL6 counterparts, their AR/AA ratio is much greater. This raises the question of whether 
stratifying the GenTAC dataset either by aortic root size, or by AR/AA ratio, may help 
identify patients that show relative protection against CCB-mediated ascending aortic 
growth. Searching for causal genetic modification in this cohort of patients could unearth 
novel genes that may relate to the ones we have already identified in 129 Marfan animals. 
There is of course the question of whether the genes we have identified in mice 
play any role in human disease. Recent work identified genetic variation in MMP17 in a 
patient with inherited TAA, while Mmp17 knockout mice show predisposition to Ang-II 
infusion induced aortic aneurysmal changes.619 Furthermore, we have recent linkage data 
to show that protection against severe aortic disease in 5 families with MFS links to a 
chromosomal locus that is coincident with the MAP3K4 gene (which lies directly 
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upstream and activates Map2k6), while haploinsufficiency for Map3k4 leads to rescue of 
aortic root growth in Marfan mice (Fig.5-24). This suggests that the candidate genes we 
have identified on the 129 background may indeed have direct human relevance. Future 
work assessing the effect of these genes in large human cohorts could add further proof.  
One also has to think about the generalizability of these findings. It remains to be 
determined whether the chromosomal loci and candidate genes we have identified in this 
work are Marfan-specific, or whether they may influence disease severity or penetrance, 
in disorders such as stiff skin syndrome (SSS), Loeys-Dietz syndrome (LDS), 
Shprintzen-Goldberg syndrome (SGS), and Noonan syndrome (NS). Given that mouse 
models for each of these disorders either exist or are in development, it should be feasible 
to answer this in the future. Given that survival of both LDS and NS mice varies between 
BL6 and 129 backgrounds due to differential penetrance of lethal cardiac developmental 
abnormalities,620,621 it seems more than feasible that post-natal aortic growth or other 
phenotypic manifestations in these mice may indeed be influenced by the candidate 
modifier genes that we have identified for aortic disease in our Marfan mouse model. 
Given that there are many other mouse background strains, this work also raises 
the question of the potential utility of crossing the Fbn1C1039G/+ mutation onto these other 
strains, in order to try to identify yet more chromosomal loci and/or candidate modifier 
genes for MFS and related conditions. Similar approaches in other disease states, such as 
muscular dystrophy (which has parallels to the skeletal myopathy seen in MFS), has 
already led to the identification of discrete genetic variation in genes that encode known 
TGFβ-related proteins.622 Whether these genes may also influence the Marfan phenotype 





Much progress has been made in recent years in elucidating the role that aberrant 
TGFβ signaling plays in MFS. Furthermore, the genes causing a number of Marfan-
related conditions have also been identified, many of which appear to converge on the 
TGFβ signaling cascade.623 These insights have led to the identification of a number of 
novel therapeutic agents for these diseases, several of which have been validated in pre-
clinical models, and are now moving into the clinical realm (Fig.6-1). Notwithstanding 
this, the magnitude of progress in our understanding has been more than matched in both 
volume and complexity by the questions it has raised. The variety of genetic defects that 
lead to perturbations in TGFβ localization, activation, cell surface receptor interaction, 
and downstream intracellular signaling, have revealed a complex system of interacting 
proteins that can have an array of partially overlapping phenotypic consequences.  
For example, initial work suggested that the pathways driving MFS occurred in a 
linear fashion: failed TGFβ sequestration by abnormal or insufficient fibrillin-1 leads to 
interaction with its cell surface receptors; this drives intracellular signaling cascades (e.g. 
Smad2/3), leading to the expression of TGFβ-responsive gene elements (e.g. collagens). 
More recent data suggest that it is not this simple. TGFβ appears to activate multiple 
intracellular signaling cascades (both canonical and noncanonical). These themselves 
may act in parallel or in series, and may possess context-dependence. TGFβ-dependent 
proteins such as MMP2 and MMP9 are secreted from cells and can modulate the ECM 
environment in which TGFβ is sequestered, creating potentially deleterious feed forward 
loops. This may include not only TGFβ activation, but also activation of other pathways, 





Fig.6-1. Integrated signaling cascades in MFS and related diseases. Canonical (green) and noncanonical 
(blue) TGFβ signaling cascades, as well as intracellular proteins not currently implicated in downstream 
TGFβ signaling (red), are illustrated accordingly. Disorders caused by a mutated gene product are shown in 
brackets next to the protein. Drugs shown in green have been tested in Marfan mice and/or patients. Drugs 
shown in red are untested but may have hypothetical benefit, based on our current understanding of disease 
pathogenesis. MFS: Marfan syndrome; SSS: Stiff skin syndrome; WMS: Weill-Marchesani syndrome; 
ELS: Ectopia lentis syndrome; GD: Geophysic dysplasia; AC: Acromelic dysplasia; HHT T1: Hereditary 
hemorrhagic telangiectasia Type 1; HHT T2: Hereditary hemorrhagic telangiectasia Type 2; ATS: Arterial 
tortuosity syndrome; PVNH: Periventricular nodular heterotopia; LDS: Loeys Dietz syndrome; iFTAA: 
Isolated familial thoracic aortic aneurysm; FSS: Ferguson Smith syndrome. NAb:  Neutralizing antibody; 
ARB: Angiotensin II Type 1 receptor blocker (e.g. losartan); ACEi: Angiotensin-converting enzyme 
inhibitor (e.g. enalapril). 
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TGFβ activation in diseases caused by mutations in intracellular contractile and non-
contractile proteins, suggests the existence of both outside-in and inside-out signaling, 
with respect to cells and the ECM. Finally, identification of integrin involvement in SSS 
suggests that the cell-ECM dynamic may in fact more closely constitute a continuous 
back-and-forth sampling of the ECM by the cell, which then adjusts its gene expression 
repertoire to try to maintain a suitable homeostatic ECM environment for it to occupy.  
It also remains to be determined what the common mechanisms are by which the 
plethora of extracellular, cell membrane bound, and intracellular proteins that appear to 
influence TGFβ in fact do so. For example, mutations in both fibulin-4 and fibulin-5 
cause cutis laxa with arterial tortuosity, which most likely relates to a severe perturbation 
in elastogenesis. Yet only fibulin-4 mutations show TGFβ-dependent aortic aneurysm. 
Why this is the case is yet to be determined. If it does indeed relate to its recruitment of 
LOX, then it is unclear why LOX-deficient mice only show a very low penetrance of 
aortic aneurysm.624 It also seems curious that therapies aimed at blunting TGFβ signaling 
at the level of ligand bioavailability (such as TGFβ NAb or ARBs) or events that may be 
far downstream of TGFβ (such as MMP2 and MMP9 inhibition) ameliorate aortic disease 
in Marfan mice, whereas mutations or manipulations that target cell membrane proteins 
(e.g. TGFΒR1 or TGFΒR2 mutations in LDS) or intracellular signaling cascades (e.g. 
Smad4 haploinsufficiency in Marfan mice) exacerbate aortic disease.  
Furthermore, this work has primarily focused on aortic disease in MFS and 
related conditions. However, BL6 Marfan mice also show a number of other phenotypic 
manifestations seen in patients, including pulmonary, bone, heart valve, skeletal muscle, 
and perhaps even ocular.625 Certain contexts may even precipitate other phenotypes not 
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previously identified in Fbn1C1039G/+ animals (e.g. DCM in Marfan mice on a 129 
background; data unpublished). While we touched upon some of these briefly in this 
work (e.g. 129-mediated exacerbation of lung and skeletal phenotypes are discussed in 
Chapter 5), there is much work that could still be done to further define the responses of 
these phenotypes to the genetic and pharmacological manipulations discussed herein.   
The current work was facilitated by use of our Fbn1C1039G/+ Marfan mouse model, 
which shows post-natally progressive aortic aneurysm growth, that we are able to image 
longitudinally in-vivo, and which is clearly malleable to both protective and detrimental 
genetic and pharmacological influences. Furthermore, we have optimized protocols 
already in place to assess the histological and biochemical changes seen in the aortas of 
mice, allowing us to directly link our in-vivo observations with robust ex-vivo analyses. 
While we already have in place some of the in-vivo imaging techniques needed to 
explore these other systemic phenotypes in mice (e.g. spinal X-rays, ultrasound 
measurement of eye axial length), further work will be needed to optimize the necessary 
complimentary ex-vivo analytical methods that will allow more complete assessment of 
these other systemic phenotypes in the future. 
In genetically-inherited conditions such as MFS, every cell in the body possesses 
the same mutation. Hence the phenotypic manifestations in each organ system develop as 
a result of this same genetic defect. It is reasonable to assume that there may well be 
overlap in the mechanisms driving disease development and progression in the different 
tissues. Certainly, evidence showing that losartan is able to rescue disease progression in 
the lungs, skeletal muscle, mitral valves, and possibly even the eyes of Marfan mice,623 
attests to a common mechanistic link between the different organ systems. 
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However, there will also no doubt be tissue-specific etiological differences. In the 
aorta alone, the question remains as to which cells are actually driving disease. Is it 
resident cells within the aortic media (e.g. vascular smooth muscle cells), resident cells of 
the adventitia (e.g. fibroblasts) or cells recruited from more distal locations such as the 
bone marrow (e.g. plasmacytoid dendritic cells). Every affected tissue in MFS will have 
its own unique cellular composition that is likely to respond to defects in fibrillin-1 in a 
different way. Even in a single organ, it is feasible that some tissues may be influenced 
by aberrant growth factor signaling (e.g. the sclera of the eye, which may drive axial 
globe elongation), while others feasibly may not. For example, ciliary zonule elongation 
and eventual rupture, which results in ocular lens dislocation, may well relate more to a 
structural weakness of the tissue rather than aberrant growth factor signaling.  
Not only this, but fibrillin-1 is known to interact with a number of other cytokines 
in the ECM.626 It is feasible that aberrant activation of these other molecules could 
strongly influence disease pathogenesis in other organ systems. For example, the 129 
background strongly modifies the aortic phenotype in Marfan mice, with significant 
upregulation of both canonical and noncanonical TGFβ-signaling cascades. However, it 
has a proportionally much lesser effect on the spine phenotype. Fibrillin-1 is known to 
interact with several of the bone morphogenic proteins (BMPs), which are well-known 
modulators of bone development (hence the name). It may be that aberrant activation of 
BMPs, and their downstream Smad1/5/8 pathway, may play a role in driving disease 
pathogenesis in tissues such as the spine. Hence there may be organ-by-organ or tissue-
by-tissue specific differences in the relative contributions of each of these fibrillin-1 
associated ECM cytokines, which are yet to be ascertained.  
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Furthermore, there are likely to be tissue-specific nuances in their response to 
therapeutic interventions. In the same way that elimination of a deleterious environmental 
pathogen such as ethanol, may allow cellular regeneration and architecture restoration in 
a tissue with known regenerative capacity such as the liver, our work suggests that 
suppression of a deleterious genetically-driven pathogen (TGFβ), may allow tissue 
regeneration and architecture restoration in the aorta, which was previously thought to be 
relatively inert during post-nastal life. While TGFβ antagonism may be able to prevent 
progression, or even reverse existing disease, in certain scenarios (e.g. axial globe 
elongation), other phenotypic manifestations may show little capacity for reversal (e.g. 
ciliary zonule fracture, with the two broken ends no longer being in apposition).  
Finally, given that TGFβ is a ubiquitous molecule with pleiotropic effects in many 
organ systems, the dysregulation of which has been implicated in many non-MFS related 
disease states, it remains to be determined whether the intracellular pathways, as well as 
pharmacological and genetic modifiers discussed herein, may hold relevance to these 
other conditions. The answer to this, as well as the many other questions raised in this 
discussion, may ultimately bring us closer to a better understanding of all of these 
conditions, and in doing so, may provide us with the opportunity to develop a more 
comprehensive therapeutic armamentarium against the very disease states that have 
















All mice were cared for under strict compliance with the Animal Care and Use 
Committee of the Johns Hopkins University School of Medicine.  
Fbn1C1039G/+ mice that were considered to exist on a ‘pure’ BL6 background had 
been backcrossed more than 10 generations onto a C57BL/6J background strain (Jackson 
Laboratories, Bar Harbor, ME). Those that were considered to exist on a ‘pure’ 129 
background were backcrossed more than 10 generations onto a 129S6/SvEvTac 
background strain (Taconic, Derwood, MD). 
The AT2R KO mouse line was obtained as a generous gift from Dr. Inagami, and 
was maintained on a pure C57BL6/J background (backcrossed more than 10 generations). 
The Agtr2 gene resides on the X chromosome and therefore we used either male mice 
carrying the mutated allele (who are hemizygous) or homozygous females, both of which 
have been previously shown to be functionally null for the AT2R.627 
The Tgfb2+/- mouse line was purchased from Jackson Laboratories (Bar Harbor, 
ME). Tgfb2+/- mice show impaired fertility on pure backgrounds and were therefore 
maintained on a mixed background at the Jackson Laboratories. To accommodate for 
possible background-specific variation, all comparisons were made between littermates. 
Mice were checked daily for evidence of premature lethality. All mice that were 
found dead were immediately necropsied to assess for evidence of aortic dissection. At 
the end of a trial, any remaining mice were sacrificed by intraperitoneal injection of 
ketamine and xylazine. Following death or sacrifice, mice underwent immediate 
laparotomy, descending abdominal aortic transection, and PBS (pH 7.4) was infused 
throughout the vascular tree via the left ventricle.  
213 
 
Mice undergoing Western blot analysis had their aortic root and ascending aorta 
(aortic root to right brachiocephalic trunk) harvested, snap-frozen in liquid nitrogen and 
stored at minus 80 degrees centigrade until processed. Protein was extracted using a Total 
Protein Extraction Kit containing a protease inhibitor and protein phosphatase inhibitor 
cocktail (Millipore, MA). Aortas were homogenized using a pellet pestle motor (Kimble-
Kontes, NJ) as per the extraction kit protocol. Samples were then stored once more at 
minus 80 degrees until Western blot analysis was performed.  
Mice undergoing quantitative RT-PCR had their aortic root and ascending aorta 
(aortic root to the origin of right brachiocephalic trunk) harvested, placed in RNAlater 
(ThermoFisher, Grand Island, NY), and stored at minus 80 degrees centigrade until 
processed. RNA was extracted from the aorta using Trizol (ThermoFisher), as per the 
manufacturer’s recommendations.  
Mice that were analyzed for aortic histology had latex infused into the left 
ventricle at a pressure between 70 and 80mmHg, as confirmed using a handheld digital 
manometer (Fisher Scientific, Pittsburgh, PA). Mice were then fixed for 24 hours in 10% 
buffered formalin, after which time the heart and aorta were removed and stored in 70% 
ethanol, until histological analysis was performed.  
Mice that were analyzed for lung histology had their trachea intubated with a 20-
gauge blunted needle, and 0.5% agar was infused under a low and constant pressure to 
gradually inflate the lungs. The trachea was then tied-off using vicryl and the needle was 
removed. Mice were fixed for 24 hours in 10% buffered formalin, after which time the 
lungs were removed and stored in 70% ethanol.  
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Mouse Drug Treatment 
 
Losartan was dissolved in drinking water and filtered to reach a concentration of 
0.6g/L, giving an estimated daily dose of 60mg/kg/day (based on a 30g mouse drinking 
3mls per day). Enalapril was dissolved in drinking water and filtered to reach a 
concentration of 0.15g/L, giving an estimated daily dose of 15mg/kg/day. This dose of 
enalapril had previously been shown to achieve a comparable hemodynamic effect as the 
aforementioned dose of losartan.628 Amlodipine was dissolved in drinking water and 
filtered to reach a final concentration of 0.12g/L, giving an estimated daily dose of 
12mg/kg/day. Verapamil was dissolved in drinking water and filtered to reach a 
concentration of 1.4g/L, giving an estimated daily dose of 140mg/kg/day. Hydralazine 
was dissolved in drinking water and filtered to reach a concentration of 0.16g/L, giving 
an estimated daily dose of 16mg/kg/day. Placebo-treated animals received drinking 
water. Mice given these medications were started on treatment at 8 weeks of age. 
RDEA119 (25mg/kg/day) and enzastaurin (15mg/kg/day) were reconstituted in 
10% 2-hydroxypropyl-beta-cyclodextrin (Sigma-Aldrich, St. Louis, MO) dissolved in 
PBS, and administered twice daily by oral gavage. 10% 2-hydroxypropyl-beta-
cyclodextrin dissolved in PBS was the control. Erlotinib (50mg/kg/day) was reconstituted 
in 1% methylcellulose (Sigma-Aldrich) dissolved in PBS, and administered daily by oral 
gavage. Treatment for each drug was from 2 to 4 months of age. Mouse monoclonal 
TGFβ NAb (1d11; R&D Systems, Minneapolis, MN) was reconstituted in PBS and 
administered via intraperitoneal injection 3 times a week at a dose of 5mg/kg/day. 
Treatment was from 1 to 3 months of age. IgG (Zymed Laboratories Inc, San Francisco, 





Nair cream was used to remove fur from the anterior thorax of the mice the day 
prior to echocardiography. All images were obtained on awake, unsedated mice using a 
Visualsonics Vevo 2100 device and 30MHz transducer. Mice were imaged at baseline, 
and every 2 months thereafter, until death or sacrifice. Parasternal long axis views were 
obtained. Three measurements of the maximal internal dimension at the sinus of Valsalva 
and proximal ascending aorta during systole were made in separate cardiac cycles and 
averaged. All imaging and analysis was performed blinded to genotype and treatment. 
 
Mouse Blood Pressure 
 
Blood pressure was measured by tail cuff plethysmography 4 weeks after starting 
a drug trial. Mice were habituated for 4 days. On the 5th day, 10-12 blood pressures were 
obtained and averaged. Four or more mice per treatment group were analyzed. 
 
Mouse Spine X-Ray 
 
Mice undergoing spine X-ray were anesthetized using a combination of ketamine 
and chlorpromazine. They were then placed in the left lateral decubitus position on a 
radiolucent platform with adjacent scale bar and imaged at 1x magnification using a 
Faxitron MX20 (Faxitron, Tucson, AZ). The output electronic file was processed using 
ImageJ analysis software (NIH, MD). Spine kyphosis was quantified using a modified 
kyphosis index.629 In brief, a line was drawn from the anterior superior iliac spine to the 
point of maximal lordosis of the cervical spine. A line was then drawn perpendicular 




Mouse Aorta and Lung Morphometric and Histological Analyses 
 
Latex-infused aortas were transected just above the level of the aortic valve, and 
2-3mm transverse sections were mounted in 4% bacto-agar prior to paraffin fixation. Five 
micron aortic sections underwent Verhoeff-van Giesen (VVG) and Masson’s Trichrome 
staining, and were imaged at 40x magnification, using a Nikon Eclipse E400 microscope. 
Wall architecture of 4 representative sections for each mouse was assessed by 3-5 blinded 
observers and graded on an scale of 1 (normal histology) to 5 (indicating diffuse elastic 
fiber fragmentation and histological damage), and the results were averaged. 
Individual lobes of the lungs were mounted in 4% agar and fixed in paraffin. Five 
micrometer lung sections underwent hematoxylin and eosin staining and were imaged at 
10x magnification, using a Nikon Eclipse E400 microscope. Five fields were analyzed for 
each lobe of each lung by a single blinded observer, and a mean linear intercept was 
calculated using a previously described method.630  
 
Human Cell Culture 
 
For the Shprintzen Goldberg syndrome study, primary human dermal fibroblasts 
were derived from forearm skin biopsies of 2 controls and 2 patients with Shprintzen 
Goldberg syndrome. They were cultured in Dulbecco’s modified eagle medium (DMEM) 
with 10% fetal bovine serum (FBS) in the presence of antibiotics and passaged at 
confluence. All cell experiments were conducted in serum-starved media for 24 hours 
prior to drug administration. Stimulation was performed using 5 ng/mL recombinant 
human TGFβ2 (R&D Systems, Minneapolis, MN). Cells were collected at baseline, 30 
minutes and 24 hours after stimulation. 
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For the calcium channel blocker study, primary human dermal fibroblasts were 
derived from forearm skin biopsies of Marfan patients and controls. They were again 
cultured in DMEM with 10% FBS in the presence of antibiotics and passaged at 
confluence. All experiments were conducted in serum-starved media for 24 hours prior to 
drug administration. Amlodipine dissolved in PBS was administered at a dose of 1µM, 
based on prior work showing that it influences ERK1/2 activation at this concentration.631 
Cells were collected at baseline, 2 hours after amlodipine administration (for Western 
blot analysis) and 24 hours after amlodipine administration (for RNA analysis).   
 
Mouse and Human Western Blot Analyses and Antibodies 
 
Aortic tissue or lysed cell protein homogenates were dissolved in sample buffer, 
run on a NuPAGE Novex 4-12% Bis-Tris Gel (Invitrogen, CA), and transferred to 
nitrocellulose membranes using the iBlot transfer system (Invitrogen). Membranes were 
washed in phosphate-buffered saline (PBS) and blocked for 1 hour at room temperature 
with 5% instant non-fat dry milk dissolved in PBS containing 1% Tween-20 (Sigma, 
MO; PBS-T). Equal protein loading of samples was initially determined by a protein 
assay (BioRad, CA), and was confirmed by probing with antibodies against β-Actin or 
GAPDH (Sigma, MO).  
Membranes were probed overnight at 4 degrees centigrade with primary 
antibodies from Santa Cruz, CA (pJNK1/2), Cell Signaling, CA (pSmad2, Smad2, 
pERK1/2, ERK1/2, JNK1/2, pp38, p38, pMEK1, MEK1, Smad3, pPKCβ, PKCβ pPLCγ, 
PLCγ), and Millipore (pSmad3), dissolved in PBS-T containing 5% milk. Blots were then 
washed in PBS-T and probed with HRP-conjugated anti-rabbit secondary antibody (GE 
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Healthcare, UK) dissolved in PBS-T containing 5% milk at room temperature. Blots were 
then washed in PBS-T, developed using SuperSignalWest HRP substrate (Pierce 
Scientific, IL), exposed to BioMax Scientific Imaging Film (Sigma, MO) and quantified 
using ImageJ analysis software (NIH, MD).  
For the dermal fibroblast analysis in Shprintzen Goldberg syndrome cells, 
separate membranes were used for the control and Shprintzen Goldberg patients due to 
the large number of samples, when run in triplicate over a timecourse. The membranes 
were processed together at all stages, and exposed to the same piece of imaging film 
simultaneously, allowing for valid comparisons. 
 
Human Quantitative RT-PCR Expression Analyses 
 
Total RNA was isolated from cultured cells or aortic tissue using Trizol 
(Invitrogen, CA), in accordance with the manufacturer’s protocol. For the Shprintzen 
Goldberg syndrome study, quantitative RT-PCR was performed using the following pre-
validated probes, as per the manufacturer’s instructions: Hs01060665 (β-ACTIN), 
Hs00164004 (COL1A1), Hs00943809 (COL3A1), Hs00287359 (FN1), Hs00185584 
(VIM), Hs00355782 (CDKN1A), Hs01026927 (CTGF), Hs01126606 (SERPINE1), 
Hs00161707 (SKI), Hs01045418 (SKIL) and Hs00998193 (SMAD7) (Life Technologies, 
Carlsbad, CA). For the calcium channel blocker study, the same COL1A1 and β-ACTIN 
probes were used. Relative quantification for each test gene transcript was obtained by 




Mouse Linkage Analysis  
  
SNPs were selected from the Illumina mouse medium density linkage panel array 
that were divergent between the C57BL/6J and 129S6/SvEvTac background strains. 
Genotyping was performed using an Illumina mouse medium density linkage panel, and 
was run using standard GoldenGate chemistry on an iScan microarray scanner (Illumina, 
San Diego, CA). Genotypes were called using Illumina GenomeStudio software 
(GenomeStudio 2011.1, Genotyping Module 1.9.4 and Gentrain version 1.0). The 
average physical coverage was 2.9 Mb, the maximum gap was 22.4 Mb and there were 
10 gaps >12 Mb. The genotype quality score cut-off for a “no call” genotype was 0.25. 
Only SNPs of sufficient quality were used for downstream analysis.  
R/qtl software (http://www.rqtl.org) was utilized to calculate LOD scores for the 
whole-genome SNP analysis.632 All of the animals for which there was both genotype and 
phenotype data were included in the analysis. First, the “scanone” function was used to 
perform a single-QTL genome scan utilizing a nonparametric model and 1000 
permutations. The results were expressed as a LOD score and p-value. The “scanone” 
function calculated the genome-wide LOD significance threshold for this dataset as 3.82. 
Next, the “scantwo” function was used to perform a two-dimensional genome scan with a 
two-QTL model utilizing a binary model. The recommended significance threshold for a 
mouse intercross using this function was a Mf LOD >9.1. Since the "scantwo" function 
does not compute a p-value, we performed ANOVA plus a post-hoc linear trend test of 




Human Circulating Plasma TGFβ1 Analysis 
 
The samples and analysis method have been described previously.633 In short, 
plasma and clinical data from patients diagnosed with Marfan syndrome (MFS) were 
collected through the National Registry of Genetically Triggered Thoracic Aortic 
Aneurysms and Cardiovascular Conditions (GenTAC). Blood was collected on ice using 
EDTA. Samples were centrifuged at 3000g for 15 minutes at 4 degrees centigrade, and 
plasma was stored at minus 80 degrees centigrade. Samples were assayed for levels of 
total TGFβ1 with the use of a commercially available, ruthenium-based 
electrochemiluminescence platform (Meso Scale Discovery, Gaithersburg, MD), as per 
the manufacturer’s recommendations. Samples were first acid-activated using 1N HCl 
before assaying. All samples were run in duplicate. Data validity was determined as 
previously described.634  
 
Patients with Loeys-Dietz-Like & Shprintzen Goldberg Syndromes 
 
Patients were recruited from Connective Tissue Clinics at Johns Hopkins, 
Radboud University Hospital/Antwerp University Hospital, the Nemours Children's 
Clinic, Genetic Medicine Central California, or Washington University Hospital. All skin 
biopsies and research protocols were performed in compliance with the Institutional 
Review Board at each respective institution after informed consent was obtained.  
 For the Loeys-Dietz-like syndrome study, 86 samples were obtained from 
individuals with features of syndromic connective tissue abnormalities, including thoracic 
aortic aneurysm, who did not fulfill the diagnostic criteria for MFS as per the 2010 Ghent 
nosology, and who were negative for TGFBR1/2 and FBN1 mutation analysis. 
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For the Shprintzen Goldberg syndrome study, diagnosis was made after exclusion 
of other known congenital syndromes on the basis of distinguishing phenotypic features. 
Echocardiograms were performed and interpreted as previously described.634 Aortic root 
aneurysm was defined by a maximal aortic root z-score ≥ 2.0.  
 
GenTAC Patient Cohort  
 
This was performed using clinical data from the GenTAC registry. Patients were 
recruited from 5 regional clinical centers in the United States, including Johns Hopkins 
University, Oregon Health & Science University, University of Pennsylvania, University 
of Texas Health Science Center at Houston / Baylor College of Medicine, and Weill 
Cornell Medical College. Each site obtained approval to conduct the study from their 
respective institutional review boards, and informed consent was obtained at each site.  
Longitudinal observational data was collected on adults and children diagnosed 
with one of 12 thoracic aortic aneurysm-related conditions, primarily including Marfan, 
Loeys-Dietz, Ehlers-Danlos and Turner syndromes, bicuspid aortic valve, and familial 
thoracic aortic aneurysm. Designated registry investigators at each enrolling site 
confirmed diagnostic classifications of genetically associated aortic conditions. 
Demographic indices were abstracted from medical records at the time of registry 
enrollment by site-specific research coordinators, and all samples were de-identified to 
preserve patient confidentiality.  
The current analysis was limited to aortic dissection or aortic surgery that 
occurred in the aortic root, ascending aorta and/or aortic arch, and excluded patients who 
had previously had aortic dissection or surgery in these regions prior to enrollment into 
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the study. Calcium channel blocker use was considered positive if patients had taken the 
drugs prior to, or were taking them at the time of, enrollment into the study. Aortic 
dissection or surgery was assessed prospectively in the follow-up period after enrollment. 
Mean follow-up was 50.8±1.6 months for the Marfan patients and 43.4±0.8 months for 
all other thoracic aortic aneurysm syndrome patients.  
Statistical analyses for this study were performed using SAS Version 9.3 (SAS 
Institute, Cary NC). Exact odds ratios and two-sided p-values were calculated using 
PROC LOGISTIC. Models were adjusted for potential cofounders identified a priori (i.e. 
systolic blood pressure, aortic root size, and use of β-blocker therapy, at the time of 
enrollment). Interaction terms were determined not to be statistically significant (p>0.05), 




All quantitative data are shown as bar graphs produced using Excel (Microsoft, 
Redmond, WA). Mean ± 2 standard errors of the mean (SEM) are displayed. Statistical 
analyses were performed using two-tailed t tests. For the calcium channel blocker study, 
additional statistical analyses included use of two-way ANOVA to assess whether there 
was a significant interaction between the genotype of the mice and the medication effect. 
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    Johns Hopkins School of Public Health, Baltimore, MD, USA.  
    - 22-courses, including epidemiology, biostatistics, process of care improvement, interpersonal   
and public health communication, health care accounting, politics in health policy, healthcare 
planning & marketing. 
    - Coursework: ‘A’ grade obtained in all 22 courses. GPA: 4.0. 
    - Graduated Summa cum Laude. Offered membership to Delta Omega Honor Society. 
    - Internship at Yale SPH & Kirkland Fellowship at Harvard SPH as part of MHS degree.  
 Preclinical Medicine / BA(Hons). Oct 1998 - June 2001.  
    Worcester College, Oxford University, United Kingdom.  
    - Foci: Physiology, Neuropathology, Neuropharmacology. Supplicated to MA(Oxon), 08/2005. 
    - Bachelor of Medicine, Pt 1A/B completed in June 2000. Pre-clinical part of medical degree. 
Other Professional Experience 
 Ophthalmology Residency. Wilmer Eye Institute, Johns Hopkins.  July 2014 - Present 
    - PGY2 rotations: 
 Neuro-ophthalmology      July 2014 - Sept 2014 
 Oculoplastic and Reconstructive Surgery    Sept 2014 - Nov 2014 
 Bayview Rotation (Comprehensive Ophthalmology)  Dec 2014 - Feb 2015 
 Anterior segment / Pediatrics     Feb 2015 - Apr 2015 
 Emergency Medicine Consult / Glaucoma    Apr 2015 - June 2015 
    - PGY3 rotations: 
 Pediatrics and Strabismus Surgery    July 2015 - Sept 2015 




 University College London (UCL) Foundation Program  Aug 2005 - July 2006 
    - Royal Free Hospital, Hampstead, London, UK.    Feb 2006 - Aug 2006 
 Neurology        May 2006 - July 2006 
 Cardiology / Internal Medicine     Feb 2006 - Apr 2006 
    - Lister Hospital, Stevenage, Hertfordshire, UK.    Aug 2005 - Feb 2006 
 Orthopedic Surgery       Nov 2005 - Feb 2006 
 General and Vascular Surgery      Aug 2005 - Nov 2005 
Additional Research Experience 
 Ongoing Research Projects. Collaborations in the Wilmer Eye Institute, Johns Hopkins. 
- Development of streak retinoscopy to measure refractive error in mice; Dr David Guyton. 
- Analysis of the predisposition of Marfan mice for glaucoma; Dr Harry Quigley. 
- In-vivo analysis of axial length in Marfan mice; Dr Albert Jun & Zeiss (Jena, Germany). 
 Harvard Medical School / Brigham & Women’s Hospital, Boston. July 2002 - Aug 2002.  
Summer Fellowship in the Multipurpose Arthritis and Musculoskeletal Diseases Research 
Center, under the auspices of Dr. Matthew Liang, Director of the MAC, Professor of 
Medicine at Harvard Medical School. Work focused upon: 1. An analytical review of the 
U.S. Orphan Drug Act and how it has influenced the development of drugs for SLE; 2. 
Development of a patient survey to assess the impact of corticosteroid treatment in SLE. 
 Yale Medical School / NEPEC, New Haven, CT. May 2002 - June 2002. 
Based at the Division of Mental Health Services and Outcomes Research Northeast 
Program Evaluation Center (NEPEC), under the auspices of Dr. Robert Rosenheck, 
Director of NEPEC, and Professor of Psychiatry at Yale University School of Medicine. 
Published paper examining the mechanisms through which antipsychotic-mediated 
alterations in clinical status influences health care and non-health care costs.  
 Johns Hopkins School OF Public Health, Dept of Mental Health. Feb 2002 - April 2002. 
Research Assistant for a randomized intervention study to determine the effects of Positive 
Behavioral Interventions and Supports (PBIS) on student behavior and school organizational 
climate. Involved in the collection of baseline data on the initial 24 schools. Collaborators included 
the Maryland State Department of Education, Sheppard Pratt Health System, and four local 
Maryland school systems. 
 Oxford University. BA(Hons.) Thesis. September 2000 - June 2001. 
Studied the effects of sleep deprivation on cognitive functioning in humans with 
obstructive sleep apnea. Included the development of an analytical computer-based 
tracking tool for use in an MRI scanner to assess the negative effects of sleep deprivation 
on brain function. 
Scholarships, Fellowships & External Funding 
 National Marfan Foundation (NMF) Victor A. McKusick Fellowship. July 2011 - June 2013. 
$150,000 over 2 years. Title: Effect of Calcium Channel Blockers in Marfan Syndrome. 
 National Marfan Foundation (NMF) Victor A. McKusick Fellowship. July 2009 - July 2011. 
$150,000 over 2 years. Title: Antagonizing ERK activation in Marfan Syndrome. 
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Honors and Awards 
 2014/2015 Wilmer Research Grant Recipient.  
 2014  Preliminary Intern of the Year. Good Samaritan Hospital. 
 2011 Johns Hopkins Young Investigators’ Day: Michael A. Shanoff Award Winner. 
 2011 Johns Hopkins Post-Doctoral Association Seminar Series Award (2nd Place). 
 2011 National Marfan Foundation (NMF) Victor A. McKusick Fellowship. 
 2010 American Society Human Genetics Translational Research Prize Finalist (1 of 3). 
 2010 Johns Hopkins GSA Travel Award to ARVO 2010 Research Meeting. 
 2009 American Society Human Genetics Translational Research Prize Winner. 
 2009 American Society Human Genetics Meeting. Hawaii. Plenary talk. 
 2009 National Marfan Foundation (NMF) Victor A. McKusick Fellowship. 
 2004 Cambridge University International Elective Commendation. 
 2004 Emmanuel College Windsor Committee Scholarship.   
 2004 Haberdashers’ Foundation Thomas Arno Scholarship. 
 2004 Vandervell Foundation Scholarship.  
 2003 National Health Service (NHS) Clinical Bursary.   
 2002 Kirkland Summer Fellowship to Harvard Medical School / BWH. 
 2001 Rotary Academic Scholarship to Johns Hopkins Medical Institute. 
 2001 Hertfordshire LEA International Academic Travel Scholarship.  
 2000 Nuffield Academic Bursary from Worcester College, Oxford.  
 2000 Association of Physicians of Great Britain & Ireland Academic Bursary. 
Professional Affiliations and Society Membership 
 American Society for Cataract and Refractive Surgery (ASCRS) member. 2014 - Present.  
 American Society of Human Genetics (ASHG) member. 2009 - 2014. 
 Association for Research in Vision & Ophthalmology (ARVO) member. 2009 - 2011. 
 IQ: 175 (99.97th percentile of UK population).  
    Offered and accepted membership to British Mensa (April 1994).  
 UK General Medical Council full registration. GMC Number: 6113403. July 2006 - Present.  
 Fellow of the Royal Society of Medicine (RSM), London, UK. September 2005. 
 Alpha Chapter, Delta Omega Public Health Honor Society.  
    Based on MHS GPA & academic contributions. April 2004. 
Additional Academic Information 
 Other Languages: French, Latin. 
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Peer-Reviewed Publications              * Denotes equal contribution of authors 
 Doyle J.J.,* Doyle A.J.,* Wilson N., et al. A deleterious gene-by-environment interaction 
imposed by calcium channel blockers in Marfan Syndrome. eLife. Accepted September 2015. 
 Srikumaran D., Son H., Doyle J.J., et al. Correlation of Corneal Parameters and Visual 
Acuity Outcomes after DSEK. J Clin Exp Ophthalmol 2013; 4:308.  
 Doyle A.J.,* Doyle J.J.,* Bessling S.L., Maragh S., et al. Mutations in the TGFβ repressor 
SKI cause Shprintzen-Goldberg syndrome with aortic aneurysm. Nature Genetics 2012; 
44(11):1249-54. 
 Li Y., Foss C.A., Summerfield D.D., Doyle J.J., Torok C.M., et al. Targetting collagen 
strands by photo-triggered triple helix hybridization. PNAS 2012; 109(37):14767-72. 
 Lindsay M.E., Schepers D., Bolar N.A., Doyle J.J., et al. Loss of function mutations in 
TGFβ2 cause a syndromic presentation of thoracic aortic aneurysm. Nature Genetics 2012; 
44(8):922-7. 
 Doyle J.J., Gerber E.E., Dietz H.C. Matrix-dependent perturbation of TGFβ signalling and 
disease. FEBS Letters 2012; 586:2003-15. 
 Haskett D., Doyle J.J., Gard C., et al. Altered tissue behavior of a non-aneurysmal 
descending thoracic aorta in the mouse model of Marfan syndrome. Cell Tissue Research 
2012; 347(1):267-77. 
 Holm T.,* Habashi J.,* Doyle J.J.,* Bedja D., Chen Y., et al. Noncanonical TGFβ signalling 
contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011; 
332:358-61. 
 Habashi J.,* Doyle J.J.,* Holm T., Aziz H., Schoenhoff F., et al. Angiotensin II type 2 
receptor signalling attenuates aortic aneurysm in mice through ERK antagonism. Science 
2011; 332:361-5. 
 Engler C., Chakravarti S., Doyle J.J., Eberhart C.B., Meng H., et al. Transforming growth 
factor-β signaling pathway activation in keratoconus. American Journal Ophthalmology 
2011; 151(5):752-9. 
 Matt P., Huso D.L., Habashi J., Holm T., Doyle J.J., et al. Murine model of surgically 
induced acute aortic dissection type A. J Thorac and Card Surg 2010; 139(4):1041-7. 
 Rosenheck R.A., Doyle J.J., et al Changing environments and alternative perspectives in 
evaluating cost-effectiveness of new antipsychotic drugs. Schiz Bull 2003; 29(1):81-93. 
 Robinson G.V., Doyle J.J., et al. Visuo-motor tracking function in patients with obstructive 
sleep apnea before and after nasal CPAP treatment. Thorax 2001; 56(S3):28. 
Book Chapters and non-Peer Reviewed Publications 
 Doyle A.J., Doyle J.J., Dietz H. Chapter 693: Marfan Syndrome. In Nelson Textbook of 
Paediatrics. 20th Edition. Updated, August 2013. 
 Doyle J.J., Dietz H. Chapter 206: Marfan Syndrome and Related Disorders. In C Scriver et 
al. (eds): Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York, McGraw-
Hill, 2001. Updated, November 2012. 
 Doyle J.J., Dietz H. Chapter 693: Marfan Syndrome. In Nelson Textbook of Pediatrics.19th 
Edition. 2011; 2440-6. 
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Oral Presentations  
 Doyle A.J., Doyle J.J., et al. Identification of Major Genetic Modifiers in Marfan Syndrome 
mice. American Society of Human Genetics (ASHG). Baltimore, MD. October 2015.  
 Doyle J.J. Elucidation of Modifier Genes in Humans and Mice with Marfan Syndrome. 
Invited Talk. EDS IV Research Consortium Conference. Chicago, IL. September 2015. 
 Doyle A.J., Doyle J.J., et al. Delineation and Therapeutic Implications of a Modifier Locus 
of Aortic Aneurysm in Marfan Syndrome. American Society of Human Genetics (ASHG). 
San Diego, CA. October 2014.  
 Doyle J.J. CCBs Impose a Deleterious Gene-by-Environment Interaction in Marfan 
Syndrome: Implications for Aortic Disease Pathogenesis. Invited Talk. American Heart 
Association (AHA). Dallas, TX. November 2013. 
 Doyle J.J., Doyle A.J., Wilson N., et al. ERK Activation Unifies Deleterious Gene-by-Gene 
and Gene-by-Environment Interactions in Marfan Syndrome. American Society of Human 
Genetics (ASHG). Boston, MA. October 2013.  
 Doyle J.J. Deleterious Consequences of Calcium Channel Blocker Treatment in a Mouse 
Model of Marfan Syndrome. Invited Presentation. National Marfan Foundation Annual 
Patient Meeting. Chicago, IL. August 2012. 
 Schepers D., Lindsay M.E., Ajit Bolar N., Doyle J.J., et al. Loss of function mutations in 
TGFB2 cause Loeys-Dietz syndrome. European Society of Human Genetics Conference. 
Nuremberg, Germany. June 2012. 
 Doyle J.J. Therapeutic Strategies for Marfan Syndrome: A Scientific Update. Invited 
Presentation. Marfan Association UK Annual Conference. London. March 2012. 
 Doyle J.J. Ying-Yang of Angiotensin Receptors in Aortic Aneurysms. Invited Presentation. 
Gordon Research Conference on Emerging and Evolving Paradigms in the Renin 
Angiotensin System. Ventura, CA. February 2012. 
 Doyle J.J. Novel Mitigating Factors in Aortic Aneurysm Disease. Invited Presentation. St. 
George’s Hospital, London, UK. November 2011. 
 Doyle J.J., Jun A.L., Guyton D., Quigley H., Dietz H. Inhibition of TGFβ Signalling 
Prevents Axial Myopia in a Model of Marfan Syndrome. American Society of Human 
Genetics (ASHG). Washington D.C. November 2010. 
 Doyle J.J., Habashi J., Lindsay M., Bedja D., Dietz H. Calcium Channel Blockers Exacerbate 
Aortic Disease in Marfan Syndrome. American Society of Human Genetics (ASHG). 
Washington D.C. November 2010. 
 Doyle J.J., Habashi J., Lindsay M., Bedja D., Dietz H. Noncanonical TGFβ Signalling in 
Marfan Syndrome. Invited Presentation. National Marfan Foundation Annual Research 
Meeting. Warrenton, VA. August 2010.  
 Doyle J.J., Lindsay M., Habashi J., Bedja D., Dietz H. Calcium Channel Blockers Exacerbate 
Aortic Disease in Marfan Syndrome Mice. Invited Presentation. NMF Annual Research 
Meeting. Warrenton, VA. August 2010.  
 Doyle J.J., Jun A.L., Gehlbach P., Guyton D., Quigley H., Dietz H. Pharmacological 
Inhibition of TGFβ Signalling Ameliorates Disease in a Genetic Model of Axial Myopia. 




 Doyle J.J., Habashi J., Holm T., Bedja D., Dietz H. Dissection of a Marfan Modifier 
Network Reveals New Therapeutic Targets. American Society of Human Genetics (ASHG) 
Annual Meeting. Honolulu, HI. November 2009. 
Poster Presentations 
 Doyle J.J. Calcium Channel Blockers Accelerate Aortic Aneurysm and Cause Premature 
Lethality in Marfan Syndrome and Related Conditions. American Heart Association (AHA). 
Chicago, IL. November 2014. 
 Doyle J.J., Habashi J., Lindsay M., Bedja D., Dietz H. Calcium Channel Blockers Exacerbate 
Aortic Disease in Marfan Syndrome mice. American Heart Association (AHA) Meeting. 
Chicago, IL. November 2010. 
 Hinton R., Opoka A., Osinska H., Doyle J.J., Juraszek A.L., et al. Elastic fiber dysregulation 
in syndromic aortic valve disease. American Society of Molecular Biology (ASMB) Annual 
Meeting. Charleston, SC. November 2010. 
 Schoenhoff F., Habashi J., Huso D., Aziz H., Doyle J.J., et al. Abrupt Withdrawal of 
Losartan Accelerates Aortic Root Growth in Marfan Syndrome Mice. American Heart 
Association (AHA) Annual Meeting. November 2010. 
 Doyle J.J., Dietz H. Losartan Ameliorates Disease in a Murine Model of Axial Myopia. 
Model Organisms to Human Biology (MOHB) Conference. Boston, MA. June 2010. 
 Habashi J., Holm T., Doyle J.J., Dietz H. AT2 Signalling is a Positive Prognostic & 
Therapeutic Modifier of Marfan Syndrome: Lessons for ACEi & ARBs. American Heart 
Association (AHA) Meeting. November 2009.  
 Habashi J., Doyle J.J., Holm T., Aziz H., Bedja D., Dietz H. AGT2R is a Genetic and 
Therapeutic Modifier of Marfan Syndrome. American Society of Human Genetics (ASHG) 
Annual Meeting. November 2008.  
 Srikumaran D., Doyle J.J., Munoz B., Stark W.J., Jun A.S. Relationship Between Visual 
Acuity Outcomes and Corneal Parameters After Descemet Stripping Endothelial 
Keratoplasty. ARVO Annual Meeting. May 2008. 
 Ghandari M., Doyle J.J., Roberts L., Chakravarti S. Lumican expression is mediated by NF-
kB in LPS-mediated Immune Response. ARVO Annual Meeting. May 2007.  
Inventions, Patents and Copyrights 
 2012: International Patent PCT/US2012/033613: ERK Inhibitors for Aortic Aneurysm. 
Service, Leadership and Teaching Activities 
 Graduate School Lecture: ‘Eye Phenotyping in Mice;’ part of Johns Hopkins School of 
Medicine Mouse Biology, Pathology, Genetics for Phenotyping and Translational Research 
course (ME300.712). Summer 2012 & 2015. 
 Graduate School Lecture: ‘Histopathology and Imaging of Ocular Pathology in Animals;’ 
part of Johns Hopkins School of Medicine Basic Mechanisms of Disease course 
(ME300.713). Winter Term 2010, 2011, 2012 & 2015. 
 Graduate School Lecture: ‘Grant Writing Tips and Strategies;’ part of Johns Hopkins School 
of Medicine CMM PhD Training Program Grant Writing Course. Winter Term 2012. 
 
